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ABSTRACT
Prostate cancer is the most common cancer in men in Australia, with 18,138 new diagnoses
and 3,398 deaths projected to occur in 2016 alone. The disease results from the accumulation
of mutations in the epithelial cells of the prostate gland and is incurable once it metastasises
outside the prostate. As such, it is important that new therapeutic targets for this disease are
identified and developed to improve outcomes for those suffering from this disease. One such
potential target is EphB4, a member of the Eph receptors family of receptor tyrosine kinases
(RTKs). EphB4 is anchored in the plasma membrane of expressing cells and interacts with its
membrane-tethered ligand ephrin-B2 expressed on neighbouring cells. Signalling therefore
requires close proximity of the two cells and has been shown to contribute to a number of
developmental processes.
Several studies have shown increased EphB4 expression in epithelial cancer cells including
recent studies that reported over-expression of EphB4 in approximately 60% of prostate
tumours. A key study by Xia et al. in 2005 showed that EphB4 is essential for cancer cell
survival, invasion and spread. It is clear that EphB4 plays an essential role in prostate cancer
cell survival and appears to contribute to key hallmarks of cancer progression including
increased invasive potential and avoidance of apoptosis. However, it is not clear how EphB4
performs these functions or which pathways are affected, and there is little known about the
binding partners of EphB4. As such, the first aim of this research project was to identify and
characterise interacting partners of EphB4 and to identify pathways that potentially
contribute to prostate cancer development.
Our laboratory developed a novel technique to identify protein complexes that interact with
EphB4 called 2 Dimensional Native Affinity Compromised Electrophoresis (2D-NACE). This
technique was optimised for use with a model 22Rv1 EphB4 over-expressing prostate cell line
and in-house EphB4 antibodies, and a large number of putative EphB4-interacting proteins
were identified. One of these, Thrombospondin-1, was further validated to interact directly
with EphB4. In conjunction with the 2D-NACE analysis, co-immunoprecipitation pull down
assays coupled with mass spectrometry analysis were used to identify additional putative
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binding partners of EphB4. There were a number of potential candidates for further
investigation, and of these, PAK4, JNK1 and MCF2L were found to co-precipitate with EphB4,
suggesting that these proteins interact in a complex. These findings of novel putative
interacting partners for EphB4 add valuable information to the understanding of the signalling
networks of this receptor. Our laboratory has also shown that EphB4 contains a nuclear
localisation signal and is present in the nucleus. This project further identified that EphB4 was
able to interact with importin-α and that this interaction was the mechanism for the nuclear
transport of EphB4. The novel finding of nuclear EphB4 and its transport mechanism adds
greater insight to the potential role of full length EphB4 in the cell nucleus.
Cancer cells are also known to secrete a variety of microvesicular bodies (MVBs) including
exosomes into their surroundings, which are thought to be involved in cell to cell
communication as well as the pathogenesis of various diseases, including cancer. Thus the
second aim of this project was to isolate and characterise exosomes from EphB4-positive
cancer cells. It was found that cells overexpressing EphB4 produced exosomes that contained
high levels of EphB4 protein; and that the addition of EphB4 positive exosomes to prostate
cancer cells significantly decreased their proliferation, while the addition of EphB4 positive
exosomes to HUVECs was detrimental to their growth and resulted in cell death.
This research study provides data identifying novel actions of EphB4, specifically, the
identification Thrombospondin-1 as a new binding partner for EphB4, as well as identification
of additional putative binding proteins PAK4, JNK1 and MCF2L. The development and
optimisation of the novel 2D-NACE technique will also provide a useful tool that will help to
offer new insights into the action of EphB4 in prostate cancer cell lines. The novel finding of
full length EphB4 in the cell nucleus transported there by importin-α also opens up a large
field of potential research with the goal of understanding the mechanisms of action and the
cellular consequences of this new role for EphB4. Finally, identifying EphB4-positive exosomes
that are secreted from prostate cancer cells gives novel insight into the role of EphB4 outside
the host cell, suggesting a role for EphB4 containing exosomes as cellular messengers or
transport vesicles. Further investigation may also lead to a use for these EphB4 positive
exosomes as biomarkers to identify prostate cancer tumours.
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Introduction
2Chapter 1: Introduction
1.1 Literature Review
1.1.1 Prostate Cancer
Cancer
Cancer is a generic term referring to over 100 diseases which develop through a multistep
process in which cells divide unregulated, form tumours and invade surrounding tissue,
spreading to other sites in the body using the lymphatic system or the blood stream in a
process called metastasis. This often results in death. However, not all tumours are
metastatic, and some can remain benign and in the body without being life threatening. A
variety of genetic and epigenetic factors can influence cancer formation by destabilising
cellular growth control, differentiation and organization, which in turn leads to the
development of malignant tumours (Anand et al. 2008; Berclaz et al. 2002). It has been
suggested that cancer cells must acquire six capabilities, or hallmarks, in order for them to
gain malignant growth (Hanahan & Weinberg, 2011). Firstly, the cells must provide their own
growth signals, after which they promote angiogenesis,  and then acquire the ability to ignore
cell death signals that cause apoptosis, acquire the ability to ignore anti-growth signals,
acquire the ability to replicate indefinitely, and finally, they must become able to invade other
tissues. Two emerging hallmarks have also been recently identified, these being
reprogramming of energy metabolism and evading immune destruction. All these factors are
further enhanced through genome instability and the composition of the tumour
microenvironment (Hanahan & Weinberg, 2011).
There are a number of different types of cancer including:
 Carcinoma—cancer initiating in skin or tissues that line internal organs
 Sarcoma—cancer initiating in bone, cartilage, fat, muscle, blood vessels or tissue
3 Leukaemia—cancer initiating in blood-forming tissue, including bone marrow
 Lymphoma—cancer initiating in immune system cells
 Central nervous system cancers— cancer initiating in brain tissues and the spinal cord
(AIHW: Cancer in Australia, 2014)
Cancer is a worldwide disease and a leading cause of morbidity and mortality, responsible for
over 8 million deaths annually (Stewart & Wild, 2014). In Australia, cancer accounts for about
a third of all deaths, with the most common forms being colorectal, prostate, breast,
melanoma, lung and uterine cancers. It is estimated that 1 in 2 men and 1 in 3 women will be
diagnosed with some form of cancer before the age of 85 (AIHW: Cancer in Australia, 2014).
Prostate cancer is the most common cancer in men in Australia, accounting for around a
quarter of all cancer diagnosed (AIHW: Cancer in Australia, 2014). Cancer made up between
16-19% of all disease burden in 2012, and cost approximately $4.5 billion in health
expenditure (AIHW: Cancer in Australia, 2014; Begg et al. 2007).
Many factors can affect the risk of developing cancerous tumours, including genetic makeup,
bacterial infection, and carcinogens such as UV light, and chemicals (Hanahan & Weinberg,
2011). However, the most common risk factors, which are implicated in 30% of all cancers
include low nutrient levels, low physical activity levels, high body mass index, and smoking
and alcohol use, with smoking alone implicated in 22% of worldwide cancer deaths and 71%
of all lung cancer deaths. Ageing is also an important risk factor with 70% of people diagnosed
with cancer in Australia being over 60 years of age (AIHW: Cancer in Australia; 2014, Begg et
al. 2007).
Prostate Disease
One of the most prominent cancers that affect men around the world is prostate cancer. The
prostate is a walnut sized gland which is part of the male reproductive system, located in the
pelvis and surrounding the urethra (Romer & Parsons, 1977) (Figure 1.1). Its primary function
is to secrete a fluid which is the major constituent of semen and its growth is normally
regulated by the male hormone dihydrotestosterone (Lilja, 1988).
4There are four common prostate disorders
that manifest with similar symptoms
including difficulty in urination, frequent
urination, painful urination or ejaculation,
erectile dysfunction and blood in urine or
semen. These four diseases are 1)
prostatitis, a benign inflammation of the
prostate caused by infections; 2) benign
prostatic hyperplasia (BPH), a benign
enlargement of the prostate often found in
older men which can squeeze and block the
urethra; 3) prostatodynia, a chronic disease
of the prostate causing frequent and painful
urination and fever; and finally, 4) prostate cancer, a potentially life threatening cancerous
overgrowth of the prostate which may then metastasise to other areas of the body. Prostate
cancer is caused by an accumulation of mutations in the epithelial cells of the prostate gland.
Often it is hard to distinguish prostate cancer specific symptoms from other benign diseases
of the prostate (Garnick, 1993).
Epidemiology
The 2012 report from the Australian Institute of Health and Welfare on prostate cancer shows
that it is the most common cancer in males in Australia, with 18,138 new diagnoses
(accounting for almost a third of all cancer diagnosis in men) and 3,398 deaths projected to
occur in 2016 alone, with numbers expected to increase over the coming years (AIHW: Cancer
Incidence, 2014). The disease is incurable once it metastasises outside the prostate and is the
second deadliest cancer (after lung cancer) in men. Five year survival rates for local prostate
cancer (that has not spread to other areas) is almost 100%, although, once the cancer
metastasises, the five year survival rate drops to just below 30% (Garnick, 1993; AIHW: Cancer
Incidence, 2014). Prostate cancer occurrence is strongly correlated with increased age, with
Figure 1.1: The human male prostate
Depiction of a normal and enlarged prostate showing
the manipulation of the bladder and urethra. Used
from Prostate Cancer Foundation of Australia (Romer
& Parsons, 1977).
5incidence and mortality in males over 50 increasing at almost exponential rates (Pienta &
Esper, 1993) and almost 25% of all prostate cancer tumours being detected in patients over
75 (Fitzpatrick, 2008).
Diagnosis
The severity of prostate cancer is categorized by stage and grade. The Gleason Grade is a
measure assigned by pathologists, based on histological appearance, to evaluate the
prognosis of the cancer and indicates the speed of growth and aggressiveness of the cancer.
It is ranged on a scale of 2 - 10, with 10 being the most aggressive type of cancer (Shah, 2009;
Arora, 2012). Staging refers to whether, and how far the tumour may have spread. There are
four stages: 1 - the cancer is small contained in the prostate gland; 2 - the cancer is larger, but
is still within the prostate; 3 - the cancer has invaded surrounding tissue; and 4 - the cancer
has metastasised to distant areas including the bone (PCFA: Staging & Grading,
www.prostate.org.au/articleLive/pages/Staging-and-Grading.html).
Few diagnostic markers currently exist that can identify prostate tumours that will have a
poor outcome (Kristiansen, 2012) and this often leads to tumours growing undetected which
in turn leads to increased mortality rates. The initial methods of prostate cancer detection
include the digital rectal exam (DRE) and testing Prostate Specific Antigen (PSA) levels in blood
(Catalona et al. 1994; Polascik et al. 1999; PCFA Prostate Cancer Statistics,
www.prostate.org.au/articleLive/pages/Prostate-Cancer-Statistics.html). The DRE involves
the use of a finger to indirectly inspect the prostate gland through the rectal wall to check for
lumps or changes in size. The PSA test checks the blood for increased levels of the Prostate
Specific Antigen, a protease otherwise known as Kallikrein-3, which is secreted by epithelial
cells of the prostate. Normal PSA levels have been indicated to fall between 2-4 ng/mL
whereas higher PSA levels generally point to increased cancer progression, with levels below
10 ng/mL usually indicating localised disease and levels above suggesting metastasis outside
the prostate. However, although PSA is prostate specific, this test is not prostate cancer
specific as patients with BPH and prostatitis may also present with increased PSA levels. In
some cases, patients with prostate cancer can also present with normal PSA levels (Garnick,
61993; Nadji et al. 1981; Catalona et al. 1991; Gerber & Chodak, 1991; Guinan et al. 1980)
making the PSA test indicative, but not a definitive determinant of the presence of prostate
cancer. Nevertheless, both tests are recommended for males over 50 years of age. If the first
round of testing returns results suggestive of prostate cancer, then a biopsy is performed to
confirm the cancer and provide a grading using Gleason values reflecting the aggressiveness
and stage of the cancer by pathological criteria (PCFA Prostate Cancer Statistics,
www.prostate.org.au/articleLive/pages/Prostate-Cancer-Statistics.html).
Treatment of local tumours
A number of treatment options are available for the management of prostate cancer. These
are based on a number of factors including the age, health and family history of the patient
and the PSA levels, grade and stage of the tumour. For low stage, non-metastasising tumours,
'watch and wait' or active surveillance is often employed to monitor the tumour and
associated PSA levels, as at this stage tumours are often slow growing and pose a low level of
threat. It has been reported that 50% - 70% of prostate cancer patients will die from causes
other than the prostate tumour (Phillips, 2011). As such, this approach is used to prevent
over-treatment as well as to reduce the loss of quality of life from the potential side effects
of harsher treatments. Active surveillance requires regular PSA tests, DREs and biopsies and
if the tumour stage increases, treatment options are then initiated. These can include surgery,
for the removal of the prostate through a radical prostatectomy procedure to completely
remove the tumour; high-intensity focused ultrasound (HIFU), where the entire prostate is
ablated using heat generated through ultrasound; or radiation therapy, where the cancer is
targeted with X-rays to destroy or reduce the size of the tumour. These options are primarily
used to remove localised tumours before they metastasise (CCA: After Diagnosis,
www.cancer.org.au/about-cancer/after-a-diagnosis/after-a-diagnosis-of-prostate-
cancer.html; PCFA: Post Diagnosis, www.prostate.org.au/articleLive/pages/Post-
diagnosis.html; Lu-Yao et al. 2009; Picard et al. 2009; Mohan & Schellhammer, 2011; Blana et
al. 2004; Thüroff et al. 2003).
7Treatment of metastasised prostate tumours
Once the tumour spreads outside of the prostate gland, systemic treatments are required
such as chemotherapy, anti-hormonal treatment, and novel therapeutics as the final stages
of prostate cancer include metastasis primarily to bone which significantly increases mortality
rates (Siegel et al. 2012; Jimenez-Andrade et al. 2010; Guise, 2010). Growth of the prostate
gland and early stages of prostate cancer rely on male androgenic hormones such as
testosterone and dihydrotestosterone.
Hormone treatments, or other chemotherapy approaches, involve the use of drugs to
decrease the availability of androgens such as testosterone and dihydrotestosterone to the
prostate which reduces tumour growth in androgen dependent cancers (Huggins & Johnson,
1947). Androgens are responsible for the promotion of growth in prostate cancer cells so
therefore lowering androgen levels can cause tumours to shrink or grow at a slower rate.
Hormone therapy does not cure prostate cancer, but can help manage the disease along with
surgery and radiation treatments (Nanda et al. 2010). There are a number of hormone
therapies that are available for the treatment prostate cancer that either block or lower
androgen levels, including:
 Orchiectomy – the surgical removal of the testicles is a form of hormone therapy as it
removes the main androgen production organ.
 LHRH (luteinizing hormone-releasing hormone) analogues – also referred to as LHRH
agonists or GnRH agonists, are treatments that lower testosterone levels and often
shrink the size of the testicles. LHRH analogues include leuprolide, goserelin,
triptorelin and histrelin.
 LHRH antagonists – this treatment reduces testosterone levels quickly by binding to
the LHRH receptors on pituitary gonadotropin-producing cells. This does not initiate
an initial release of luteinizing hormone or follicle-stimulating hormone, thus avoiding
the hormonal spike or “flare” that occurs with LHRH agonists.
8 Abiraterone – this treatment blocks androgen production in cells outside the testicles
so it must be paired with LHRH agonist or antagonist treatments. Abiraterone can also
lower other hormones levels.
 Anti-androgens – these block androgens binding to specific proteins in prostate cancer
cells which in turn prevent androgens from working effectively. This treatment is often
used in combination with orchiectomy or LHRH analogues.
 Enzalutamide – this is an anti-androgen treatment that prevents androgen proteins
from signalling cancer cells to grow and divide. (Nanda et al. 2010; Nelson et al. 2008).
However, androgen deprivation treatments often become ineffective in advanced stages of
the disease as prostate cancer can develop into a castrate-resistant state which does not
respond to traditional androgen depriving therapies, making it very difficult to treat
effectively (Isaacs, 1994; van Steenhrugge et al. 1991). One key reason for the eventual failure
of androgen deprivation therapy is that the prostate acquires the ability to synthesise its own
androgens and also adapts to use various growth-promoting factors to continue growth and
dissemination (Lubik et al. 2012). Additionally, androgen deprivation has been shown to
promote both epithelial-to-mesenchymal transition (EMT) and neuroendocrine
transdifferentiation (NEtD), which in turn can stimulate tumour progression phenotypes and
increase resistance to anti-cancer therapies. As such the use of androgen deprivation
therapies can in fact provide a means for tumour cells to adapt and grow and for the cancer
to recur. This process has been found to be primarily driven by Brachyury, Axl, MEK, and
Aurora kinase A, however inhibitors for these molecular drivers are currently undergoing
clinical trials (Nouri et al. 2014).
Currently, treatments for castrate resistant prostate cancer are largely palliative and do not
provide a cure. Treatments include the use of the drugs Docetaxel (an anti-mitotic and
microtubule inhibitory agent) and Cabazitaxel (a microtubule inhibitor), in combination with
an immunosuppressive steroid drug prednisone, which increases median survival by 2 - 3
months (Yagoda & Petrylak, 1993; Casciano & Petrylak, 2001; Tannock et al. 2004; de Bono et
al. 2010); immunotherapy treatments such as Sipuleucel-T (a prostate cancer vaccine), which
9increases survival by 4 months (Kantoff et al. 2010); and other hormonal treatments including
abiraterone (in combination with prednisone), which blocks the CYP17 enzyme, a crucial
protein in the production of testosterone, and thereby is able to extend survival by 4 - 5
months (de Bono et al. 2011; Attard et al. 2009). Although these treatment are useful for
tumours that have spread outside the prostate and for castrate resistant cancer,
chemotherapy has many side effects including loss of appetite, nausea, hair loss, mouth
lesions, and fatigue and is often used after all other treatment options have failed (CCA:
Chemotherapy, www.cancer.org.au/cancer/prostatecancer/detailedguide/prostate-cancer-
treating-chemotherapy.html).
Biomarkers for Prostate Cancer
Many therapies are being developed for the detection and treatment of prostate cancer, with
new drugs and therapeutics constantly being tested in clinical trials seeking an indication of
treatment benefits and therefore, approval for use as anti-cancer therapeutics. Specifically,
there is a focus on non-invasive early detection strategies, including research that found that
patients with prostate cancer secreted the transcription factor EN2 in their urine suggesting
that EN2 may be a viable biomarker for prostate cancer (Morgan et al. 2011). Another such
marker may be Prostate Cancer Antigen 3 (PCA3) mRNA which is expressed by prostate cells
and is up-regulated in prostate cancer (Bourdoumis et al. 2010). Many proteins have also
been identified to be up-regulated in prostate cancer, or are involved in the development of
the disease. One particular protein group, the Eph receptor tyrosine kinase family, has been
implicated in many different types of cancer, including prostate cancer, and is known to be
involved in important cancer progression pathways.
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1.1.2 The Eph receptor family
Structure
Receptor tyrosine kinases (RTKs) are key components in the transduction of extracellular
signals across the cell membrane. They play important roles in normal cellular growth,
including cellular differentiation, survival and migration, but when expression is deregulated
they are also implicated in the development of cancer (van der Geer et al. 1994). The largest
RTK family is the Eph (erythropoietin-producing human hepatocellular carcinoma) group of
proteins with 14 distinct members in humans (Krasnoperov et al. 2010) divided into two
subclasses, designated A (9 members from EphA1 to EphA8 and EphA10) and B (5 members
from EphB1 to EphB4 and EphB6), based on sequence homologies.
A common structure exists within the family with
an extracellular domain made up of a ligand
binding globular domain, a cysteine rich domain
which is also involved in binding the ligand, and
two fibronectin type III domains (which are
thought to stabilise dimerisation of receptors);
the transmembrane domain; and an intracellular
domain that consists of the tyrosine kinase
domain (which activates signalling cascades after
phosphorylation), the  sterile alpha motif (SAM)
domain and the PDZ domain (both of which
interact with the cytoskeleton) (van der Geer et
al. 1994; Kullander & Klein, 2002; Pasquale, 2005)
(Figure 1.2).
Eph receptors interact directly with their ligands, the ephrins. These are also divided into two
subclasses designated A and B. However, unlike other RTK ligands, such as epidermal growth
factor (EGF) and vascular endothelial growth factor (VEGF), the ephrins are attached to the
Figure 1.2: Eph receptor structure
Schematic diagram illustrating the different
structural domains of the Eph receptor
tyrosine kinase protein family.
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membrane of cells. The class A ephrins (A1 to A6) are anchored to the plasma membrane
through a glycosylphosphatidylinositol (GPI) linkage whereas the B class ligands (B1 to B3) are
anchored through a transmembrane domain (Pasquale, 2010). Cell to cell interaction in trans
(opposing cells) is required for interaction between these ligands and their receptors as both
are membrane bound and expressed on separate neighbouring cells (though it has been
suggested that certain Eph receptors and ephrins can be expressed on the same cells and can
interact in cis (Figure 1.3) (Yin et al. 2004)). Signalling occurs through the formation of a
heterotetrameric structure which consists of two receptors and two ligands (Pasquale, 2005).
This receptor-ligand interaction causes forward signalling into the receptor expressing cell
through phosphorylation of the tyrosine kinase domain, as well as reverse signalling into the
neighbouring ligand expressing cell through phosphorylation of the Src family kinases and
subsequent activation of signalling
pathways through the phosphorylation of
the cytoplasmic domain of ephrin-B2
(Krasnoperov et al. 2010; Kullander &
Klein, 2002; Noren et al. 2004; Himanen &
Nikolov, 2003; Palmer et al. 2002;
Pasquale, 2010) (Figure 1.3).
Eph receptors (Ephs) and ephrin ligands
have been shown to be promiscuous in
their interactions with each other, often
with one receptor being able to interact
with multiple ligands, such as EphB2 which
can interact with all B class ephrins and
with ephrinA5 (Kullander & Klein, 2002).
However, EphB4 is an exception to this as
it has a sole physiologically relevant ligand,
ephrin-B2 (Sakano et al. 1996; Brambilla et
al. 1995).
Figure 1.3: Eph receptor signalling complex
Schematic diagram illustrating the heterotetrameric
signaling complex formed by two ephrin ligands
interacting with two Eph receptors in trans.
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Function
Eph receptors and their ligands are involved in many different cellular pathways and
processes. Initially they were found to play a role in developmental patterning and cell
guidance (Boyd & Lackmann, 2001) as the interaction between ligand and receptor is known
to play a role in cell adhesion and repulsion responses. Adhesion responses occur during low
levels of activation of Eph receptors by their ligands (Pasquale, 2005; Holmberg et al. 2000).
Repulsion is the more common effect, and is seen when the receptor-ligand pair are
separated either through protease mediated cleavage (for example by ADAM10) or through
endocytocis of the entire signalling complex and surrounding plasma membrane (Pasquale,
2005; Pasquale, 2010; Pitulescu & Adams, 2010; Zimmer et al. 2003).
These two responses are important in regulating developmental processes especially in the
establishment of tissue boundaries and guiding cells during morphogenesis. Eph receptor and
ephrin ligand interaction has also been shown to be important in other processes during
embryonic development including signalling cascades that affect morphology, migration,
axon guidance and neuron development (Lai et al. 2004; Shamah et al. 2001; Penzes et al.
2003; Wang & Anderson, 1997; Davy et al. 2004; Segura et al. 2007). Although Ephs and
ephrins are expressed predominantly during developmental process, adult tissues also
express these receptors and ligands. Studies show that normal Eph/ephrin signalling is
important for maintaining organs such as the prostate (Schaeffer et al. 2008; Hafner et al.
2004), the colon and breast (Miao & Wang, 2009; Andres & Ziemiecki, 2003) through
mediating signalling cell adhesion, invasion and migration responses that work with integrins
to modify the actin cytoskeleton within cells (Pasquale, 2010).
The above tissues are also where Eph receptor over-expression is often found associated with
disease states, and particularly in cancer where these embryonic regulatory receptors which
are normally expressed at low levels in adult tissue, are expressed in high quantities and
induce signalling which promotes tumourigenesis (Hafner et al. 2004). For example, several
studies have shown that over-expression of EphA2 and down regulation of its ligand ephrinA1
in non-small cell lung, breast, ovarian, brain and other cancers, causes the tumours to become
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more aggressive and invasive (Kinch et al. 2003; Brannan et al. 2009; Han et al. 2005; Martin
et al. 2008; Li et al. 2007b).
This is similar for other Eph receptors from both classes such as EphA3 (Xi & Zhao, 2011),
EphA4 (Oki et al, 2008; Iiizumi et al. 2006), EphB3 (Kang et al. 2009; Ji et al. 2011) and EphB4
(Xia et al. 2005a; Kumar et al. 2007; Kumar et al. 2006; Stephenson et al. 2001). In some
disease types the receptors are expressed at much lower levels, due to mutations and
epigenetic silencing, as is the case with EphA5 (Fu et al. 2010), EphA7 (Wang et al. 2005;
Dawson et al. 2007; Tsuboi et al. 2010) and EphB2 (Batlle et al. 2005).
The Eph receptors and ephrins are involved in a wide variety of processes both in
development and in adult tissue and they also play an important role in disease progression,
especially in cancer. As such, a large amount of research is investigating this family of receptor
tyrosine kinases. Of particular interest to our group is EphB4 and its ligand ephrin-B2 as these
are both involved in many processes, particularly angiogenesis, and also play an important
role in the progression of a variety of cancer types (see Table 1.1) including prostate cancer
(Lisle et al. 2013).
1.1.3 The receptor tyrosine kinase EphB4
EphB4
EphB4 is a B class Eph receptor of 120 kDa first identified as Htk (hepatoma transmembrane
kinase) from human bone marrow cells, and separately but concurrently from mouse embryo
and mouse mammary epithelial cells (Bennett et al. 1994; Andres et al. 1994). In the genome,
the EphB4 locus is found on chromosome 7q22, a locus often amplified in cancers (Xia et al.
2005a). The transcript is expressed, albeit at low levels, in the liver, lungs, muscle, heart,
intestine and kidney, but interestingly not in the brain, which is in contrast to all other Eph
receptors (Andres et al. 1994). As with other Eph receptors, EphB4 is an intrinsic membrane
protein and ephrin-B2, its specific ligand, is membrane bound on different cells and requires
close proximity of cells for interaction (Pasquale 2010; Davis et al. 1994).
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Interaction between EphB4 and ephrin-B2 is strong enough to hold the two communicating
cells together. The cells can only be separated by removing the signalling complex through
endocytic mechanisms which internalise the structure or through protease-mediated
cleavage of the interacting extracellular domains which results in their degradation (and a
down regulation of EphB4 in the cell) (Georgakopoulos et al. 2006; Hattori et al. 2000; Litterst
et al. 2007; Tanaka et al. 2007; Lin et al. 2008). This separation of the cells leads to a repulsion
that is characteristic of the Eph family.
Activation and Signalling
As is common to the Eph family, activation of the EphB4 receptor can initiate both forward
and ligand mediated reverse signalling through tyrosine phosphorylation of intracellular
residues. The interaction between EphB4 and its preferred ligand, ephrin-B2, is initially a one
to one high affinity interaction. This is then followed by tetramerization, oligomerization and
clustering of the signalling structure and subsequent phosphorylation of the EphB4
cytoplasmic domains and resulting downstream signalling. Crystal structure analysis of the
signalling structure has shown that EphB4 and ephrin-B2 form a tetrameric, ring-like complex
containing two receptor and two ligand molecules interacting through two distinct interfaces.
When binding, the receptor and ligand must be re-orientated to adopt an active conformation
in order to initiate signalling (Himanen et al. 2007). Varying degrees of multimerization of the
ligand–receptor complexes can modulate the resulting cellular signalling, which adds further
complexity to signalling pathways and may explain the varied physiological effects that are
seen from these interactions (Genander & Frisen, 2010).
The activation of the EphB4 receptor by its ligand is modulated through phosphorylation of
two juxtamembrane tyrosine residues, which disrupts the inhibition of the kinase domain and
allows for enzymatic stimulation of the activation loop as well as opening binding sites for
adaptor proteins. This phosphorylation of juxtamembrane tyrosine residues is essential for
activation of the protein tyrosine kinase domain of the receptor. The signalling complex is
further maintained by additional domains and interfaces, specifically through the fibronectin
type III repeats and the cysteine-rich and the sterile alpha motif (SAM) domains. These
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domains hold the interacting proteins in an orientation that is favourable to phosphorylation
in trans (Kullander & Klein, 2002; Himanen & Nikolov, 2003a; Murai & Pasquale, 2003;
Himanen et al. 2007).
The resulting signalling cascade is bi-directional, with a forward intracellular signalling
cascade being initiated upon ligand engagement through auto-phosphorylation of several
tyrosine residues in the kinase domain of each EphB4 receptors in the heterotetramer, This
results in the activation of cellular signalling pathways through Src-Homology-2 (SH2) and SH3
containing adaptor proteins (Kullander & Klein, 2002; Himanen & Nikolov, 2003b; Lisle et al.
2013). At the same time, reverse signalling into the ephrin-B2 containing cell is triggered
through the phosphorylation of cytoplasmic tyrosine residues of Src kinases that in turn allow
binding of the SH2 domains of interacting signalling proteins, establishing a signalling cascade
into the ephrin-B2 expressing cell (Murai & Pasquale, 2003).
Role and function
Signalling through the EphB4 receptor is known to recruit other intercellular proteins which
through signalling cascades affect cellular processes such as proliferation, differentiation and
bone remodelling (Pasquale, 2010; Matsuo, 2010). EphB4-ephrin-B2 interaction has also been
shown to be involved in a number of developmental processes such as neural network
formation, axon guidance, endothelial cell migration, and patterning and morphogenesis
through the repulsion and adhesion response (Wang & Anderson, 1997; Helbling et al. 2000;
Bruhl et al. 2004; Poliakov et al. 2004). The signalling processes activated through EphB4
interaction with its ligand are also responsible for regulation of angiogenesis and the
formation of the cardiovascular system during embryonic development and its maintenance
in adults.
Forward signalling though EphB4, which is expressed on venous endothelial cells, causes cell
repulsion and decreases intermingling with arterial endothelial cells that express ephrin-B2
(Erber et al. 2006; Martiny-Baron et al. 2004; Gerety et al. 1999; Wang et al. 1998a; Fuller et
al. 2003). Knock-down experiments of either EphB4 or ephrin-B2 genes in mice show that
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deregulation of angiogenesis resulted in embryonic death, which illustrates that EphB4 and
its ligand perform an essential role in cardiovascular development (Fuller et al. 2003; Adams
et al. 1999; Gerety & Anderson, 2002).
EphB4 has also been shown to promote differentiation of pluripotent embryonic stem cells,
which is initiated by ephrin-B2 expressing bone marrow stromal cells which cause the EphB4
expressing hematopoietic progenitor cells to differentiate into mature erythroid cells
(Suenobu et al. 2002; Wang et al. 2002). Another study implicates EphB4-ephrin-B2
interaction in the bone remodeling processes where the ephrin-B2 expressing osteoclasts,
which degrade bone, interact with EphB4 expressing osteoblasts, which form bone, to initiate
reverse signalling into the osteoclasts and drive them to a precursor state. This decreases the
differentiation of the osteoclasts while the forward signalling through the EphB4-positive
osteoblasts works to increase it, thus regulating bone homeostasis (Zhao et al. 2006). Overall,
the EphB4-ephrin-B2 signalling complex is responsible for regulating many important cellular
functions both during development and in adult life.
Although EphB4 is involved in many cellular processes and interacts with a variety of
pathways, not much is known about proteins that directly interact with the receptor.
However, EphB4 has been shown to interact with certain protein partners among which are
other Eph receptors including EphB6 (Truitt et al. 2010); ephrin ligands including strongly with
ephrin-B2 (Hamada et al. 2003), and weakly with ephrin-B1 and ephrin-B3 (Chrencik et al.
2006). Additionally, links have been shown between EphB4 and Rac1 and MMP2 (Noren &
Pasquale, 2007); and angiogenesis related proteins PI3K, PTEN and VEGF (Herbert & Stainier,
2011; Rodriguez & Huynh-Do, 2012).
Role in cancer
Deregulation of EphB4 has also been implicated in disease, most notably in cancers. Although
a Northern analysis performed by Bennett et al. in 1994 detected EphB4 mRNA in many adult
tissues including placenta, liver, lungs, kidneys, intestine, skeletal muscle and heart,
immunohistochemistry studies have shown that only a low level of protein is produced by
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normal stromal cells, endothelial cells, lymph tissue, fibroblasts and adipose tissue (Bennett
et al. 1994). In contrast, tumour tissues commonly over-express the EphB4 protein and this
over-expression is directly related to tumourigenesis and metastasis including changes to
levels of angiogenesis, proliferation, cell morphology, and attachment and migration rates
(Wimmer-Kleikamp & Lackmann, 2005).
It has also been found that EphB4 can promote cancer progression through crosstalk with
oncogenic signalling pathways while its ligand, ephrin-B2, is localised in lipid rafts and can
activate the transcription of the RAC1 gene, which increases tumour cell migration and
invasiveness (Nakada et al. 2006; Jiang et al. 2008; Xu & Henkemeyer, 2009). A recent study
using targeted gene knock-down approaches revealed that EphB4 is essential to cancer cell
survival and invasion in vivo (Kumar et al. 2006). Similar experiments using cell lines
representing other epithelial cancers (including breast, prostate, colon, endometrial, cervical,
head and neck, lung, mesotheliomal, ovarian, bladder, oesophageal, and pancreatic)
(references in Table 1.1 below) support the hypothesis that EphB4 over-expression is required
for cancer cell survival as EphB4 over-expression induces angiogenesis (through interaction
with ephrin-B2) and inhibits apoptosis in these cells. These studies establish EphB4 as a
potential target for anti-cancer therapies.
Table 1.1. Summary of literature that reports EphB4 up-regulation in tumours
Tumour type % positive (total cases) References
Breast 58 (12); 94 (94); 100 (2);
38 (124); 53 (126)
Kumar et al. 2006; Wu et al. 2004; Berclaz et al. 1996;
Brantley-Sieders et al 2011
Prostate 66 (62); 66 (15) Xia et al. 2005a; Lee et al. 2005
Colon 63 (62); 100 (20) Stephenson et al. 2001; Liu et al. 2002
Endometrium 100 (68) Alam et al. 2007, Berclaz et al. 2002
Cervix 95 (90) Zhang et al. 2007
Head and neck 100 (37) Masood et al. 2006
Lung 100 (4); 100 (79) Tang et al. 1999; Ferguson et al. 2013
Mesothelioma 75 (16); 77 (39) Xia et al. 2005b; Liu et al. 2013
Ovaries 80 (115); 97 (30); 86 (85) Wu et al. 2006; Castellano et al. 2006; Kumar et al.
2007
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Bladder 93 (15) Xia et al. 2006
Oesophagus 72 (61); 95 (201) Tachibana et al. 2007; Hasina et al. 2013
Pancreas 15 (15) Li and Zhao 2013
Glioma 13 (23) Chen et al. 2013
1.1.4 The role of EphB4 in prostate cancer
EphB4 plays an important role in prostate cancer development and progression. In 1996,
Robinson et al. identified the EphB4 gene as one of several RTK genes that were expressed in
a PC3 cell line xenograft model of prostate cancer (Robinson et al. 1996). Then in 2005, two
independent studies showed the up-regulation of EphB4 in approximately 66% of prostate
tumours when compared with matched normal tissue (Xia et al. 2005a; Lee et al. 2005). EphB4
up-regulation has now been shown to be a common occurrence in many other epithelial
cancers, and increased expression is often associated with cancer progression (Kumar et al.
2007; Kumar et al. 2009; Noren & Pasquale, 2007).
Initially it was believed that EphB4 would be contributing to tumour neo-angiogenesis (Gerety
et al. 1999). Consistent with this hypothesis, a report in 2002 found high levels of EphB4
expression on the invasive front of tumours and in small lesions with many capillaries in the
immediate area although not throughout the whole tumour (Berclaz et al. 2002). This implied
that the role of EphB4 in cancer progression is associated with invasion and angiogenesis.
More recently, studies using siRNA and anti-sense knockdown strategies on PC3 prostate
cancer cells, found an 80% reduction in cell survival, a 7.9 fold increase in apoptosis due to
increased caspase activity, an 88% reduction in cell migration and invasion when compared
with control siRNA-GFP treated cells and a 72% inhibition of in vivo tumour growth (Xia et al.
2005a).
The dual role of EphB4
Although a large body of evidence identifies EphB4 as a tumour promoter due to its over-
expression in many cancers, contradicting studies have reported the role of EphB4 as a
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tumour suppressor, particularly in breast and colon cancers. Despite many publications that
report the opposite (Stephenson 2001; Masood et al. 2006; Kumar et al. 2006; Kumar et al.
2007; Kumar et al. 2009; Hasina et al. 2013), these reports suggest that EphB4 is down-
regulated in these tumours (Batlle et al. 2005; Berclaz et al. 2002). However, it should be
noted that studies by Kumar et al. and Stephenson et al. detected EphB4 using antibodies
specific to the extracellular domain of the protein, whereas Batlle et al. and Berclaz et al. used
an antibody that is C-terminal specific. This difference in identifying EphB4 may lead to a
hypothesis that the C-terminal is degraded while the extracellular domain continues to signal,
inducing neo-angiogenesis and as such, show EphB4 to appear to function as both a cancer
promoter and suppressor. Another explanation for this paradox could be that EphB4 may be
involved in both ligand dependent and ligand independent signalling pathways where
changing the balance between EphB4 and ephrin-B2 increases tumour promotion, i.e. EphB4
up regulation increases invasion and migration of tumours while ephrin-B2 up regulation
increases angiogenesis (Noren, 2004; Rutkowski et al. 2012).
Jin Chen's group from Vanderbilt University have proposed a working model for EphB4 having
a dual role in both tumour promotion and tumour suppression (Chen et al. 2008). In this
model, the interaction of ephrin-B2 with EphB4 promotes forward signalling of the receptor
that leads to tumour suppression (such as inhibiting tumour cell growth and motility through
the activation of the Abl/Crk pathway) and reverse signalling through the ligand that stabilizes
cell-cell adhesion (Noren & Pasquale, 2007; Chen et al. 2008). Disruption of cell-cell junctions,
as in tumour cells, or changes in the Eph-ephrin balance (e.g. through the over-expression of
EphB4), promotes tumour development by decreasing ligand-receptor interaction (which has
been shown to be less effective in cancer cells (Zantek, 1999)) which then leads to the use of
ligand-independent signalling pathways. This was shown in experiments when the over-
expression of EphB4 in prostate cells significantly increased anchorage independent growth,
migration and invasion, which are common phenotypes of aggressive cancers (Rutkowski et
al. 2012).
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EphB4 is often found to be highly expressed but poorly tyrosine phosphorylated in many types
of cancer cells. This indicates a limited interaction between EphB4 and its ligands. However,
when EphB4 levels are reduced, the malignant properties of cancer cells are still affected,
suggesting that these receptors can stimulate cancer cells independently of the ephrin ligand.
Multiple studies have demonstrated the ligand-independent signalling of Eph receptors
(Noren et al. 2009). These include receptor dimerization as a result of over-expression of
EphA2 (Zantek, 1999); phosphorylation of Eph receptors in the absence of ligand (Zelinski et
al. 2001); loss of ligand stimulation of Eph receptors is required for progression of colorectal
cancers (Winter et al. 2009); and Eph receptors have both kinase-dependent and -
independent functions (Kullander & Klein, 2002). A study by Noren et al., conducted in 2009,
showed that kinase activity in the EphB4 receptor affected cancer cell behaviour in an ephrin-
independent manner by inhibiting integrin-mediated (specifically β1 integrin) cell adhesion,
spreading and migration. This occurred through the reduction of (Noren et al. 2009).
Furthermore, it has been shown that activating certain Eph receptors with soluble ligand
(including EphB4 with ephrinB2-Fc) inhibits proliferation, migration and invasion and
decreases the survival of many types of cancer cells in vitro and in vivo (in mouse models)
(Noren & Pasquale, 2007; Pasquale, 2005; Noren et al. 2006; Chiu, 2009; Hess, 2006;
Rutkowski et al. 2012) and also inhibits oncogenic signalling pathways such as the HRAS/Erk,
PI3K/Akt and Abl/Crk pathways (Pasquale, 2010). Many studies have also shown that there is
high expression but low activation (limited phosphorylation) of Eph receptors in cancer cell
lines (Noren & Pasquale, 2007; Kumar, 2009; Noren et al. 2006; Zelinski et al. 2001; Pasquale,
2008; Miao & Wang, 2009). This led to a hypothesis that the ephrin-dependent forward
signalling of Eph receptors leads to tumour suppression (Figure 1.4).
A study by Rutkowski et al. (2010) tested this hypothesis and further confirmed EphB4 as a
tumour promoter, also reporting the tumour suppressive effects of ephrin-B2 mediated
forward signalling. It was found that EphB4 over-expression increased cell migration and
invasion, and anchorage-independent growth in 22Rv1 prostate cancer cells and in MCF-10A
non-transformed breast cells. These increases in metastatic characteristics were reversed
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after stimulation with the ligand ephrin-B2 which initiated forward signalling and decreased
EphB4 protein levels and proliferation of the cells. This suggests that EphB4 ligand
independent signalling directs cells towards a metastatic phenotype and this can be reversed
through ligand mediated forward signalling (Rutkowski et al. 2012).
Figure 1.4: EphB4 receptor signaling mechanisms
Schematic diagram illustrating ligand dependent and independent EphB4 signaling. The ligand dependent
heterotetrameric Eph-ephrin signaling complex requires cell to cell contact to initiate bidirectional signaling
which is tumour suppressive. The ligand independent pathway is tumour promoting and is a result of over-
expression of the EphB4 receptor. Both signaling complexes are thought to recruit protein partners for signaling.
It is this deregulation of the EphB4 signalling system which is involved in cancer promotion.
The receptors interact with many other signalling networks and in some ways are said to be
overarching regulators of many oncogenic signalling pathways. This is performed through the
bi-directional signalling of the receptor-ligand complex which allows it to perform both
tumour suppression or promotion roles (Pasquale, 2010). However the exact mechanisms of
action of the EphB4 receptor in prostate cancer are still mostly unknown. It may be that
through different mechanisms, EphB4 can be both a cancer suppressor and cancer promoter
depending on its environment and cell type, other protein interactions, and the interplay and
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balance of ligand to receptor (Noren & Pasquale, 2007). However further study into the role,
function and signalling pathways of the EphB4 receptor needs to be conducted before this is
made clear. Understanding this mechanism of action will clarify the role that EphB4 plays in
cancer development and progression.
1.1.5 EphB4 as a therapeutic target
The EphB4 receptor and its ligand ephrin-B2 and changes in the balance in their interaction
are driving forces in cancer progression and control. As such, both these proteins have been
investigated as potential anti-cancer therapeutic targets. Of particular interest are prostate
cancer therapies, as over-expression of EphB4 in prostate cancer initiates ligand-independent
signaling which in turn increases the metastatic and oncogenic characteristics of the cells
(Noren, 2004). As this is reversed through the addition of soluble ephrin-B2 ligand which
initiates tumour suppressive ligand-dependent signaling (Rutkowski et al. 2012), many groups
have proposed methods of targeting both of these pathways.
Monoclonal antibodies
One common therapy in cancer treatment is the use of monoclonal antibodies to target
specific receptors, to block the ligand from binding the receptor and decrease ligand-
dependent signaling resulting in down-regulation and internalization of the receptor
(Rowinsky et al. 2007; Belleudi et al. 2012; Scott & Wolchok, 2012). Some progress in this area
has been made by Carles-Kinch et al. who have developed antibodies that target the
extracellular domain of EphA2 in breast cancer cells. These monoclonal antibodies were able
to increase EphA2 phosphorylation and degradation (Carles-Kinch et al. 2002). Another
monoclonal antibody against EphA2 called 1C1 used in vivo has been shown to also increase
receptor phosphorylation and internalization as well as stimulating cell death and reducing
tumour cell proliferation (Jackson et al. 2008).
Furthermore, two EphB4 specific monoclonal antibodies have been tested on xenograft
tumours. These antibodies targeted the extracellular fibronectin-like domain regions of
EphB4 with one decreasing tumour growth by degrading EphB4 and the other inhibiting
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angiogenesis and increasing apoptosis in the tumours (Krasnoperov et al. 2010). These
antibodies have also been used to detect and target EphB4 positive tumours (Li & Zhao, 2013).
Thus, monoclonal antibody therapy is a useful method for specifically inhibiting signaling
pathways initiated by Eph receptors in tumours and can be further developed for therapeutic
use.
Soluble receptors and ligands
Another method to manipulate the EphB4-ephrin-B2 interaction is through the use of soluble
ligands to initiate signaling events which lead to tumour suppressive mechanisms being
activated. In my recently published paper we reported that the stimulation of EphB4-positive
cells with ephrin-B2 clustered with anti-Fc specific antibody (Figure 1.5) decreased cell
proliferation (Rutkowski et al. 2012). Similar results have been reported with ephrinA1
stimulation down regulating the EphA2 expression on tumour cells and initiating anti-
oncogenic effects including caspase-dependent apoptosis of the tumour cells (Wykosky et al.
2007). Noblitt et al. also suggested a means of utilising adenoviral vectors to express soluble
ligands to directly use this therapy against tumour cells (Noblitt et al. 2004). In their study,
ephrinA1 was over-expressed from a human adenoviral type 5 vector. This caused signigicant
increases in EphA2 activation and subsequent degradation which decreased tumour cell
anchorage independent growth as well as preventing the formation of tumours in a xenograft
model (Noblitt et al. 2004).
The EphB4 receptor itself can also be utilised in therapy. For example, a study by Noren et al.
stimulated tumour xenografts with a kinase-defective form of the EphB4 receptor, with no
forward signalling ability, and found that this was able to increase the growth of these
tumours through increased recruitment of endothelial cells, which in turn increased
angiogenesis, survival and proliferation in the tumour (Noren et al. 2004). Also, it has been
found that the addition of a soluble form of the extra-cellular domain of EphB4 to tumour
cells was able to prevent EphB4-ephrin-B2 interaction which inhibited the angiogenic effects
usually initiated by this signalling event (Kertesz et al. 2006). The use of soluble forms of both
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EphB4 and ephrin-B2 can thus be used effectively in blocking the tumourigenic effects of Eph-
ephrin signalling mechanisms.
Small molecule inhibitors and agonists
The use of small molecule drugs is another potential option being investigated for their ablility
to inhibit EphB4 signalling by blocking tyrosine kinase activity and preventing
autophosphorylation (Sonpavde et al. 2006; Gallick et al. 2012). A number of small molecule
inhibitors that specifically target EphB4 are also being developed, including  tyrosine kinase
inhibitors (Miyazaki et al. 2007; Pietanza et al. 2012) and an inhibitor which blocks the ATP
binding pocket of EphB4 (Martiny-Baron et al. 2010).
Another group of benzoic acid
based molecules have found use as
inhibitors of EphA2 and EphA4
ligand binding activity, preventing
ligand-dependent phosphorylation
and subsequent signaling.
Molecules that inhibit ligand
binding to Eph receptors may be
used in therapies where receptor
activation is involved in the
progression of disease (though not
in cancer) (Noberini et al. 2008)
(Figure 1.5).
Another study found small molecule
agonists of EphA2 and EphA4 through in silico techniques that interact with the extracellular
domain of the receptors. One of the agonists identified was doxazosin, which has been
marketed by Pfizer as an α1 adrenergic receptor blocker used to alleviate high blood pressure
and urine retention in patients with benign prostate hyperplasia (BPH). It was found that
Figure 1.5: Eph receptors treated with soluble ligand and
small molecule inhibitors
Schematic diagram illustrating a) the Eph receptor signaling
complex being stimulated with soluble ephrin ligand clustered
with α-Fc antibody and b) small molecule inhibitors preventing
binding of ligand to the receptor complex.
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doxazosin was able to block EphA2 and EphA4 activity through inhibition of Akt and ERK
kinase pathways (Petty et al. 2012). In an in vivo mouse model, doxazosin was shown to
reduce metastasis of prostate tumours and increase the survival of the mice in the study by
preventing ligand binding through interaction with the extracellular domain of the EphA2
receptor (Petty et al. 2012). This was further supported by a previous study which indicated
that doxazosin initiated cell death in LNCaP prostate cancer cells (Arencibia, 2005). These
studies indicate the potential of small molecule agonists in blocking Eph-ephrin signaling and
thus their use a novel therapeutics in treating prostate cancer.
EphB4 as an imaging agent for prostate cancer
The Eph receptors have also been investigated as potential tumour imaging agents where
antibodies against the receptors can be utilized to visualize prostate tumours. One such study
used positron emission tomography (PET) along with an EphA2 antibody labeled with copper
molecules to visualize EphA2 positive tumour models (Cai et al. 2007). Vearing et al.
performed a similar study where they tested the use of EphA3 antibody labeled with
111Indium for imaging tumours expressing EphA3 with a gamma ray camera (Vearing et al.
2005). Finally, a group has also labeled an EphB4 specific kinase inhibitor with fluorine-18
radiotracers and used PET to image tumours (Mamat et al. 2012). These studies show that
these receptors have great potential and value in the prostate tumour imaging field as they
can be specifically bound by imaging agents.
Eph receptors as biomarkers
Biomarkers are molecules which can identify the presence of cancer in a body (e.g. PSA levels
in blood can be predictive of prostate cancer) and can be used to isolate specific cells from
fluid obtained from patients. This is particularly useful in prostate cancer therapies where
patient urine and blood can be relatively non-invasively analysed for markers of cancer.
Currently these fluids are tested for Prostate Specific Antigen levels, but research is being
conducted to also screen these samples for circulating tumour (CTC) cells (cells that have shed
from primary tumours and often migrate to distant organs and form secondary tumours) and
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exosomes (small vesicles secreted by cells which have been correlated with increased
metastatic risk; these are discussed in the following section (Mitchell et al. 2009)).
Currently, density centrifugation (which isolates CTCs based on their specific density) and
magnetic beads coupled to antibodies to antigens specifically expressed by tumour cells are
employed to recognize and isolate these cancerous cells (Pantel & Alix-Panabières, 2012).
These and other techniques have been clinically trialled by a number of research groups (Alix-
Panabières et al. 2005; Nagrath et al. 2007; de Bono et al. 2008), but specific prostate tumour
markers which are expressed at high levels on CTCs compared to normal tissue still need to
be identified (Kruck et al. 2012).
EphB4 is highly over-expressed in many cancers including in prostate tumours and as such
would lend itself well to being a diagnostic and prognostic biomarker. EphB4 and ephrin-B2
signalling plays a role in bone development and homeostasis, but when the normal function
of this signalling network is disrupted, such as in cancer, it can lead to deregulation of the
bone environment allowing for tumour formation in the bone, often resulting in bone
degradation (Zhao et al. 2006). Thus, identifying EphB4-positive circulating tumour cells in
prostate cancer patients could significantly increase the chance of survival by detecting the
cancer before bone metastasis occurs. Recently, immuno-magnetic beads coupled with
EpCam (epithelial glycoprotein) recognising antibodies have been used to detect cancer
tumour cells. Using sensitive RT-PCR assays, to identify expression of markers including
EphB4, the researchers were able to isolate a single tumour cell from 100 peripheral blood
mononuclear cells as well as identify circulating tumour cells from patient peripheral blood
(Raynor et al. 2002; Raynor et al. 2009; Winter et al. 2009). Further developing these
techniques, as well as identifying novel CTC identification methods could lead to earlier
diagnosis of cancers which can significantly increase survival rates of patients.
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1.1.6 The role of exosomes in cancer
Introduction
Exosomes are small membrane vesicles of approximately 30-100 nm that are secreted into
the extracellular environment from a variety of cells including neural, epithelial, immune,
muscle, stem and hematopoietic cells (Denzer et al. 2000a; Keller et al. 2006; Krämer-Albers
et al. 2007; Lachenal et al. 2011). Exosomes are formed through a complex endosomal
pathway which may have a number of stimulating factors which are cell dependent. The
formation of exosomes begins at the cell plasma membrane, where the molecular cargo is
encapsulated though inward budding of the membrane. These internal vesicles are sent to
the endosome for sorting and then grouped together to form larger bodies called
multivesicular bodies (MVBs). The endosome then directs the MVBs either to the plasma
membrane where they are exuded from the cell as exosomes, or to the lysosome for
degradation (Février & Raposo, 2004; Théry 2011).
First discovered over 30 years ago, they were considered to be only involved in discarding
unwanted or excess molecular components, such as the removal of the transferrin receptor
in reticulocytes (Harding et al. 1983; Pan & Johnstone, 1983; Denzer et al. 2000a). However,
over the years exosomes have been shown to be involved in intercellular communication,
immune system regulation, cancer progression and removal of excess proteins, among other
varied actions suggesting that exosomes may play an important role in homeostasis (Février
& Raposo, 2004; Théry 2011). Studies into exosomes and their function have increased
dramatically over the last decade as new roles for these vesicles have been discovered.
Definition of exosomes
Cells commonly release vesicular structures for signalling functions through exocytosis, which
can be triggered by a number of mechanisms including transformation, cell stress, cell death
and signalling factors (Keller et al. 2006; Rak, 2010). These microvesicles can be exuded from
the plasma membrane (shed membrane vesicles), produced through the endosomal pathway
(exosomes) or form from apoptotic blebs during cell death (Rak, 2010). These various vesicles
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are distinguished by their biogenesis and origin, their morphology and their biochemical
contents and as such, various interchangeable terms have been used to describe them
including exosomes, tumour vesicles, cellular vesicles, shedding vesicles, microvesicles,
microparticles, ectosomes, oncosomes, and prostasomes (Pilzer et al. 2005; Johnstone, 2006;
Krishnan & Sprott, 2008; Cocucci et al. 2009; Rak, 2010).
Specifically, apoptotic vesicles form during apoptosis through fragmentation and membrane
blebbing. These vesicles contain components which can be utilised and recycled by
surrounding cells (Bergsmedh et al. 2001; Ehnfors et al. 2009). Microvesicles, on the other
hand, are formed by viable cells through outward blebbing of the plasma membrane often
corresponding with the activation of transformation (Pilzer et al. 2005; Johnstone, 2006;
Simak & Gelderman, 2006). This produces vesicles of 100 nm to 1000 nm in diameter (Pilzer
et al. 2005; Cocucci et al. 2009). These vesicles usually contain high amounts of flotilin-1
suggesting that they form in lipid raft regions of the plasma membrane (Del Conde et al. 2005;
Yu et al. 2005). Finally, exosome formation is a different form of vesiculation as it occurs
through the endosomal pathway rather than directly through the manipulation of the plasma
membrane (Williams & Urbe, 2007). Initially, target cargo proteins are recruited from the
plasma membrane and directed to the endosome, where they are packaged into vesicles and
then grouped together into multivesicular bodies. These bodies then fuse with the plasma
membrane and release their contents as exosomes (Rak, 2010).
The identifying features of exosomes are their morphology and biochemical cargo. They are
of small size (30-100 nm) and as such transmission electron microscopy is best used to
visualise these vesicles where they are described as round and often with an indentation to
form a cup shape (due to the negative staining) (Figure 1.6). The cargo of exosomes is cell
type specific, but is usually enriched for common markers such as tetraspanins, as well as
components of the sorting machinery such as TSG101 and Alix (Février & Raposo, 2004;
Gastpar et al. 2005; Johnstone 2006; Zoller, 2009; Théry 2011; Witwer et al. 2013).
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Figure 1.6: Electron microscope view of exosomes from prostate cells
TEM images of negatively stained exosomes from various prostate cancer cell lines including PC3, DU145, VCaP,
LNCaP, C4–2 and RWPE-1. Exosomes are cup shaped vesicular bodies and are 30-100 nm in size (From Hosseini-
Beheshti et al. 2012).
Exosome purification
Due to the many types of vesicles released by cells, a method of extracting and purifying
exosomes is required to achieve a pure and specific sample for study (Mathivanan et al. 2010).
Exosome isolation is confirmed through examining the size, morphology and flotation density
of the exosomes as well as confirming the presence of marker proteins such as TSG101, Alix,
HSP70 and CD9 (Simpson et al. 2009).
Currently there are three commonly used methods for isolating exosomes from cell media:
ultracentrifugation, density gradient centrifugation, and immune-affinity isolation (using anti-
EpCAM-coated magnetic beads). A comprehensive evaluation these methods was conducted
by Greening et al. and found that although all three methods are useful for isolating
exosomes, immune-affinity isolation was the most effective method. However, this method
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is specific and requires more resources than the other techniques (Greening et al. 2015; Lobb
et al. 2015).
Exosome purification through ultracentrifugation is a simpler process, requiring less
resources, while still effectively isolating exosomes. It involves the sequential centrifugation
of exosomes from the cell medium (Théry et al. 2001; Ji et al. 2008; Mathias et al. 2009;
Vlassov et al. 2012, Witwer et al. 2013). If the starting medium is a viscous liquid such as
plasma then a dilution step is first required as well as an increase in centrifugal time and speed
in order to purify the exosomes (Tauro et al. 2012).
The cellular cargo of exosomes
Exosome cargo is cell type specific and is related to the function of the cells. The majority of
exosome cargo originates from the plasma membrane, the exocytic pathway, or the cytosol
though small amounts of proteins and lipids are targeted from their intracellular
compartments (Théry, 2011).
Studies have shown that exosomes contain cell specific cargo that is grouped into specific
protein family sets rather than being a random collection of molecules. It has been reported
that exosomes can contain enriched amounts of lipids as well as a number of protein families
including heat shock proteins (Hsp70, Hsp90), tetraspanins (CD9, CD63, CD81, CD82) and
signal proteins including members of the Rab family, G-proteins and kinases (Gastpar et al.
2005; Keller et al. 2006; Zoller, 2009). Exosome markers including TSG101, Alix and flotillin
(Lee et al. 2011) are common to many exosomes because they play an important role in their
biogenesis. Specifically, TSG101 and Alix are part of the conserved Endosomal Sorting
Complexes Required for Transport (ESCRT) machinery which sorts ubiquitinated proteins into
exosomes (Katzmann et al. 2002; Raiborg et al. 2003); whereas flotillin is a membrane protein
commonly associated with lipid rafts and is found in exosomes along with other membrane
components including cholesterol, tubulin, actin and stomatin (de Gassart et al. 2003; Mobius
et al. 2003; Keller et al. 2006). Exosome cargo consists of a limited subset of proteins from the
cytoplasm, exocytic pathway and plasma membrane of cells, with proteins originating in the
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nucleus, endoplasmic reticulum, Golgi apparatus and mitochondria not appearing in exosome
preparations (Mears et al. 2004).
Recent studies have also identified the presence of viruses (Azmi et al. 2013) and nucleic acids
including mRNA, microRNA and DNA within exosomes (Valadi et al. 2007; Pisetsky et al. 2010;
Witwer et al. 2013; Azmi et al. 2013); however, it is still unclear how these nucleic acids are
sorted into the exosomal vesicles though it is suggested that this may be due to RNA binding
properties of components of the ESCRT machinery which may encapsulate RNA during
exosome formation (Raposo & Stoorvoge, 2013).
Another study has shown that exosomes could transfer this genetic material between cells as
the nucleic acids in the exosomes were functional and could be translated into proteins in
target cells (Valadi et al. 2007). Although there are commonalities between exosomal cargos,
the majority of proteins, lipids and nucleic acids is cell context dependent and varies greatly
between exosomes. In fact, an online database of exosome cargo called Exocarta has
catalogued a vast variety of over 4500 different proteins, 2300 mRNA and 700 miRNAs
identified in exosomal cargo as of February 2014 collected from 146 published studies
(Simpson & Mathivanan, 2012; Azmi et al. 2013). This shows the vast number of potential
targets that are involved with and carried by exosomes further signifying the importance of
exosomes in cancer research.
Once exuded by the host cell, the exosomal cargo carried by these vesicles can be delivered
to neighbouring cells and can instigate signalling events and stimulate the cell either through
interaction of the exosomes with surface receptors on the target cells (de Gassart et al. 2003),
or through direct fusion with the cell membrane and delivery of the protein and nucleic acid
cargo into the cell (Miranda et al. 2010; Balaj et al. 2011; Peinado et al. 2012).
Biogenesis of exosome
Exosomes are formed through a complex cellular process involving a number of pathways.
The predominant mechanism involved in exosome biogenesis is the endosomal sorting
complex required for transport, or ESCRT, which has four distinct complexes conserved by all
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eukaryotes, ESCRT-0, ESCRT-1, ESCRT-2 and ESCRT-3 (Williams & Urbe, 2007; Simons &
Raposo, 2009). The initial formation process involves the inward budding of the plasma
membrane in lipid rich regions into clathrin coated pits which then form into early endosomes
within the cell. These early endosomes then bud internally to produce vacuoles called
intraluminal vesicles (ILVs) containing the internalised proteins in their same orientation as
the whole cell (due to the double invagination, first of the extracellular domain then of the
ILVs) (Théry et al. 1999; Pant et al. 2012). These ILV vacuoles in turn group together to form
multivesicular bodies (Denzer et al. 2000a; Lee et al. 2001; Murphy et al. 2009).
The vesicles containing the internalised cargo can at this stage be returned to the membrane;
degraded by existing lysosomes; or expelled from the cell as exosomes (Figure 1.7) (Johnstone
et al. 1991; Blume-Jensen & Hunter, 2001; Pilzer et al. 2005; Sherer & Mothes, 2008; Théry et
al. 2009). One function of lysosomal degradation of the MVBs is allowing cells to regulate the
amount of proteins being expressed by removing unnecessary cell surface proteins and
membranes from the cell. An example of this is the down regulation of the epidermal growth
factor receptor (EGFR), which is degraded after ligand stimulation (Futter et al. 1996; Bishop
et al. 2002; Keller et al. 2006). Exosome release from cells is thought to have many purposes
including cell to cell communication, the transfer of cellular components between cells, and
cell type specific functions (Stoorvogel et al. 2002; Théry, Zitvogel & Amigorena, 2002; Keller
et al. 2006).
The fate of the cellular cargo is mediated by the presence of ubiquitin where proteins tagged
with mono-ubiquitin are sorted by the ESCRT mechanism into intraluminal vesicles (ILVs)
which are then either degraded in lysosomes or collected and packaged into exosomes. The
exact process which determines the fate of proteins is still relatively unknown, though it is
thought to be determined by the level of ubiquitination of a protein which is sorted by the
ubiquitin binding components of ESCRT-0, ESCRT-1 and ESCRT-2. The sorting of nucleic acid
cargo into exosomes is thought to mediated by the ESCRT-2 complex which can bind RNA
directly (Irion & St, 2007; Williams & Urbe, 2007; Hurley & Hanson, 2010; Lee et al. 2011). The
final component of the ESCRT machinery, ESCRT-3, removes ubiquitin (using the enzyme
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Doa4) from the tagged proteins before transferring the cargo into ILVs (Amerik et al. 2000;
Williams & Urbe, 2007).
However, recent studies have also revealed a subset of exosomes that are produced and
released independent of the ESCRT machinery (Raposo & Stoorvoge, 2013) as a study showed
that when all four subunits of the ESCRT complex were removed from cells, exosomes were
still able to be released (Stuffers et al., 2009). Mechanisms for this have been proposed
utilising ceramide, a cone shaped lipid that may be involved in the encapsulation process
(Pant et al. 2012; Urbanelli et al. 2013). Other studies have shown that exosome biogenesis
relies on the sphingomyelinase enzyme which produces ceramide (Trajkovic et al. 2008). This
method of ceramide based release is yet to be fully understood, but may provide a new
pathway for targeting the mechanisms of exosome formation and release.
Exosome Release and Uptake
Exosome release from cells is thought to be influenced by a number of mechanisms, including
the p53 pathway, which regulates maspin and TSAP6 expression. These in turn, induce the
release of exosomes containing these two proteins in vitro (Yu et al. 2006). Rab proteins
(Rab3, Rab11, Rab27, Rab35) have also been implicated in exosome release (Azmi et al. 2013),
as have calcium levels, cholesterol levels and membrane pH (Jaiswal et al. 2002; Savina et al.
2002; Tolmachova et al. 2004; Stoeck et al. 2006; Llorente et al. 2007; Hosseini-Beheshti et al.
2012; Azmi et al. 2013).
The mechanism for the fusion and uptake of exosomes by target cells is not well understood,
but studies have been conducted to understand these processes. Recent findings have shown
that calcium levels, potassium ion levels and oligodendrocytes may all play roles in exosome
release (Urbanelli et al. 2013), whereas the fusion of exosomes with target cells may be
dependent on a number of factors including the presence of certain molecules including
tetraspanins and integrins (Raposo & Stoorvoge, 2013).
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Exosomes that reach neighbouring (or distant) target cells can facilitate the exchange of
exosomal cargo with the cell and induce cell-to-cell communication. This can occur through a
number of mechanisms including: activating signalling partners by the interaction of exosome
receptors to their cell bound ligands
(without internalisation); the cleavage
of exosome bound receptors which
then are free to interact with cell
surface ligands (again without
internalisation); the fusion of
exosomes with the cell membrane and
the subsequent release of exosomal
cargo into the target cell cytoplasm;
and finally the internalisation of
exosomes through endocytocis which
again releases the contents of the
exosomes within the target cell
(Urbanelli et al. 2013).
The function of exosomes
Current research suggests that
exosomes play an important role in
intercellular communication
(Stoorvogel et al. 2002; Théry, Zitvogel
& Amigorena, 2002); however it is
unknown how exosomes directly
target and interact with their neighbouring cells. Several hypotheses have been suggested;
including the incorporation of exosomes into the target cell through endocytocis (Figure 1.7F),
or alternatively, the direct fusion of the exosomes to the target cell plasma membrane and
the subsequent release of exosomal cargo into the cell (Figure 1.7G). It has also been
Figure 1.7: Exosome formation and transport
A. The host cell membrane buds into the cell forming an
early endosome containing membrane bound proteins (red
dots). B. Intraluminal vesicles (ILVs) are formed through
early endosomal internal budding and contain proteins (now
orientated to their original position with the extracellular
domain facing out), lipids and nucleic acids. C. ILVs collect
together to form multivesicular bodies (MVBs). D.MVBs can
be targeted for degradation by fusing with the lysosome. E.
Alternatively, the MVBs can fuse with the plasma
membrane, releasing the intraluminal vesicles as exosomes.
F. Exosomes can travel to neighbouring cells were they can
be incorporated into the target cell through endocytocis. G.
Exosomes can interact with target cells by means of
exosome bound signaling proteins and receptors or they can
fuse directly with the plasma membrane of target cells,
releasing their contents into the cytoplasm.
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proposed that exosomes may bind to the target cell membrane and communicate with the
cell through surface receptors, without actually entering the cell (Denzer et al. 2000b; Février
& Raposo, 2004). It is thought that exosomes interact with cells through complementary
surface receptors expressed by both the target cell and the vesicles, initiating signalling that
causes the endocytic internalisation of the exosomes and the release of their content directly
into the cytoplasm, which can further impact the target cell (Théry, 2011).
Exosomal transfer of proteins and nucleic acids is unique in that it allows for the transport of
a large variety of cell specific molecules at one time, including insoluble cargo as well as
molecules in their intact and active state. As such, cargo like receptor proteins and mRNA can
leave the cell in its natural working conformation, with all post-translational modifications
intact (Ratajczak et al. 2006b; Skog et al. 2008; Al-Nedawi et al. 2009). In vitro studies have
shown that the exosomes can transfer protein, lipid and nucleic acid cargo to neighbouring
cells. For example, antigen presenting dendritic cells release exosomes which contain multi
histocompatibility complexes (MHCs), which are taken up by other cells and increase the
effectiveness and range of the immune response, and in the case of T cells, increase their
proliferation (Raposo et al. 1996; Zitvogel et al. 1998; Wolfers et al. 2001; Théry et al. 2002;
Théry, 2011).
A study by Théry et al. in 2002, reported that antigen peptide bearing exosomes were able to
activate naive CD4+ T cells in vivo and the exosomes were also able to transfer MHCs between
dendritic cells and increase the primary adaptive immune response (Théry et al. 2002). Other
studies have reported that mesenchymal cells secrete exosomes which aid in tissue repair,
lung cells produce exosomes which stimulate differentiation and neural cells express
exosomes which stimulate other neural cells (Théry, 2011). Together, these studies highlight
the role of exosomes as intercellular messengers and transport vesicles and research is
underway how to best utilise these mechanisms for therapeutic use.
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Biological significance of exosomes in cancer
Cancer cells have been reported to have higher rates of vesicle release, including exosome
secretion, and many of the components of these exosomes and their cargo have been
associated with tumour growth and progression (Dolo et al. 2005; Ratajczak et al. 2006; Al-
Nedawi et al. 2009; Lee et al. 2011). As such, it is hypothesised that tumour cell exosome
production increase cancer cell growth through stimulation of proliferation and angiogenesis,
while reducing immune responses that would negatively impact tumour progression. It has
also been suggested that tumour cell released exosomes can be transported to distant sites
where they establish premetastatic niches (environments with conditions ideal for increased
tumour growth) thus allowing tumours to metastasise to secondary sites (Kaplan et al. 2005;
Jung et al. 2009; Théry, 2011; Alderton, 2012).
Establishing the premetastatic niche
Tumour metastasis can be propagated by cancer initiating cells (CICs) which help establish
suitable micro-environments in premetastatic regions for tumour growth and spread. This
relatively small population of cells communicates over large distances in order to establish
tumour favourable niches (Li et al. 2007a; Yilmaz et al. 2007; Alix-Panabières et al. 2008;
Bidard et al. 2008; Werbowetski-Ogilvie & Bhatia, 2008). The premetastatic niche is initiated
in part by exosome release from the tumour. These vesicles are able to influence the
formation of the microenvironment necessary for tumour growth and affect tumour
initiation, metastasis and angiogenesis (Ratajczak et al. 2006b; Deregibus et al. 2007; Al-
Nedawi et al. 2009; Castellana et al. 2009; Jung et al. 2009).
A recent study by Jung et al. has reported that exosomes released from pancreatic tumour
cells worked in conjunction with CICs expressing CD44 (a protein involved in cell to cell
adhesion and interaction that has also been linked to breast and prostate cancer) to establish
a premetastatic niche in distant organs which increased successful secondary metastasis and
tumour survival (Jung et al. 2009). Another recent study, by Alderton in 2012, found that
exosomes from metastatic cells were able to enter the circulation and travel to common
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metastatic sites including the lungs, liver, spleen and bone marrow, which increased the
tumour burden in a mouse model and supported metastasis by creating a suitable
environment for tumour growth (Alderton, 2012).
Cancer progression and metastasis
Exosomes have been shown to increase proliferation, angiogenesis, metastasis, invasion and
survival in tumour cells, thus progressing the cells to a more aggressive cancer (Janowska-
Wieczorek et al. 2005; Ratajczak et al. 2006; Di Vizio et al. 2009; Jung et al. 2009; Lima et al.
2009; Rak, 2010). Exosomal cargo can also include immunosuppressive antigens which
inactivate natural killer cells thereby limiting an immune response against the cancer (Théry,
2011). Exosome based signalling has also been implicated in cell differentiation, where one
study reported that microvesicular mRNA transmitted from embryonic stem cells was able to
trigger gene expression leading to the differentiation of hematopoietic progenitors (Ratajczak
et al. 2006).
Exosome release can be triggered by the oncoprotein EGFR, which is then transported out of
the cell in its active state by the released vesicles and is able to be transported to other
neighbouring cells where it can stimulate signalling pathways such as MAPK and AKT, inducing
gene expression and regulating cell propagation, colony growth and survival (Al-Nedawi et al.
2008; Al-Nedawi et al. 2009). Other studies have also found that exosomes containing EGFR
were able to activate proliferation of glioma cells (Sanderson et al. 2008; Skog et al. 2008).
Tumour vascularisation
Tumour derived exosomes have been linked to blood vessel formation and regulation as they
often carry important angiogenic factors including growth factors and cytokines as well as
mRNA which can induce vascularisation (Kim et al. 2004; Janowska-Wieczorek  et al. 2005;
Gesierich et al. 2006; Deregibus et al. 2007; Al-Nedawi et al. 2009; Aoki et al. 2010). A large
variety of cells, including cancer initiating cells, fibroblasts and endothelial cells, work
together through complex signalling networks during angiogenesis (Carmeliet, 2000; Kerbel,
2008).
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Endothelial cells can fuse with exosomes carrying neovascularisation signal molecules and
mRNA, activating an angiogenic response in the cells and initiating blood vessel formation
(Deregibus et al. 2007; Skog et al. 2008; Al-Nedawi et al. 2009). It has also been suggested
that tumour cells may be able to increase blood vessel growth through coordinated exosome
release, as this would affect a higher number of neighbouring cancer cells. As cancer cells are
often bounded by stromal cells which can block angiogenesis signals to the tumour mass,
releasing a large amount of exosomes would allow the tumour cells to amplify vascularisation
signals and overcome the inhibitory effects of the surrounding stromal cells (Rak et al. 2000;
Al-Nedawi et al. 2008; Rak, 2010).
Anti-cancer effects
The role of exosomes secreted by tumour cells is not currently well understood and there has
been some conflicting hypotheses suggesting that exosomes may also play a tumour
suppressive role. For example, studies on mice have reported exosomal mediation of the
immune system through antigen presentation (as part of their cargo) to cytotoxic T cells which
initiate an anti-tumour response and limit tumour growth (Andre et al. 2002; Escudier et al.
2005; Taylor & Gercel-Taylor, 2005; Valenti et al. 2007). Exosome cargo also includes
microRNA (miRNA) which is known to have both cancer promoting and cancer inhibiting
functions depending on the genes they affect. As such, the exosomal transfer of miRNA to
neighbouring cells may in fact aid in reducing tumour growth and spread (Valadi et al. 2007;
Skog et al. 2008; Gibbings et al. 2009).
Exosomes have also been shown to carry other tumour suppressive proteins, antigens and
other immune response elements, as well as proteins regulating angiogenesis, apoptosis,
adhesion and proteolytic cleavage, which in some cases may work to stem cancer progression
(Maass et al. 2000; Baj-Krzyworzeka et al. 2002; Gasser & Schifferli, 2004; Minetti et al. 2004;
Yu et al. 2006; Coren et al. 2008; Sbai et al. 2008; Perez-Casal et al. 2009). However, as
exosomal cargo is cell specific, their function can be flexible and as such, the most commonly
held hypothesis is that exosomes can both stimulate and repress tumour growth depending
on the cellular context (Rak, 2010).
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Exosomes as cancer biomarkers
Detection of exosomes isolated from body fluids such as blood, urine and seminal fluid may
be a novel method of non-invasive cancer prognosis as exosomes can be easily obtained and
assayed for common cancer related biomarkers (Tesselaar et al. 2007; Al-Nedawi et al. 2008;
Witwer et al. 2013). For example, the presence of the oncogene EGFRvIII was detected in
glioma cell derived exosomes collected from patient blood (Al-Nedawi et al. 2008; Graner et
al. 2009). Thus the analysis of molecules contained in exosomes released by tumour cells may
yield vital information on biomarkers for diagnosis and targets for treatment of these deadly
diseases (Rak, 2010; Witwer et al. 2013).
Identifying new cancer biomarkers is an important step in detecting and treating cancer, and
as such several studies have investigated the presence of the cancer related family of Eph
receptors and ligands, the ephrins, in exosomes originating from cancer cells. Proteomic
analysis of proteins and peptides contained in exosomes isolated from a variety of cancer cells
have identified many members of the Eph family and their ligands to be present in these
vesicles including EphA2 - EphA8; EphB1 - EphB4; and ephrinB1 and ephrin-B2 (Simpson &
Mathivanan, 2012; Tauro et al. 2012).
A recent study has also identified ephrinA2 to be present in exosomes expressed by PC3
prostate cancer cells (Sandvig & Llorente, 2012), while a study by Jansen et al., also in PC3
cells, identified important prostate cancer proteins within exosomes, including ADAM10, a
protease known to cleave ephrin; Kallikrein-3 (KLK3) otherwise known as Prostate Specific
Antigen (PSA) a common marker of prostate cancer; and Thrombospondin-1, a secreted
protein involved in cell to cell communication, angiogenesis and tumourigenesis, with links to
EphB4 and ephrin-B2 expression (Janes et al. 2005; Jansen et al. 2009; Avouac et al. 2011).
However, no reports have yet been published identifying the EphB4 receptor in prostate
cancer derived exosomes.
The function and mechanism of action of exosomes and other microvesicles released by cells
are not yet fully understood, however it is plainly seen that they are involved in modulating
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many cellular processes and affect many signalling pathways, including those related to
cancer progression and metastasis. As such, research into these vesicles is now increasing
dramatically as their importance is being realised.
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1.2 Preliminary Work
As discussed in the literature review above, overexpression of the EphB4 is common in
epithelial cancers and has been linked to tumour progression as well as tumour suppression
pathways. These functions were hypothesised to be mediated by the absence or presence of
the ephrin-B2 ligand. This theory was explored as part of my research work completed during
my Honours degree and this laid the ground work for the research presented in this thesis.
The salient points of the work undertaken are summarised below. Full details are provided in
the published report (Rutkowski et al. 2012) located in Appendix 2 - Preliminary work from
Honours project.
1.2.1 Key Results
Characterization of the 22Rv1-B4 EphB4 overexpressing cell line
The  22Rv1  cells  were  constructed  to  overexpress EphB4 (22Rv1-B4) and these 22Rv1-B4
cells, along with those containing the empty vector (22Rv1-VO), were subjected to Western
immunoblotting (Figure 1.8A) and immunofluorescence (Figure 1.8B) to confirm that
exogenous EphB4 is expressed in the stably selected polyclonal populations. 22Rv1-B4 cells
strongly expressed EphB4 on the cell surface with specific staining being associated with the
plasma membrane. The vector only (VO) and wild type (WT) control cells displayed only very
low immunoreactivity for EphB4.
Transmembrane proteins often localise to lipid rafts, which have been implicated as signalling
hubs (Patra, 2008). To determine whether this was the case with EphB4, lipid raft fractions
were prepared and analysed by Western blotting analysis (Figure 1.8C). Immunoreactivity to
the EphB4 protein was mostly seen in fractions 1 and 2, which corresponded to the fractions
that contained a high-lipid concentration as evidenced by the presence of flotillin, an
independent marker of lipid rafts.
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Figure 1.8 Characterization of exogenous overexpression of EphB4.
A. 22Rv1 prostate cancer cells were transfected with pIRES-Neo2 containing EphB4 (B4) or the empty vector (VO) and
analyzed using immunoblotting for EphB4. There was an increase in EphB4 expression after stable transfection of both cell
lines. B. Localization of EphB4 in 22Rv1-overexpressing cells. Immunofluorescent staining of EphB4 (green) reveals localization
of EphB4 on the surface of 22Rv1-B4 cells with little immunoreactivity seen in WT and 22Rv1-VO-transfected cells. Background
controls shown are: mouse IgG control; secondary antibody only; and no antibodies. Cell lines were co-stained for F-actin
using phalloidin (red) to visualize the cytoskeleton and DAPI to visualize nuclei (blue). C. Lipid-raft preparations and
immunoblotting showed that EphB4 was present in high lipid-containing membrane fractions 1 and 2. Flotillin was used as a
lipid raft marker.
Confirmation of overexpressed EphB4 functionality
To determine whether the overexpressed EphB4 was functional and responded to stimulation
with its ligand, clustered ephrin-B2/Fc (eB2/Fc) was added to the 22Rv1-B4 cells for 15 min,
before immunoprecipitation of phosphorylated proteins using the 4G10 platinum antibody
and an EphB4-specific antibody. As expected, significant phosphorylated EphB4 was detected
in the cells treated for 15 min with the clustered soluble ephrin-B2/Fc, with little
A C
B
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phosphorylation detected in the cells treated with clustering antibody (Fc) alone and no
phosphorylation in untreated samples (Figure 1.9A).
Immunofluorescence was used to determine the localization of EphB4 in 22Rv1-B4 cells after
stimulation with ephrin-B2. EphB4 protein was internalized and appeared in punctuate foci
15 min after addition of soluble ephrin-B2/Fc (Figure 1.9B). Ligand stimulation of 22Rv1-B4
cells also resulted in activation of extracellular-signal-regulated kinase1/2 (ERK1/2) with
phosphorylation levels markedly higher than in VO cells (Figure 1.9C). Extended stimulation
of 22Rv1-B4 cells for 24 hr, 72 hr and 11 days resulted in a decrease in EphB4 protein
confirming that degradation is a consequence of internalization after ligand stimulation
(Figure 1.9D).
Figure 1.9. Overexpressed EphB4 responds to ephrin-B2.
A. EphB4 is phosphorylated after addition of ephrin-B2: 22Rv1-B4 cells were treated with 2 µg/ml soluble
clustered ephrin-B2/Fc (eB2/Fc), clustering antibody (Fc only) or left untreated for 15 min followed by
immunoprecipitation using a 4G10 platinum phosphotyrosine antibody (IP: pTYR) followed by immunoblotting
for EphB4 (IB: EphB4). A duplicate sample was immunoprecipitated using an EphB4 (IP: EphB4) antibody followed
by immunoblotting for EphB4 to assess protein input. B. EphB4 is internalized in response to its ligand:
Immunofluorescent staining of EphB4 after treatment of 22RV1-B4 cells with Fc alone (i) or soluble clustered
ephrin-B2/Fc (ii) for 15 min shows internalization of EphB4 after ligand addition. C. ERK1/2 is activated after
addition of ligand: Treatment of 22RV1-B4 cells (B4) or VO control cells with clustered ephrin-B2/Fc (5–60 min)
led to phosphorylation of ERK1/2 (p-ERK1/2). D. EphB4 protein degrades after 24 hr, 72 hr and 11 days of ligand
stimulation: 22Rv1 cells were stimulated with 2 µg/ml soluble clustered ephrin-B2/Fc (eB2) or Fc alone and EphB4
protein expression was assessed using immunoblotting. GAPDH was used as a loading control. In both 22Rv1-VO
and-B4 treated cells, EphB4 is markedly decreased.
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EphB4 enhances cell migration, invasion and anchorage-independent growth, but ephrin-
B2 reverses these effects
The effects of overexpression of EphB4 on the migratory, invasive and anchorage-
independent growth ability of 22Rv1 cells was examined. The cells showed a significant
increase in migration as determined by a scratch wound monolayer assay (Figure 1.10A); a
significant increase in colony growth and size as determined by a soft agar assay (Figure
1.10B); and a significant increase in cell invasion as determined using the Xcelligence system
(Figure 1.10C). It was also determined that treatment with ephrin-B2 reversed these effects.
These results demonstrated that EphB4 expression is sufficient to convert a non-transformed
cell line into an invasive and migratory phenotype, and addition of ephrin-B2 ligand reverses
this, initiating tumour suppression pathways in EphB4 overexpressing cells.
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Figure 1.10. EphB4 overexpression enhances migration and invasion, ephrin-B2 suppresses this effect
A. Confluent monolayers of 22Rv1-B4 or -VO cells were wounded and live cell movement was monitored. After
24 hr, the wound area was quantitated. Data are represented as 6SEM of triplicate wells. **p < 0.01.
Representative photomicrographs are shown at 0 and 24 hr after wounding. B. 22Rv1-B4 cells formed larger
colonies than the 22Rv1-VO cells when grown in soft agar for 21 days. Treatment with soluble, clustered ephrin-
B2 significantly reduced EphB4-induced colony growth. Photomicrographs show representative colonies. *p <
0.05, **p < 0.01, ***p < 0.001. C. Invasion of 22Rv1 cells through collagen I was monitored using the Xcelligence
system (Roche). The cell index indicates increased impedance at the electrodes which correlates with increased
number of cells that have invaded through the collagen layer. ***VO+Fc vs. B4+Fc, p < 0.001; *VO+Fc vs. VO+eB2,
p=0.018; #B4+Fc vs. B4+eB2, p=0.022. Data are shown 6 SD from one experiment carried out in triplicate.
Stimulation of EphB4 with ephrin-B2 causes reduced cell growth and increases apoptosis
To determine the effect of extended ligand stimulation on cell growth, 22Rv1-B4 and-VO cells
were stimulated with clustered ephrin-B2/Fc ligand for 11 days and were assessed using the
MTT assay at several time-points (Figure 1.11A). There was little effect of EphB4
overexpression on cell proliferation in standard anchorage-dependent cell culture conditions,
however, a significant decline in cell growth was noted by day 9 in the ephrin-B2-treated
22Rv1-B4 cells. Untreated or ligand-treated 22Rv1-VO cells showed no significant difference
in cell growth.
Caspase activity was also measured in the cells to determine whether apoptosis was
responsible for the decreased cell growth in response to ligand stimulation. 22Rv1-B4 cells
treated with control Fc alone displayed a significant reduction in apoptosis compared to
22Rv1-VO cells. Stimulation of EphB4 overexpressing cells with soluble ligand significantly
increased caspase 3/7 (Figure 1.11B) and caspase 8 (Figure 11.C) activity in the EphB4
overexpressing 22Rv1 cells compared to Fc only treated cells. There was no significant
difference in apoptosis in 22Rv1-VO cells treated with ligand.
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Figure 1.11. Ephrin-B2 inhibits cell growth and causes apoptosis
A. Stimulation of 22Rv1-B4 cells with soluble clustered ephrin-B2/Fc causes a significant decrease in cell growth
compared to unstimulated 22Rv1-B4 cells after 9 days of treatment (***p < 0.001). There was no change of cell
growth of VO cells in the presence of ephrin-B2. Stimulation of 22Rv1-B4 cells with soluble ephrin-B2/Fc caused
a significant increase in apoptosis after 3 days compared to Fc-treated VO cells as determined by enhanced
caspase-3/7 B. and caspase-8 C. activities. Fc-treated 22Rv1-EphB4 overexpressing cells showed a significant
decrease in apoptosis as determined by a decline in both caspase-3/7 and -8 activities. Addition of ligand had no
significant effect on the caspase-3/7 activity in 22Rv1-VO cells. *p < 0.05, **p < 0.01, ***p < 0.001.
1.2.2 Conclusion
An EphB4 expression construct was used to over-express full length EphB4 on the surface of
the prostate cancer cell line 22Rv1. The resultant cell line, named 22Rv1-B4, was shown to
over-express EphB4 localized to lipid-rich regions of the plasma membrane. The receptor was
shown to be functional (ligand-responsive) as demonstrated by increased phosphorylation of
ERK1/2 and internalization. This correlated with enhanced migration, invasion and anchorage
independent growth when compared with the parental cells containing the empty vector.
These characteristics are hallmarks of an aggressive cancer phenotype, and as such, these
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results support the hypothesis that overexpressed EphB4 can facilitate tumour promotion.
Importantly, stimulating these cells with ephrin-B2 led to a reduction in EphB4 protein levels,
and extended treatment significantly decreased proliferation (correlating with a rise in
caspase-3/7 and caspase-8 activities), demonstrating that ligand-dependent signalling
induces tumour suppressive characteristics.
Together, these results demonstrate that overexpression of EphB4 confers an increased
metastatic phenotype in 22Rv1 cells and this can be restrained by stimulation with ephrin-B2.
As a result, the 22Rv1-B4 cell line is now used as an important research tool to further
investigate the effects of EphB4 expression and is a key model in the research present in this
thesis, i.e. in identifying proteins that interact with EphB4.
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1.3 Hypothesis
The interaction of EphB4 with its ligand ephrin-B2 is known to activate diverse signalling
pathways, resulting in alterations of cell functions. EphB4 is also able to signal in a ligand-
independent pathway. Furthermore, EphB4 has been identified in exosomes from a variety
of cancer cell models and was also shown to be found in the nucleus of prostate cancer cell
lines (work undertaken in the host lab and subsequently published – See Appendix 3,
Mertens-Walker et al. 2015). However, the effectors of EphB4 and more specifically its direct
partners are still not identified. As such, I propose that:
1. The receptor tyrosine kinase EphB4 interacts directly with other protein partners both
on the cell membrane and within the cell. These interactions result in specific
signalling pathways being initiated.
2. The EphB4 protein is transported from the host cell as part of the cargo of secreted
microvesicles, especially exosomes, and can then effect signalling in other
neighbouring cells.
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1.4 Aims
To investigate the above hypothesis I have carried out the following aims:
1. To identify proteins which interact with EphB4 at the cell membrane and within the
cell using a variety of techniques including the novel 2-Dimensional Native Affinity
Compromised Electrophoresis (2D-NACE) method, co-immunoprecipitation, and
confocal microscopy.
2. To determine whether EphB4 is a cargo protein in exosomes secreted from prostate
cancer cells and to investigate the potential effect of the EphB4-positive vesicles on
both cancer and endothelial cells.
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Chapter 2
Materials and Methods
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Chapter 2: Materials and Methods
2.1 Materials
2.1.1 General reagents
Mouse recombinant chimeric ephrin-B2 produced as a fusion protein with the human IgG
antibody Fc fragment (ephrinB2-Fc) was obtained from R&D Systems (Minneapolis, MN, USA).
Recombinant EphB4 was purchased from Invitrogen (Carlsbad, CA, USA). The Complete
protease inhibitor cocktail tablets were purchased from Roche (Basel, Switzerland), all
restriction enzymes were purchased from Genesearch Pty Ltd (Arundel, QLD, Australia), and
Superscript III was obtained from Invitrogen.  HotStarTaq DNA polymerase and the QIAprep
miniprep kit were from Qiagen (Hilden, Germany).
Chemicals used in the 2D-NACE method were purchased from Sigma Aldrich (St. Louis, USA)
unless stated otherwise. The Sigma Kit for Molecular Weights 14,000-500,000 Non-
denaturing PAGE was used to create a molecular weight marker with the addition of 1 mM
Ponceau S for both loading and monitoring electrophoretic migration.  Where required,
antibodies were fluorescently labelled using the NHS-Fluorescein or DyLight 650 Amine-
reactive dyes as per the manufacturer's instructions (Thermo Fisher Scientific, Waltham, MA,
USA; Pierce, Rockford, IL, USA).
2.1.2 Antibodies
The “Zymed” mouse-anti-EphB4 monoclonal antibody (Clone 3D7G8) was purchased from
Invitrogen. A panel of murine monoclonal antibodies targeting amino acids 218 to 239 in the
cysteine-rich region of the human EphB4 extracellular domain (PVAGSCVVDAVPAPGPSPSLYC)
- C1, C2, 11H4 and 13A7 - were developed by Dr Sally Stephenson (Stephenson S (2002)
Methods for regulating cancer, Patent WP 2004/024773, Assignee BenEphex Biotechnologies
Pty Ltd.), and were provided under agreement with BenEphex (Adelaide, SA, Australia).
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2.1.3 Solutions
Agarose gel loading dye: 0.09% (w/v) bromophenol blue, 0.09% (w/v) xylene cyanol, 60% (v/v)
glycerol, 60 mM EDTA, 1M Tris (pH 8.0)
TAE: 40 mM Tris-acetate, 1 mM EDTA (pH 8.0)
Phosphate buffered saline (PBS): 137 mM NaCl, 10 mM Na2HPO4-2H2O, 2.7 mM KCl, 2 mM
KH2PO4 (pH 7.4).
Tris buffered saline with Tween-20 (TBS-T): 100 mM Tris, 137 mM NaCl, 0.1% (v/v) Tween-20
(pH 7.5).
4x SDS loading buffer: 0.01 M Trizma-HCl, 40% (v/v) glycerol, 4% (v/v) SDS, 0.006% (w/v)
Bromophenol blue, 5% (v/v) β-mercaptoethanol, pH 6.8.
6x SDS-PAGE loading dye: 430 mM Tris (pH 6.8), 30% (v/v) glycerol, 18% (w/v) SDS, 15% (v/v)
β-mercaptoethanol, 0.2% (w/v) bromophenol blue.
SDS-PAGE running buffer: 25 mM Tris, 192 mM glycine, 0.1% (w/v) SDS (pH 8.3)
Transfer buffer: 25 mM Tris, 192 mM glycine, 0.1% (w/v) SDS, 20% methanol (pH 8.3)
The Importin-α (8G5) mouse monoclonal antibody, Thrombospondin-1 (N-20) polyclonal
goat-antibody and EphB4 (H200) rabbit polyclonal antibody were obtained from Santa Cruz
Biotechnologies through Quantum Scientific Pty Ltd (Murarrie, QLD, Australia). The rabbit
polyclonal anti-PAK4, rabbit polyclonal anti-PGRMC1, rabbit polyclonal anti-JNK1, rabbit
polyclonal anti-MMP2, rabbit polyclonal anti-beta-Tubulin, rabbit monoclonal anti- Anti-PI 3
Kinase p85 alpha and mouse monoclonal anti-TSG101 antibodies were all purchased from
Abcam through Sapphire Biosciences Pty Ltd (Redfern, NSW, Australia). Abcam also supplied
the anti-Clathrin heavy chain rabbit polyclonal, anti-Early Endosome Antigen 1 protein (EEA1)
rabbit polyclonal, anti-GM130 rabbit polyclonal, anti-Calnexin rabbit polyclonal and anti-
TSG101 mouse monoclonal antibodies. The cross linking agent DTBP (Dimethyl 3,3´-
dithiobispropionimidate•2 HCl) was purchased from Pierce (Rockford, IL, USA). Secondary
antibodies (goat anti-mouse IgG, goat anti-rabbit IgG, donkey anti-goat IgG) were purchased
from Abcam and diluted as per the manufacturer’s instructions.
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2.1.4 Primers for the amplification of JNK1, MMP2, PAK4 and PGRMC1
The following intron spanning primer sequences were designed to using BLAST analysis to
amplify the JNK1, MMP2, PAK4, and PGRMC1 genes:
JNK1 - Forward: TTA TAG GGG GGC AGC CCT CTC
JNK1 - Reverse: CTG CTG TGT CTA TCA GAG GCC
MMP2 - Forward: CCC CAT GAA GCC CTG TCC ACC
MMP2 - Reverse: ATG GCG GTC TCA GGG CAG AAG
PAK4 - Forward: GCC ATC CCT GAA GGG CTT CCT
PAK4 - Reverse: CCT CAT CTG GTG GGG TTC TGG
PGRMC1 - Forward: ACC TGC TGC TGC TTG GCC TCT
PGRMC1 - Reverse: TGA GTA TGC GCC GGT CCT GGA
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2.2 Methods
2.2.1 Cell culture
All cell lines were obtained from the American Type Culture Collection (ATCC) (Manassas, VA,
USA). Cell culture media and additives (penicillin/streptomycin, Glutamax) were purchased
from Invitrogen. Fetal calf serum (FCS) was from Sigma Aldrich and G418 was from In Vitro
Technologies Pty Ltd (Noble Park, VIC, Australia).
For the production of polyclonal derivative cell lines that stably overexpressed EphB4, an
expression vector containing the full length coding sequence of human EphB4 (Genbank
accession number NM_004444) was produced using the pIRES-neo2 vector (Clontech,
Mountainview, CA, USA). 14 µg of Nru1-linearized pIRES-B4 construct or empty vector was
combined with 15 µl lipofectamine 2000 (Invitrogen) and transfected into 22Rv1 prostate
cells grown to 80% confluence. Transfected cells were cultured for 24 hr before stably
transfected cells were selected using a pre-optimized dose of 900 µg/ml G418 (Invitrogen) for
2 weeks. Cells over-expressing EphB4 were designated as 22Rv1-B4 and cells expressing the
empty vector were designated 22Rv1-VO (Vector Only).
The non-tumourigenic prostate epithelial cell line BPH-1, and the transformed human
prostate cancer cell lines 22Rv1, LNCaP, C42B, DU145 and PC3 were cultured in RPMI 1640
medium (Invitrogen), pH 7.4.  The medium was supplemented with 100 U/mL penicillin, 100
µg/mL streptomycin, Glutamax-I (Invitrogen) and 10% heat-inactivated foetal bovine serum
(JRH Biosciences, Lenexa, KS, USA). MCF-10A and MCF10A-B4 cells were grown in Dulbecco's
Modified Eagle Medium (DMEM) (ThermoFisher Scientific, Waltham, MA, USA)
supplemented with 5% horse serum, 20ng/mL EGF, 10ug/mL insulin, 100ug/mL
hydrocortisone and 10ng/mL cholera toxin. HUVEC-C cells were grown in Ham's F-12
(Kaighn’s) nutrient medium (Invitrogen), pH 7.4, supplemented with 100 U/mL penicillin, 100
µg/mL streptomycin, 0.1 mg/mL Heparin (Sigma Aldrich), 0.03 mg/mL Endothelial Growth
Supplement (BD Bioscience, North Ryde, NSW, Australia) and 10% heat-inactivated foetal
bovine serum (Sigma Aldrich). All cells were grown in vented tissue culture flasks at 370C in a
5% CO2 environment.
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For passaging, cells were removed from the flask at >90% confluency using 0.25%
Trypsin/0.54mM EDTA pH 8.0) solution (2.5 g/L Trypsin and 0.2g/L EDTA•4Na, Invitrogen) or
0.48 mM Gibco Versene Solution (0.2 g EDTA in PBS) (Thermo Fisher Scientific) and incubated
at room temperature for 2 min to lift the cells. They were then collected by centrifugation for
5 min at 300 g, resuspended in phosphate buffered saline (PBS) and cell culture medium (1:9
ratio). An aliquot was then removed and added to a T25 cell culture flask containing medium.
Cells grown for less than 40 passages were used for the experiments described in this thesis.
2.2.2 Cryopreservation of cell lines
For cryopreservation, >90% confluent cells were detached from T25 growing flasks using
Gibco 0.25% Trypsin/EDTA (ThermoFisher Scientific) solution and collected by centrifugation
as described above. The cell pellet was typically resuspended in culture medium and this was
divided into 700 µL aliquots and placed in sterile 1 mL cryogenic storage vials with fetal calf
serum (FCS) and 10% dimethyl sulphoxide (DMSO). The vials were then cooled to -80oC in a
freezer overnight in cryo-vessels filled with isopropanol, then moved to liquid nitrogen for
long term storage. To thaw the cells, cryovials were warmed quickly in a 37oC water bath and
their contents transferred to a larger tube before the gradual addition of culture medium,
added drop wise with gentle shaking to gradually dilute the DMSO. The cells were then
collected by centrifugation, resuspended in a 1 mL volume of fresh culture medium and then
transferred to tissue culture flasks.  Cells were incubated overnight before the medium was
changed to remove unattached and dead cells.
2.2.3 RNA isolation
RNA was isolated from cell lines using TRIzol solution (Invitrogen). Briefly, growth medium
was aspirated from T25 growing flasks of cells and the monolayer washed with cold PBS
before the cells were lysed directly in the flask using TRIzol for 5 min at room temperature.
The TRIzol cell lysate was removed to a 1.5 mL Eppendorf tube and the RNA separated into
an aqueous phase using chloroform. After adding the chloroform, the tube was shaken for 15
sec, incubated at room temperature for 3 min and the sample then centrifuged for 15 min at
12,000 g at 4°C. The aqueous phase containing the RNA was collected using a micropipette
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and transferred to a clean tube. The RNA was then precipitated from this by the addition of
isopropanol with incubation for 10 min at room temperature, then centrifugation for 10 min
at 12000 g at 4°C. After centrifugation, the supernatant was removed and the pellet was
washed with 70% ethanol. The tube was again centrifuged for 10 min at 12000 g at 4°C, the
ethanol supernatant discarded and the RNA pellet was briefly air dried. Finally the RNA was
resuspended in 30 µL of nuclease free water. The concentration of RNA in solution was
determined using a Nanodrop Spectrophotometer (Thermo Fisher Scientific).
2.2.4 Reverse Transcription Polymerase chain reaction (RT-PCR) amplification
For cDNA synthesis, RNA (2 µg), nuclease free water, 200 ng of random hexamers (pD(N)6)
(Invitrogen) and 0.5 mM of each deoxyribonucleotide triphosphate (dNTP) (Pharmacia,
Uppsala, Sweden) were mixed together for a final volume of 13 µL. This mixture was heated
for 5 min at 65°C then cooled for 2 min on ice. A mixture containing First Strand Buffer, 10
mM dithiothreitol (DTT), 40 U RNAseout (Invitrogen), 200 U Superscript III reverse
transcriptase (Invitrogen) in water was then added to make a final reaction volume of 20 µL.
This was incubated at 50oC for 1 hr to perform first strand synthesis). Polymerase chain
reaction (PCR) experiments were performed in a PTC-200 thermal cycler (Perkin Elmer,
Waltham, MA, USA) with the following conditions: 2 µl cDNA template, 1.5 mM MgCl2, 200
µM dNTP, 50 ng of each forward and reverse primer, and 0.5 units of HotStarTaq polymerase
in 1x PCR buffer (Qiagen) for a final reaction volume of 25 µL. Cycling conditions included an
initial denaturation at 95°C for 15 min, followed by 40 cycles of denaturation at 95°C for 30
sec, annealing at 58-68°C (depending on the primer set used) for 30 sec and extension at 74°C
for 30 sec. A final extension of 74°C for 7 min completed the reaction.
2.2.5 Agarose gel electrophoresis
PCR samples and DNA Marker X (Roche) were mixed with Agarose gel loading dye (see Section
2.1) and separated by electrophoresis on 2% agarose gels with Tris acetate EDTA (TAE) buffer
(see Section 2.1). The gel was then stained with ethidium bromide and visualised under
ultraviolet light using a Syngene UV System (Geneworks, Adelaide, SA, Australia).
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2.2.6 Protein lysate preparation
Cells were grown to >90% confluence in a T75 flask then growth medium was aspirated from
the cells and the monolayer washed with 5 mL of ice-cold PBS before direct lysis using either
ice-cold RadioImmunoPrecipitation Assay (RIPA) buffer (50 mM Tris pH 7.4, 1% Triton X-100,
0.5% sodium deoxycholate, 150 mM NaCl, 2 mM EDTA, 1 mM sodium orthovanadate, 1 mM
NaF, 1 mM PMSF, 10 µg/mL aprotinin) supplemented with complete protease inhibitors
tablets (Roche), or NACE lysis buffer (50 mM Imidazole pH 7, 50 mM NaCl, 5 mM 6-
aminocaproic acid pH 7, 1 mM EDTA pH 8, 10% glycerol). Protein lysates were mixed by
rotation at 4°C for 1 hr, then insoluble proteins were removed by centrifugation at 13,000 g
for 5 minutes at 4°C. The remaining supernatant was collected into tubes and stored.
Cells to be used in 2D-NACE experiments were removed from flasks using lysis buffer and cell
scrapers, and were collected by centrifugation, resuspended in 1.5 mL PBS and divided into
three 0.5 mL aliquots before being centrifuged again and resuspended in 20 l of 1.5X
Imidazole Solublization buffer (75 mM Imidazole pH 7, 75 mM NaCl, 7.5 mM 6-aminocaproic
acid pH 7, 1.5 mM EDTA pH 8, 1.5% glycerol).  Cells were disrupted in a sonicating water bath
filled with ice cold water for 5 min and assessed for sufficient cellular disruption using light
microscopy – the appearance of unbroken nuclei and absence of large aggregates or intact
cells indicated sufficient disruption. Nuclei were removed by centrifugation at 3,000 g for 5
min at 4oC. Samples were stored at this point at -80oC and subsequently thawed on ice. Six
different w/w detergent/protein ratios, for each of three different detergents (Triton X-100 –
1, 1.5, 2, 3, 4 and 5; Dodecyl--D-maltoside (DDM) – 0.5, 0.8, 1.2, 1.6, 2.5 and 4; Digitonin –
2, 3, 5, 6, 7 and 8), were tested (Figure 3.2).
2.2.7 Protein concentration bicinchoninic acid (BCA) assay
Soluble protein concentrations were determined in triplicate samples using the BCA Protein
Assay Kit (Pierce). Bovine serum albumin diluted from 0.1 mg/mL to 5 mg/mL was used to
determine the standard curve. Triplicate 25 μl aliquots of both the standards and unknown
protein samples were pipetted into separate wells in a 96 well plate. To each of these wells
200 μl of working reagent (50:1 BCA Reagent A to BCA Reagent B) was added and the plate
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gently shaken for 30 sec. The plate was then incubated at 37°C for 30 min. After incubation,
the plate was cooled to room temperature and the absorbance of the protein samples was
measured on an ELISA plate reader at 562 nm.
2.2.8 Western blotting
Protein samples (20-50 µg) were mixed with 6x SDS-PAGE loading dye (see Section 2.1) and
heated for 5 min at 95oC to denature and reduce the individual proteins. The samples were
then loaded onto SDS-PAGE gels (4% stacking and 12% resolving) and separated by
electrophoresis in running buffer (see Section 2.1) for 1.5 hrs at 100 V.  Proteins were then
transferred overnight at 30 V onto a BioTrace™ NT nitrocellulose membrane (Pall, Pensacola,
FL, USA) using a Bio-Rad Transblot apparatus with SDS-Transfer buffer (see Section 2.1). The
membrane was blocked for 1 hr using 1X Western blocking reagent (10% purified casein
protein in maleic-acid buffer, Roche) diluted in Tris Buffered Saline with 0.1% Tween-20
(TBST), rinsed briefly then washed in TBST before the addition of specific primary antibody
added to 10 mL 1X Western blocking reagent for either 1 hr at room temperature or overnight
at 4°C.  Excess unbound primary antibody was removed by washing the membrane 4 x 15 min
with TBST and the bound primary antibody then detected using a peroxidase-conjugated
secondary antibody also diluted according to the manufacturer’s recommended ratio in the
Roche blocking buffer with a 1 hr incubation at room temperature. Excess unbound secondary
antibody was also removed by washing the membrane 4 x 15 min with TBST before detection
using the Amersham™ ECL Plus Chemiluminescence kit (GE Healthcare, Little Chalfont, UK)
and exposure SuperRX X-ray film (Fuji Film Corporation, Minato, Tokyo, Japan) for between 5
sec and 10 min.
2.2.9 Immunoprecipitation
Proteins were extracted from confluent cells growing in T25 flasks using lysis buffer as
described above and divided into equal samples. A 25 µL aliquot of Protein G Sepharose 4
Fast Flow beads (GE Healthcare) (50 µl of a 50% bead slurry) was added to 1 mL of the protein
cell lysate and the solution mixed gently for 1 hr to allow removal of proteins that bind non-
specifically to the Sepharose beads by centrifugation before immunoprecipitation.
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Approximately 4 µg of a target specific antibody was then added to the pre-cleared protein
lysate and the solution incubated for 1 hr at 4oC before the addition of 50 µL of the Sepharose
beads and continued incubation with gentle rotation overnight at 4oC to allow formation of
bead-antibody-target protein complexes. Bead complexes were collected by centrifugation at
12 000 g for 20 sec, washed three times with 1 mL lysis buffer to remove contaminating
unbound proteins, and the final pellet suspended in 12.5 µl 4X SDS loading buffer (see Section
2.1). Immunoprecipitated proteins were denatured, reduced and separated from the beads
by heating at 95oC for 5 min before being electrophoresed into 12% SDS-PAGE gels then
transferred onto nitrocellulose for immunoblotting as described above.
2.2.10 Cross-linking
Cross-linking was performed within the tissue culture flasks. Cells were washed with PBS and
then with a 0.2 M solution of triethanolamine (TEA) pH 8.0 after which 4 mL of dimethyl 3,3'-
dithiobispropionimidate (DTBP) imidoester cross-linking agent (dissolved in 0.2 M TEA to a
concentration of 1.5 mg/mL, pH 8.0) was added to the cells (growing in T75 flasks) which were
then incubated for 45 min at room temperature as per the manufacturer’s protocol. DTBP
was chosen as a cross-linking agent as it is membrane permeable and the cross-linking can be
relatively easily stopped (as stated by the manufacturer). The reaction was stopped by adding
5 mL of glacial acetic acid to the flasks. The protein lysate was then extracted from the cells
using RIPA buffer as described in Section 2.2.6 and subjected to co-immunoprecipitation as
previously outlined above. The samples were denatured by heating and reduced using β-
mercaptoethanol and were then loaded onto a 12% SDS-PAGE gel and subjected to
electrophoresis.
2.2.11 2D-NACE
The 2-NACE method effectively involves two sequential electrophoretic separations of a
native mixture with the addition of a high affinity binding molecule (e.g. a specific antibody
to the target protein) to the stacking gel of the second separation. The binding interaction
forces a change in electrophoretic mobility - much the same principle as an electromobility
shift assay (EMSA), shifting the newly formed complex away from the unbound material. For
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Several methods of adding the target-specific antibody to the protein complexes separated
in the first dimension were tested including soaking the gel strip in a solution of antibody in
anode buffer (75 mM Imidazole) but the optimal method was found to be addition of 5 g of
an antibody to the target protein of choice to the 500 l polyacrylamide solution of the stack
prior to polymerisation as this was found to immobilise the antibody in the stack. After
electrophoresis, the second dimension gel was silver stained to identify proteins either
immobilised in the stack through high affinity interactions with the immobilised antibody, or
retarded from non-interacting protein complexes through lower affinity interactions.
both dimensions, native 4-13% gradient gels were made using a Mini-PROTEAN 3 Multi-
casting Chamber, a two chambered gradient mixer and two individual polyacrylamide
solutions – heavy (20% glycerol, 0.5 M 6-aminocaproic acid pH 7, 25 mM Imidazole pH 7,
0.01% DDM (n-dodecyl β-D-maltoside, ThermoFisher Scientific), 13% 29:1 acrylamide/bis- 
acrylamide (BioRad, Hercules, CA, USA) 0.05% (w/v)ammonium persulfate and 0.05% (v/v) 
TEMED) and light (0.5 M 6-aminocaproic acid pH 7, 25mM Imidazole pH 7, 0.01% DDM, 4% 
29:1acrylamide/bis-acrylamide (BioRad), 0.05% (w/v) ammonium persulfate and 0.05% 
(v/v)TEMED).
Electrophoresis, performed using an anode buffer (75 mM Imidazole, pH 7) and cathode
buffer (50 mM Tricine pH 7, 7.5 mM Imidazole pH 7, 0.05% sodium deoxycholate, 0.02% DDM)
at 15 mA for 60 mins, gave optimal separation of protein complexes. Two thicknesses of gel
(0.75 mm and 1.5 mm) were tested and the 1.5 mm thickness was chosen because it was
more robust during the manual manipulation required for the second dimension.  For the first
dimension separation, a 3.5% stacking gel was optimal for separation of high molecular
weight complexes. For the second dimension gel, a 5% polyacrylamide concentration was
optimal. The entire lane of interest was excised from the first dimension gel and inserted
between the plates of the second dimension gel into contact with the 5% stacking gel.
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Figure 2.1 – Experimental strategy for two-dimensional native affinity compromised electrophoresis
Native protein lysates are separated in the first dimension through a stacking gel and into a native gradient gel.
A single lane containing the separated protein complexes is excised from the first dimension gel and the protein
electrophoresed into a second gel with a stacking gel containing an antibody specific to the target protein. The
antibody forms a high affinity interaction with the target protein, trapping it in the stack, or interacts with lower
affinity but still sufficient to separate the target protein complexes from the rest of the protein sample. Proteins
are then excised, digested and identified using LC-MS/MS.
2.2.12 Silver staining
After electrophoresis, gels were removed from between the glass plates and fixed in a
solution of 40% Methanol and 10% Acetic Acid for at least 30 min. The fixing solution was
then removed and the gel rinsed briefly in water. The gels were sensitized using 0.02%
sodium thiosulfate (20 mg Na2S2O3 in 100 ml water) with mild shaking for 1.5 min and the
solution was then washed off with water. A solution of 12 mM AgNO3 was then added for 20
min, the gel washed briefly twice with distilled water, and twice with 2.9% sodium carbonate,
before the protein bands were developed using a solution containing 50 l formaldehyde in
50 mL of 2.9% sodium carbonate.  When the bands were clearly visible, with little background
staining, the reaction was stopped by replacing the formaldehyde/sodium carbonate solution
with 5% acetic acid. For destaining gels prior to mass spectrometry, a reducing solution was
prepared fresh using 1 g K3Fe(CN)6 and 1.25 g Na2S2O3(5H2O) dissolved in 50 mL water. This
was added to gels and incubated with gentle shaking for 5 min.  The gels were then washed
in water and placed 200mM (NH4)HCO3 (in water) for 20 min.
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2.2.13 In gel digestion using trypsin
Gel pieces containing native protein complex spots/bands of interest were excised from the
silver stained gel using a clean scalpel blade and stored in 1% (w/v) acetic acid in a glass vial
at 4oC until further processing. To reduce the amount of 6-aminocaproic acid, a serine
protease inhibitor, the gel piece was washed twice in 50 l 500 mM Triethylammonium
bicarbonate, 50% acetonitrile pH 8.5 for 10 min, after which the gel piece was slightly
dehydrated by exposing the sample to air for 10 min.  The native protein was then denatured,
reduced and alkylated by adding 20 l 500 mM triethylammonium bicarbonate, 1 l 2% SDS,
and 2 l 50 mM tricarboxyethyl phosphine-HCl. The sample was mixed then incubated for 1
h at 60oC. Samples were cooled to room temperature before the addition of 2 l 1 M
iodoacetamide in 500 mM triethylammonium bicarbonate, pH 8.5. Samples were then
incubated for 1 hour at RT in the dark. After thioalkylation, the samples were ready for trypsin
digestion but to improve the efficiency of digestion, and maximise up-take of trypsin to the
protein within the gel slice, the gel was again dehydrated in 50% (v/v) acetonitrile/25 mM
NH4HCO3 and dried as described above. A solution of modified sequencing grade trypsin
(Sigma #T6567), 15 l of 25 ng/mL in 2 mM CaCl2/500 mM triethylammonium bicarbonate
was then added to rehydrate the gel slice, and this was left at 4oC for >60 min to allow the
trypsin to permeate into the gel slice. Digestion was allowed to proceed at 37°C overnight.
Reagents used for in-gel digestion were of proteomic grade.
2.2.14 Extraction of peptide fragments and mass spectrometry
To extract the peptides from the gel, 50 l 5% (v/v) formic acid was added and the gel piece
sonicated for 5 min with 10 second pulses using a probe sonicator. The formic acid solution
containing eluted peptides was then removed after collection by brief centrifugation into a
glass tube. Peptides still in the gel were extracted twice more using 50 l 50% (v/v) acetonitrile
with 5% (v/v) formic acid.  Peptides were then concentrated using a vacuum Eppendorf
concentrator centrifuge (spinning at 1,400 g) before being sent to the Molecular and Cellular
Proteomics Mass Spectrometry Facility within the Institute for Molecular Bioscience (IMB) at
The University of Queensland (Brisbane, QLD, Australia) for LC/MS-MS identification of the
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peptides by trained users. Briefly, molecules are ionized using electrospray ionization and
then sorted and identified according to their mass-to-charge ratios using a HPLC-Chip QTOF
LC-MS/MS system.
2.2.15 Immunofluorescence
Prostate cell lines were seeded onto sterile, uncoated and untreated 13 mm glass cover slips
(thickness of 0.13-0.17mm) in 24 well tissue culture plates at 1 x 105 cells per well in 200 µl
fresh medium and allowed to attach for 24 hrs.  Cells were fixed using 200 µl 4%
paraformaldehyde in PBS for 15 min at 37oC, then washed three times using PBS before being
permeabilised using 0.5% Triton X-100 in PBS, at room temperature for 5 min.  The detergent
was removed by washing twice using PBS before the addition of 200 µl of a blocking solution
containing 10% goat serum in PBS for at least 1 hr at room temperature. Cells were then
incubated overnight at 4oC in 200 µl of a solution containing 1 µg/mL of specific antibody
diluted in 10% goat serum in PBS. Cells were then washed three times using PBS before
incubation with 200 µl of a 1:1000 dilution of a goat anti-mouse IgG secondary antibody
conjugated to fluorescein isothiocyanate (FITC) (BD Biosciences), as well as to a 1:1000
dilution of Phalloidin conjugated to tetramethyl rhodamine isothiocyanate (TRITC) (Sigma
Aldrich), at room temperature for 1 hr. Cover slips were mounted on glass slides using Prolong
Gold Antifade with DAPI (Invitrogen) and cells were visualised using a Leica SP5 spectral
scanning confocal microscope.
2.2.16 Exosome Isolation
Cells were cultured in T-175 flasks to 90% confluency and then incubated for 24 hrs in a
serum-free medium. The medium was harvested and sequentially centrifuged at 4°C to
remove cell debris at 500 g for 10 min, 3 000 g for 10 min and 10 000 g for 30 min with the
supernatant being retained for subsequent spins and the pellet being discarded. The
supernatant was then centrifuged at 100 000 g for 90 min (at 4°C) in a SW40Ti rotor (Beckman
Coulter Inc., Brea, CA, USA) to pellet the exosomes. The resulting pellet was resuspended in
10 mL of PBS and centrifuged at 100 000 g (again at 4°C) with the final pellet being
resuspended in 50 μl of PBS and stored for further use at -20oC. The quantity of exosome
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protein was checked using a BCA assay and the quality was checked using transmission
electron microscopy (Section 6.2.4).
2.2.17 Transmission Electron Microscopy (TEM)
Isolated exosomes were placed onto 400 mesh copper grids for 2 min and rinsed with PBS.
Exosomes were then fixed in 1% glutaraldehyde and negatively stained with 1% uranyl
acetate. The grids were dried and then viewed on a JEOL 1200-EX transmission electron
microscope operating at 80 kV at the Analytical Electron Microscope Facility at the
Queensland University of Technology with assistance by the staff.
2.2.18 Proliferation and apoptosis assays
Cells were seeded into 96-well plates in triplicate with 100 µL cell suspension per well. After
24 hr incubation to allow attachment, cells were treated (with specific reagents as per
experimental protocols – e.g. Section 6.2.4) and proliferation was recorded over five days
using the colorimetric CellTiter Aqueous One Solution Cell Proliferation Assay (Promega,
Madison, WI, USA). Briefly, The CellTiter reagent was thawed to room temperature and 20 µL
was pipetted into each well containing the samples. The plate was then incubated for 1 hr at
37°C in a humidified, 5% CO2 atmosphere. After incubation, the absorbance was measured
at 490 nm using a 96-well plate reader. For the apoptosis assay, the Caspase-GloTM-3/ 7
luminescence kit (Promega) was used. Cells were seeded in 96-well plates in triplicate with
100 µL cell suspension per well. The reagent and the plate were brought to room temperature
and 100μl of the Caspase-Glo® 3/7 Reagent was added to each well. The plate was gently
shaken and incubated at room temperature for 1 hr. The luminescence was measured using
a POLARstar Optima luminometer (BMG Labtech, Mornington, VIC, Australia). All experiments
were repeated three times and the results were subjected to statistical analysis to generate
a p-value. Standard error of the mean was used to determine the error range.
2.2.19 Statistics
Results are the average of three independent experiments unless otherwise stated. Graphpad
software was used to conduct a two-tailed Student's t-test or Analysis of variance (ANOVA)
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(where appropriate) to confirm statistical significance of experiments. A value of P < 0.05 was
considered significant. This is represented in figures by * for P < 0.05, ** for P < 0.01, and ***
for P < 0.001. SEM was used unless otherwise stated.
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Chapter 3: Development of a new method, 2D-NACE, for
identifying proteins in complexes with EphB4
3.1 Introduction
EphB4 is a receptor tyrosine kinase that directly interacts with its ligand ephrin-B2, and this
interaction is responsible for initiating and maintaining a number of important cellular
processes. EphB4 is also able to instigate signalling events even when the ligand is not
present, through over-expression of the receptor, dimeric and/or multimeric complex
formation and interaction between the adjacent kinase domains of neighbouring EphB4
receptors. Both ligand-dependent and -independent signalling mechanisms likely involve
other proteins in relaying signals throughout the cell, either through downstream stimulation,
or through direct interaction with EphB4. However, proteins that directly interact with EphB4
have not as yet been identified and as such, the purpose of this study will be to investigate
and identify interacting partners of EphB4. The characterisation of these interactions will be
important to understanding both normal biological functions of EphB4 signalling and how
these are perturbed in different disease states.
Protein-protein interactions can be very stable or highly dynamic and can be dependent on
cellular localisation and post-translational modifications. As such, the key to identifying valid
interactions is to maintain the native environments as closely as possible during processing.
A plethora of techniques for understanding the cellular interactions between biomolecules
are now available, each with their own strengths and weaknesses. The conception of Yeast
Two-Hybrid screening by Fields & Song in 1989 revolutionised studies of protein-protein
interactions. Now, both the classical method and tools developed from this are some of the
most frequently used methods for exploring protein-protein interactions, but these only
define binary interactions, and can miss some types of protein-protein interactions (e.g. those
involving membrane proteins, self-activating proteins or those that require post-translational
modification (Brückner et al 2009). More recently developed techniques that couple classical
biochemical approaches such as co-purification, affinity purification and co-
immunoprecipitation with mass spectrometry are particularly powerful for identifying
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specific protein-protein interactions but require bait-specific reagents used under near-
physiological conditions.
Given the complexity of the proteome, effective fractionation and separation methods are
critical to successful identification of true biological interactions and the limiting of false
positive results. Single-dimension separations have been shown to have inadequate
resolution and techniques that use multidimensional fractionation steps are proving to be
more promising (Issaq et al, 2002). Organelles, various cellular membranes and the cytosol
can now be divided into separate fractions using combinations of different homogenisation
methods, different detergents, various salts and concentrations, and differential and density
gradient centrifugation.
Although absolute separation is not possible, the use of fractionation can significantly enrich
protein complexes specific to a particular sub-cellular localisation (Huber et al, 2003).
Combining sub-cellular fractionation with high resolution separation methods such as two-
dimensional polyacrylamide gel electrophoresis and high-performance liquid
chromatography allows isolation of even low abundance protein complexes but relies on the
ability to maintain native protein complexes during the fractionation and separation steps.
Reisinger and Eichacker (2007) recommend 2-dimensional Blue-Native SDS-PAGE for isolation
of functional protein complexes which are composed of genuine subunits. In this method,
protein complexes solubilised in a native state are first separated in one dimension and the
complex subunits are then separated in the second dimension.
My supervisor, Dr Sally-Anne Stephenson and colleague Dr Scott Stansfield, have adapted this
method and further developed it by adding an affinity-based separation step by immobilising
an antibody specific to the target protein of interest, i.e. the receptor tyrosine kinase EphB4,
into the stacking layer of the second dimension polyacrylamide gel.  Interactions between the
antibody and the target protein retard movement of complexes through the gel; with
interactions of high enough affinity resulting in retention of the complexes in the stacking
region of the gel. This novel method of isolating native interacting protein complexes has been
called 2-Dimensional Native Affinity Compromised Electrophoresis (2D-NACE) (Figure 2.1).
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Building on this work, this study will optimise this novel method and utilise these techniques
to isolate and identify interacting partners of EphB4. Identifying these interacting proteins
will significantly increase our understanding of the mechanism of action of this receptor and
the processes involved during both normal and disease state signalling.
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3.2 Results
3.2.1 Western analysis of EphB4 expression in a panel of prostate cancer cell
lines
To confirm that EphB4 is expressed in prostate cancer cell lines and to select an appropriate
line for optimisation of the 2D-NACE method, a Western analysis of total protein lysates from
one prostate (BPH-1) and three prostate cancer (LNCaP, DU145 and PC3) cell lines was
performed using an EphB4-specific antibody. Consistent with previously published results
(Rutkowski et al. 2012), two separate bands of approximately 120 kDa (the reported
molecular weight of full length EphB4) and 150 kDa were identified in all cell lines (Figure 3.1).
An antibody specific to ephrin-B2 was then used to determine the protein levels of the
cognate EphB4 ligand.  A single band corresponding to the predicted size of the ephrin-B2
protein at 37 kDa was seen in the samples from DU145, PC3 and BPH-1 but the ligand does
not seem to be expressed by the LNCaP cells used here.  Finally, this same Western blot was
probed with an antibody to the endoplasmic reticulum protein Calnexin (67 kDa) as a loading
control.  LNCaP was chosen for optimisation of 2D-NACE because it expresses EphB4 but does
not express ephrin-B2 allowing experiments to be performed with and without recombinant
ephrin-B2 to explore high affinity EphB4 interactions under different conditions.
Figure 3.1 – Expression of EphB4, ephrin-B2
and Calnexin in prostate cell lines
Western blots of protein lysates from BPH-1,
LNCaP, DU145 and PC3 prostate cells probed
with antibodies against EphB4, ephrin-B2 and
Calnexin (as a loading control). Bands
corresponding to the size of EphB4 were
identified in the all cell lines and ephrin-B2 was
identified in BPH-1, DU145 and PC3 cells.
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3.2.2 Development of 2D-NACE - Detergent optimisation
3.2.2.1 Testing Triton X-100 for native protein preparation
Triton X-100 is a commonly used non-ionic detergent often used in the preparation of total
protein lysates. Protein lysates from LNCaP, DU145 and PC3 were prepared using
solubilisation buffer with Triton X-100 in three different concentrations: 1.5%, 3% and 4%.
Samples were electrophoresed into high resolution clear native electrophoresis 4%-13%
gradient gels containing 0.01% Triton X-100 with 0.05% Triton X-100 in the cathode buffer;
and then silver stained to visualise the protein. The amount of protein complex solubilisation
increased with the increasing concentration of TX-100 detergent for certain cell lines with
better resolution of high molecular weight bands with higher concentration of detergent
(open arrow heads in Figure 3.2). Although protein complexes should be maintained in native
conformation in the presence of TX-100, bands  at  a  lower  molecular weights could  still
remain as  small  complexes  rather  than individual bands.
Figure 3.2. Comparison of Triton X-100 concentrations in the native solubilisation buffer.
Total protein lysates were made using LNCaP, PC3 and DU145 cells with native solubilisation buffer containing
TritonX-100 at three increasing concentrations (1.5%, 3% and 4%) as indicated by the arrow for each cell line.
The arrow heads indicate high molecular weight proteins or complexes that are increasingly solubilised and
therefore resolved.
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3.2.2.2 Detergent selection and concentration
Both the choice and concentration of the detergent for solubilisation of membranes is
important in order to maintain both the function and structure of the protein complexes to
be isolated (le Maire et al, 2000). Three detergents were selected for testing including Triton
X-100, a non-ionic detergent often used to make total protein lysates; dodecyl--D-maltoside
(DDM), an alkylglucoside often used to maintain the function of membrane proteins after
solubilisation; and digitonin a glycoside detergent primarily used for selective solubility of
hydrophobic and membrane proteins (Van Aken et al, 1986; Lund et al, 1989; Fleming et al
1997; Arnold & Linke, 2007). Six different detergent to protein ratios were tested for each of
these three detergents as follows:
 Triton X-100 - 1%, 1.5%, 2%, 3%, 4%, and 5% detergent to protein ratio
 DDM - 0.5%, 0.8%, 1.2%, 1.6%, 2.5%, and 4% detergent to protein ratio
 Digitonin - 2%, 3%, 5%, 6%, 7%, and 8% detergent to protein ratio
Protein lysates from LNCaP cells were separated on 4 – 13% gradient native gels and
separated proteins visualised using silver staining.
DDM at 2.5% was chosen for further experiments because individual bands of high molecular
weight protein complexes were seen more clearly than for any of the Triton X-100 tests, and
the concentration was also lower than that required for a similar result with digitonin at 8%
(although the result is comparable, digitonin is a highly toxic compound and thus not a
preferred choice) (Figure 3.3). The strong hydrophobic nature of DDM is suggested to allow
for the slow release of phospholipids from the membrane as well as membrane protein
complexes in their native state protected by the surrounding membrane through the
formation of micelles (le Maire et al, 2000).
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Figure 3.3 – Optimisation of the detergent and concentration for preparation of native protein isolates from
prostate cancer cells
Three different detergents, Triton X-100, DDM and Digitonin, were used at six different detergent to protein
ratios as indicated above each lane.  Protein lysates from LNCaP cells were separated on gradient native PAGE
gels.  Individual bands of high molecular weight protein complexes (red arrows) were seen more clearly using
DDM than for other tests. The red box indicates the optimum levels of detergent with the red star indicating the
chosen concentration of 2.5%.
3.2.3 Optimisation of separating and stacking gels for 2D-NACE
Once the solubilisation buffer was optimised and the detergent and concentration chosen,
the next optimisation step was to configure the gel thickness and composition to
electrophorese the second dimension 2D-NACE gel. As the method uses two identical
electrophoretic separations of a native mixture with the addition of a high affinity binding
molecule (an antibody) to the stacking gel for second dimension separations, the composition
and thickness of the gel could affect the results. To optimise the second dimension separation,
a gradient gel of 4% to 13% was chosen. Two thicknesses of gel, either 0.75 mm or 1.5 mm,
were tested. Additionally, the composition of the stacking gels was also varied with a 3%, 5%
and 8% acrylamide stack tested with each gel thickness.
A native protein lysate from LNCaP cells was electrophoresed in the first dimension (Figure
3.4A). The entire lane was excised and placed between the plates on top of the second gel (of
the varying thicknesses and compositions). Proteins were then electrophoresed from the lane
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of the first gel into the stacking and then separating gel of the second dimension gel. After
electrophoresis, the gels were silver stained and compared to determine which provided the
clearest and tightest grouping of protein complexes (Figure 3.4B and 3.4C). Because of the
need to physically place the gel in between the glass plates above a second gel (to run the
second dimension), the 1.5 mm gel was chosen over the 0.75 mm gel as it is more durable
during the required manipulation. Additionally, the ideal stacking layer for the second
dimension was found to be the 5% acrylamide stack as it provided the tightest migration of
proteins into the gel.
Figure 3.4 – Optimisation of the electrophoresis conditions for first and second dimension NACE gels
2D-NACE gel conditions were tested using gels with varying thickness and with three concentrations for the
stacking gel. A. A first dimension gel was run containing protein lysate which separated into distinct bands. The
two different thicknesses: 0.75 mm B. and 1.5 mm C. were tested in the second dimension. The proteins ran as a
diagonal band with high molecular weight at the left side to the lower molecular weight on the right side.  The
tightest migration of the proteins was seen in 1.5 mm gels while the 5% stack (red box) also showed the best
near linear diagonal band.
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3.2.4 Confirmation that conditions used for polyacrylamide gel electrophoresis
maintain EphB4 complexes with its high affinity ligand
The optimal detergent and concentration of the detergent to be used in the 2D-NACE buffer
in order to maintain protein complexes were previously determined (Figure 3.3). These
detergent levels as well as the general 2D-NACE conditions and the gel optimisation (Figure
3.4) were tested to confirm that EphB4 complexes were maintained during polyacrylamide
gel electrophoresis (PAGE). To test this, 250 ng of recombinant EphB4 ectodomain
(approximately 75 kDa) (Sapphire Bioscience, Waterloo, NSW) was mixed with its natural
cognate ligand ephrin-B2 - 50 ng recombinant mouse ephrin-B2-Fc chimera (approximately
120 kDa) (R&D Systems) - in 0.5 mL 1X Imidazole Solublization buffer. After incubation for 1
hr at room temperature, 50 l of this mixture (equivalent to 30 ng of protein) was separated
on a first dimension NACE gel and compared with samples of the individual proteins and then
the gel was silver stained to visualise the results (Figure 3.5).
Figure 3.5 shows a band corresponding in size to ephrin-B2-Fc (approximately 120 kDa) was
seen in lane 1 while in lane 2, recombinant EphB4 ectodomain migrated in three distinct
bands between 70 and 75 kDa which may occur due to differences in glycosylation (or may
be non-specific immunoglobulin light and heavy chains).  In lane 3 where recombinant EphB4
and ephrin-B2 were mixed together, the ephrin-B2 band does not appear at its predicted
molecular weight (120 kDa), but rather appears to run at a higher molecular weight (above
150 kDa) than in lane 1 indicating that the ephrin-B2 may have complexed with EphB4 in the
imidazole solubilisation buffer containing the DDM detergent, and this complex has been
maintained during electrophoresis into the NACE polyacrylamide gel.
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Figure 3.5 – Maintenance of protein complexes under 2D-NACE conditions.
Recombinant EphB4 and ephrin-B2 proteins were run into a first dimension NACE gel.  Lane 1 contained ephrin-
B2-Fc which migrated to approximately 120 kDa while lane 2 shows the recombinant EphB4 ectodomain which
migrated in three distinct bands between 70 and 75 kDa. Finally, lane 3 contained recombinant EphB4 mixed
with ephrin-B2-Fc where the ephrin-B2 protein migrated to a higher weight than in the ephrin-B2 only lane.
3.2.5 Confirmation that conditions used for polyacrylamide gel electrophoresis
maintain EphB4 complexes with EphB4-specific antibodies
The next experiment aimed to determine whether EphB4 antibodies could also form high
affinity interactions with the EphB4 protein while the EphB4 protein is in native protein
complexes and in the total protein lysates made using the native solubilisation buffer.  Total
protein lysates were collected from LNCaP cells and proteins were labelled using NHS-Alexa
Fluor-680 (red).  The EphB4-specific antibody C1 (recognising the extracellular domain) was
labelled with NHS-fluorescein isothiocyanate (FITC) (green) (Thermo Scientific). Antibody (50
ng) was mixed with 50 µg LNCaP protein and these were incubated for 10 min at room
temperature before the protein complexes were separated in a first dimension 4%-13%
gradient gel and then in a second dimension. The protein in the gel was then visualised using
a LICOR Odyssey Imager by the red fluorescent signal (680 channel) and the EphB4-specific
antibody by green fluorescence (488 channel, EphB4 in complexes indicated by arrows in
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Figure 3.6). Green fluorescent bands were seen in the upper portion of the gel identifying
EphB4 in complex with both the FITC labelled C1 antibody and other proteins in the lysate.
The dark band at the bottom is Ponceau S, used to ensure protein does not migrate off the
bottom of the gel. This indicated that the C1 antibody was directly interacting with higher
molecular weight complexes which presumably contained EphB4.
Figure 3.6 - Interaction of the EphB4-specific antibody C1 and protein complexes presumed to contain EphB4
in lysates of LNCaP cells.
LNCaP prostate cell lysates were labelled using NHS-Alexa Fluor-680 while the EphB4-specific antibody C1 was
labelled with NHS-fluorescein isothiocyanate (FITC). After incubation, the protein complexes were separated in a
first dimension gel and then in a second dimension. A. Total protein identified by the red fluorescent signal (680
channel) and B) the EphB4-specific antibody identified by green fluorescence (488 channel). EphB4 in complexes
is indicated by arrows. Green fluorescent bands were visible in B. indicating EphB4 in complex with other proteins.
3.2.6 Testing of methods for interaction of antibody with protein complexes
Another important step in optimising the 2D-NACE method to identify proteins interacting
with EphB4 was to identify the right antibody to use as an affinity capture antibody in the
second dimension stack of the gel. Initially, a number of methods were tested to identify the
best way for the antibody to be held within the gel, including soaking the first dimension gel
strip in a solution of cathode buffer containing the EphB4-specific antibody, as well as adding
the antibody directly to the stacking gel before polymerisation. It was found that the latter
method immobilised the antibody in the stack and it did not migrate into the gel, and was
Ponceau S
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thus a practical affinity capture system (personal communication from Dr Sally-Anne
Stephenson).
This method was then tested using recombinant EphB4 protein migrated into a first
dimension gel with three different EphB4-specific antibodies (11H4, C1 and 13A7)
immobilised in the stacking gel of the second dimension gel. After electrophoresis the gel was
silver stained to view the result. Figure 3.7 shows that the C1 antibody appeared the most
effective of the three antibodies in slowing the progression of the recombinant EphB4 into
the second gel as a strong band was seen in the C1 gel stretching from the migrating front
back up to the stack, suggesting that this antibody has a strong interaction with the
recombinant EphB4, being able to slow the progression of the protein throughout the journey
into the gel. However, the 11H4 and 13A7 antibodies were not effective in retaining the EphB4
protein within the stacking region of the second dimension gel as EphB4 appeared as a spot
of protein at the migrating front, having travelled unhindered through the gel (Figure 3.7).
The EphB4-specific antibody C1 was shown to have a high affinity for EphB4 under 2D-NACE
conditions, slowing migration of the recombinant protein from the stacking region to the dye
front. As such this antibody was used in subsequent experiments.
Figure 3.7 – Comparison of EphB4 target specific antibodies immobilised in the stack with respects to their
ability to interact with EphB4 under 2D-NACE conditions
Silver stained 2D-NACE gel showing: A. the recombinant EphB4 protein is not captured in the stack containing
the 11H4 antibody. The EphB4 protein is at the dye front as indicated by the black circle. B. The recombinant
EphB4 protein is not captured in the stack containing the 13A7 antibody. Again EphB4 is at the dye front. C. The
migration of recombinant EphB4 protein is significantly slowed within the stack containing the C1 antibody.  The
EphB4 protein is seen as a streak of protein and it is captured within the stacking region of the gel.
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3.2.7 Optimisation of the quantity of antibody for use in stack
To optimise the amount of antibody that could be immobilised in the 5% stacking gel of the
second dimension gel, two different amounts of mIgG antibody, 5 μg and 10 μg were added
to the 5% polyacrylamide gel.  A sample of LNCaP protein separated in the first dimension
was transferred within the gel slice onto each of the second dimension gels and the samples
electrophoresed through the stacking gels containing the two different amounts of
immobilised antibody and into the second dimension gradient gel.  Both gels were silver
stained for comparison and it was apparent from this that 10 μg of antibody was too much as
a darkly staining band identified the excess non-immobilised antibody had migrated to the
middle of the gel (Figure 3.8).  This band was not seen in the gel in which 5 μg of antibody had
been used suggesting that most of the antibody has been immobilised in the stack, that it
does not migrate out of the stack once polymerised into the gel and this therefore suggests
that 5 μg is a suitable amount of antibody to use.
Figure 3.8.  Determination of the correct amount of antibody to immobilise in the stacking gel.
A 5% stacking gel containing either 5 or 10 μg of mIgG antibody was polymerised on top of second dimension
2D-NACE 4-13% polyacrylamide gels.  A single lane from the first dimension gel in which LNCaP protein had been
separated was then layered on top of the stacking gels and the protein electrophoresed into the second
dimension gel.  Silver staining clearly shows a dark band of the excess antibody has migrated into the gel when
10 μg of antibody was used.  The same band is not present when 5 μg of antibody was added.  The diagonal line
is the migrated protein.
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3.2.8 Isolation of EphB4 containing protein complexes using 2D-NACE
Once the 2D-NACE method was optimised for use with EphB4 specific antibodies, it could
then be used to isolate and identify proteins that could be putative interacting partners of
EphB4. Protein lysate was collected from LNCaP cells as this cell line had a high expression of
EphB4, but did not express the ligand ephrin-B2 (see Figure 3.1). This is more like most clinical
samples that show no ephrin-B2, but high EphB4 expression and therefore would be a good
model for these experiments. The lysate was run through a first dimension gel and then
through a second dimension gel containing the anti-EphB4 antibody C1 in the stack region of
the gel. This was repeated for a second gel.
Figure 3.9 shows the two silver stained gels with circled areas corresponding to those proteins
that were either captured in the stack by the antibody (high affinity interactions) as well as
those proteins that were slowed through the main body of the gels (low affinity interactions).
These proteins appeared as dark spots and were subsequently excised and subjected to
trypsin digestion followed by mass spectrometry (LC-MS/MS) analysis to identify the
individual proteins within the complexes. A variety of spots for different areas of the two gels
were excised and analysed.
The Mascot software search engine (which uses mass spectrometry data to identify proteins
from peptide sequence databases) was used along with in-house tools to analyse the mass
spectrometry results and determine the probability that the peptides identified matched their
protein targets; as well as to determine the sequence coverage of the peptides compared to
the target protein. A full list of the peptides identified through the analysis is shown in
Appendix 1. The list identifies the protein name and NCBI reference sequence number; the
number of peptides found in the mass spectrometry analysis matching that protein (including
replicate peptides); the probability score that the peptide match is correct (calculated by the
analysis software); the percentage sequence coverage of the total protein from the identified
peptide; and a description of the protein’s known functions. Publication guidelines from the
Molecular and Cellular Proteomics journal for the analysis and documentation of peptide and
protein identifications were used to describe mass spectrometry data. From the data, eight
peptides were identified as targets of interest (shown in Table 3.1). Selection was based on
probability score and sequence coverage percentage as well as intuitive selection of proteins
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based on their known function and signalling pathways in relation to EphB4 mechanisms of
action. Peptides with a probability score below 0.7 were excluded.
Figure 3.9 – Cell selection and 2D-NACE analysis with C1 EphB4 specific antibodies in stacking gel.
Native protein lysates from LNCaP cells (as these didn’t express ephrin-B2) were loaded into two duplicated gels
and subjected to 2D-NACE as described in Section 2.2.10. The C1 EphB4-specific antibody was used in the stack
of the second dimension of the gels and protein spots found within this stack and body of the gels that were
outside the main line of protein were excised (marked in red) and analysed through mass spectrometry. The
resulting analysis is shown in Table 3.1.
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Table 3.1 – Selected putative interacting partners of EphB4 identified by 2D-NACE
Protein ProbabilityScore
Sequence
Coverage % Notes
THBS1
NCBI Reference:
NP_003237.2
0.9355 0.9
Thrombospondin-1 (or TSP1) - secreted protein that
mediates cell to cell and cell to matrix interaction and is
involved in angiogenesis and tumourigenesis, pathways
it shares with EphB4 (Hanahan & Folkman, 1996; Chen
et al. 2000; Sargiannidou et al. 2001)
MMP2
NCBI Reference:
NP_001289437.1
0.9982 2.9
Matrix metalloproteinase-2 (or gelatinase) - enzyme
that degrades the extracellular matrix and plays a role
in cell migration (including during prostate cancer
progression (Wilson et al. 2004; Roomi et al. 2009). Also
involved in Abl/Crk pathway regulated by EphB
receptors which MMP2 can cleave (Lin et al. 2008;
Pasquale, 2010)
PGRMC1
NCBI Reference:
NP_001269550.1
0.9726 4.6
Progesterone receptor membrane component 1 -
mediates apoptosis in cancer cells and modulates Akt
protein kinase (Hand & Craven, 2003)
ADAM23
NCBI Reference:
NP_003803.1
0.8797 1.6
Disintegrin and metalloproteinase domain-containing
protein 23 - protease which is highly expressed in the
brain and is involved in cell-cell and cell-matrix
interactions (Poindexter et al. 1999)
TUBB
NCBI Reference:
NP_001280141.1
1.000 7.7
β-Tubulin - subunits of the globular protein family of
tubulins that form microtubules; components of the
cytoskeleton (Dutcher, 2001). EphB4 was able to
indirectly modify microtubules during development
(Meima et al. 1997; Pasquale, 2005). β-Tubulin has also
been implicated in prostate cancer progression
(Ploussard et al. 2010)
SERPINA10
NCBI Reference:
NP_001094077
0.8027 3.3
Protein Z-dependent protease inhibitor - a serine
protease inhibitor (serpin) with roles in blocking factors
in the coagulation cascade (Han et al. 2000)
PI3KR1
NCBI Reference:
NP_852664.1
0.7908 2.8
Phosphatidylinositol 3-kinase regulatory subunit alpha -
subunit of PI3K - involved in proliferation, migration,
differentiation, insulin levels and cell survival through
the PI3K/Akt/mTOR pathway, which is regulated by
EphB4 (Steinle et al. 2003; Hale et al. 2012; Bitting &
Armstrong, 2013)
PTK2B
NCBI Reference:
NP_004094.3
0.9982 1.4
Protein tyrosine kinase 2 beta (or Pyk2) - regulates ion
channels and activates map kinase signalling (Lev et al.
1995)
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3.2.9 Confirming the interaction of Thrombospondin-1 with EphB4
3.2.9.1 Thrombospondin-1 is shown to interact with EphB4 through co-immunoprecipitation.
Thrombospondin-1 was identified as a putative protein partner of EphB4 by the 2D-NACE
technique (see Table 3.1). This protein was of particular interest because of its role in
angiogenesis and tumourigenesis, two physiological/pathophysiological processes in which
EphB4 is also known to play a role (Hanahan & Folkman, 1996; Chen et al. 2000; Sargiannidou
et al. 2001) as well as its role in mediating cell-to-cell and cell-to-matrix interaction (through
interaction with cell adhesion receptors including CD36, CD47 and the integrin protein
family), functions that EphB4 is also involved in (Simantov et al. 2003).
Furthermore, Thrombospondin-1 has been shown to be cleaved by Kallikrein-4, the same
serine protease that can also cleave EphB4 (personal communication from Ruth Fuhrman-
Luck and Jessica Lisle) and as such it is hypothesised that EphB4 works with these proteins
during cancer progression in a yet unknown pathway. To test whether EphB4 and
Thrombospondin-1 directly interact, a co-immunoprecipitation (Co-IP) pull down assay was
performed using native protein lysate extracted with RIPA buffer from 22Rv1B4 (EphB4
overexpressing) prostate cells as described in Chapter 2. An antibody against EphB4 (C1
antibody), against Thrombospondin-1 and against irrelevant IgGs (as a negative control for
non-specific interactions) were used in three separate co-immunoprecipitation pull down
assays.
The resulting blots (Figure 3.10) show a band corresponding to the size of EphB4 (120 kDa) in
both the EphB4 Co-IP and the Thrombospondin-1 Co-IP samples as well as in the positive
control cell lysate samples on the blot probed with the EphB4 specific antibody. No band at
this size is seen in the negative control IgG Co-IP lane as expected, indicating that no non-
specific binding was occurring. The same was seen on the blot probed with the
Thrombospondin-1 specific antibody, where a band corresponding to the size of
Thrombospondin-1 (240 kDa) was visible in both EphB4 and Thrombospondin-1 Co-IP samples
and in the lysate control samples (additionally indicating that Thrombospondin-1 is expressed
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by 22Rv1B4 cells), but not the IgG Co-IP negative control samples. This result suggests that
EphB4 and Thrombospondin-1 do interact as supported by the co-IP and Western blots.
Figure 3.10 - Co-immunoprecipitation pull down assays of Thrombospondin-1 and EphB4.
Co-immunoprecipitation pull down assays were performed on 22Rv1B4 cell lysates with anti-EphB4, anti-
Thrombospondin-1 and anti-IgG antibodies. The samples were loaded onto a gel along with a whole cell lysate
from 22Rv1B4 cells as a positive control. The resulting Western blot was probed for EphB and Thrombospondin-
1. A band corresponding to the size of EphB4 (120kDa) and a band at 240 kDa corresponding to the size of
Thrombospondin-1 can be seen in both the EphB4 and Thrombospondin-1 pull down assays as well as in the
protein lysate control. The IgG control is negative for both the EphB4 and Thrombospondin-1 antibodies
indicating no non-specific binding occurred.
3.2.9.2 Thrombospondin-1 is in close proximity to EphB4 in prostate cancer cells.
The interaction of EphB4 with Thrombospondin-1 had been suggested by both the 2D-NACE
studies and the co-immunoprecipitation pull down assays. However, confirmation of this
interaction still depended on whether both the proteins were located in the same cellular
space. To test whether both proteins are found together within prostate cells, a co-
localisation study was performed by using immunofluorescent antibodies specific to the two
target proteins and visualising the resulting signals with a confocal microscope (this was not
a super resolution microscope). The immunofluorescence process described in Section 2.2.15
was used, except that the cells were stained overnight with either both anti-EphB4 and anti-
Thrombospondin-1 primary antibodies, and for the control slides, with anti-EphB4 primary
antibody only (no secondary Ab), anti-Thrombospondin-1 primary antibody only (no
secondary Ab), anti-goat secondary antibody only (no primary Ab), or anti-rabbit secondary
antibody only (no primary Ab).
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Figure 3.11 shows EphB4 and Thrombospondin-1 are in close proximity and may be co-
localised. This was seen throughout the cells in all cell lines and was particularly prevalent at
the periphery, near the cell membrane and as dots in the cytoplasm in LNCaP cells.
Thrombospondin-1 itself was seen in the cytoplasm of all cell lines, but with no specific area
of localisation. EphB4 was also dispersed throughout the cells, but some surface expression
could be seen in 22Rv1 cells, while LNCaP cells had low visible intensity of EphB4 compared
to the 22Rv1 cells. The primary only and secondary only control slides did not show any
specific staining, indicating that antibodies were in fact binding to the correct targets.
Combined with the 2D-NACE and co-immunoprecipitation studies shown previously, these
results indicates that EphB4 and Thrombospondin-1 are found in the same cellular location
and therefore are likely able to interact with each other.
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22Rv1VO: EphB4 and Thrombospondin-1 22Rv1B4: EphB4 and Thrombospondin-1
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Figure 3.11 - Thrombospondin-1 is in close proximity to EphB4 in prostate cancer cells.
Confocal microscopy images of 22Rv1VO, 22Rv1B4 and LNCaP cells probed with both anti-EphB4 and anti-Thrombospondin-1 antibodies as well as control slides stained with
anti-Thrombospondin-1 primary antibody only (no secondary Ab); anti-EphB4 primary antibody only (no secondary Ab); anti-goat secondary antibody only (no primary Ab); and
anti-rabbit secondary antibody only (no primary Ab). Individual channels are shown along with the combined overlayed image. EphB4 is shown in red, Thrombospondin-1 in
green and the nuclei in blue while co-localisation of EphB4 and Thrombospondin-1 appears yellow. Co-localisation can be seen throughout the cells in all cell lines, particularly
near the cell membranes and nucleus. Thrombospondin-1 can be seen in the cytoplasm and EphB4 is also dispersed throughout the cells with some surface expression in 22Rv1
cells and lower levels in LNCaP cells compared to 22Rv1 cells. Representative control slides of LNCaP cells with primary antibody only and secondary antibody only staining do
not show any specific staining (shown in green with nuclei in blue).
LNCaP: EphB4 and Thrombospondin-1 Representative Controls
100X
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3.3 Discussion
3.3.1 2D-NACE
The EphB4 receptor tyrosine kinase is a membrane bound protein involved in the regulation
of a number of important cellular functions in development and adulthood including
angiogenesis, migration and morphogenesis (Wang & Anderson, 1997; Martiny-Baron et al.
2004; Poliakov et al. 2004; Erber et al. 2006). EphB4 activation initiates signalling cascades
which affect downstream processes including proliferation, differentiation and bone
remodelling (Zhao et al. 2006; Pasquale, 2010; Matsuo, 2010). Additionally, deregulation of
EphB4 signalling has been implicated in disease, including cancer progression, where it is
often over-expressed and affects angiogenesis, proliferation, cell morphology, and
attachment and migration (Wimmer-Kleikamp & Lackmann, 2005).
EphB4 interacts with just one physiologically relevant ligand, ephrin-B2 (Sakano et al. 1996;
Brambilla et al. 1995). This interaction occurs through the formation of a heterotetrameric
complex consisting of two receptors on one cell, interacting with two ligands on an opposing
cell in trans (Pasquale, 2005). This results in forward signalling into the EphB4 expressing cell
through phosphorylation of the tyrosine kinase domains of the receptors; and reverse
signalling into the ephrin-B2 expressing cell through Src kinase phosphorylation (Krasnoperov
et al. 2010; Noren et al. 2004; Himanen & Nikolov, 2003a; Palmer et al. 2002) (Figure 1.3).
The signalling pathways initiated by the coming together of EphB4 and ephrin-B2 are not all
well investigated, however, some research has identified some of the downstream effects of
this interaction based on the observed cellular functions. These include mediating
angiogenesis, proliferation, differentiation and bone remodelling (Gerety et al. 1999;
Pasquale, 2010; Matsuo, 2010) as well as developmental processes such as neural network
formation, axon guidance, endothelial cell migration, and patterning and morphogenesis
(Wang & Anderson, 1997; Helbling et al. 2000; Poliakov et al. 2004). This signalling is also
known to recruit other intracellular proteins which through signalling cascades affect these
cellular processes (Pasquale, 2010). However, the proteins that are recruited by EphB4 during
signalling events are largely unknown.
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As such a new technique, called 2D-NACE, was developed by Dr Sally-Anne Stephenson and
Dr Scott Stansfield and optimised as described here to identify the protein partners of EphB4.
2D-NACE is a novel method for the identification of interacting protein partners of a given
target protein. The process separates a native cell lysate on a gradient polyacrylamide gel
through electrophoresis based on the size of the proteins. This gel is then run over a second
gradient gel which has an antibody immobilised in the stacking region of the gel specific to
the target protein. This acts as a molecular sieve, slowing low affinity interacting proteins
through the gel while retaining high affinity interacting proteins within the stack. These can
then be excised and the proteins identified through mass spectrometry.
An important step in identifying valid interactions is to maintain the native conditions of the
proteins as closely as possible during processing. As such this method was designed and
optimised to retain native EphB4 containing protein complexes within the stacking region of
a polyacrylamide gel using anti-EphB4 antibodies as a molecular “trap” where interactions
between the antibody and the EphB4 containing protein complexes, either captures or slows
the progression of the complexes allowing these to be excised from the gel and analysed by
mass spectrometry. However extensive optimisation was required in order to effectively
isolate and analysis these complexes.
Initial development involved selection of a detergent that would maintain both the structure
and function of the native protein complexes. Three detergents were tested with a variety of
concentrations: Triton-X100, Dodecyl-β-D-maltoside (DDM), and Digitonin. It was determined
(Figure 3.2 and Figure 3.3) that DDM was best able to maintain the protein complexes during
lysis as it produced the highest number of bands at a concentration of 2.5 g detergent/g
protein (it had previously also been reported to retain protein function and structure of
membrane proteins during solubilisation (Van Aken et al, 1986; Lund et al, 1989; Fleming et
al 1997)). Although digitonin also produced good results, it required a much higher
concentration compared to DDM and was also much more toxic to handle.
The subsequent step in optimising the 2D-NACE method was to establish the characteristics
of the gel to be used in the electrophoresis. The 4% - 13% polyacrylamide gradient gels were
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tested with varying gel thicknesses and it was determined that the 1.5 mm gels were more
robust and thus better suited to being physically manipulated during the transfer from the
first dimension to the second dimension of the 2D-NACE protocol. Additionally, it was found
that the 5% stacking gel provided the tightest migration into the main gel (Figure 3.4).
As the gel parameters and detergent to be used were established, the subsequent step in
optimising the 2D-NACE method was to confirm that these conditions for polyacrylamide gel
electrophoresis (PAGE) were able to maintain protein complexes. To test this, recombinant
ephrin-B2, EphB4 and a complexed form of ephrin-B2 and EphB4 were electrophoresed
through the NACE gel. The combined EphB4 ectodomain and ephrin-B2-Fc were observed at
a higher molecular weight indicating that the ligand had almost completely complexed with
the receptor (as no band at the ligand size was seen, though bands corresponding to unbound
EphB4 were still seen). This also indicated that the imidazole solubilisation buffer containing
the DDM detergent and the gel used for this experiment were able to maintain this interaction
through the electrophoresis of the NACE gels (Figure 3.5 and Figure 3.6).
The final optimisation stage was to determine the optimum antibody to use in the stacking
region of the gel as the molecular net to capture the target protein through an affinity
interaction. The initial method for adding the antibody to the protein complexes was to soak
the gel strip from the first dimension in a solution containing the EphB4 specific antibody;
however, this did not prevent the antibody from migrating into the gel. A second method was
thus used, whereby the antibody was added directly to the stacking gel before
polymerisation. This embedded the antibody in the stacking gel, keeping the majority of the
antibody from migrating during electrophoresis and thereby providing a successful affinity
capture system. This capture system was tested with three EphB4 specific antibodies, C1,
11H4 and 13A7 which were immobilised in the second dimension stacking gel and the C1
antibody was most effective (Figure 3.7). As such the C1 antibody was used for further 2D-
NACE experiments. Optimisation of the quantity of antibody found that 5 μg of antibody was
an optimum concentration (Figure 3.8).
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The 2D-NACE method was tested with all optimised components (the buffer with the DDM
detergent, the gradient gel and the C1 antibody) to confirm it was able to separate and isolate
high molecular weight complexes containing EphB4. Total protein lysates from LNCaP
prostate cancer cells were used as LNCaP cells offer a good model that matches most clinical
samples that show high EphB4 expression (Figure 3.1). Using these cells would allow the 2D-
NACE method to capture proteins potentially interacting with EphB4 in a tumour promoting
cellular context (where EphB4 is expressed without its ligand and initiates auto-
phosphorylation and tumourigenic pathways). Alternatively, for future experiments, the
22Rv1-B4 cell line could also be used, where EphB4 is over-expressed and provides more
opportunities for potential partners to bind and interact with EphB4.
The optimised 2D-NACE method was used with protein lysate collected from LNCaP cells. The
resulting gel (Figure 3.9) was silver stained and spots of interest were cut from both the
stacking portion of the gel and the main gel itself. Protein spots were cut from a number of
sections of the gel, but specifically those that were outside the diagonal line, which indicate
that complexes were slowed through the gel. In fact, it is more likely that the streaks (rather
than spots) that were cut from the gel contained proteins that were slowed through
interaction with the antibody in the stack. This was the case when EphB4 alone was processed
using 2D-NACE (Figure 3.7), leaving a streak of protein in the gel. Spots found outside the
main line of protein may only be poor migrators rather than proteins slowed by the antibody
in the stack. The excised regions were analysed by mass spectrometry. Subsequent computer
analysis resulted in a large number of proteins being identified from the gel (from both high
affinity and low affinity regions of the gel) as potential binding partners of EphB4 (selected
proteins shown in Table 3.1 and full list in Appendix 1 A number of proteins of interest were
found in the data that had roles in prostate cancer progression or were involved in pathways
that EphB4 was also known to regulate. These included several proteins with known functions
in cancer including MMP-2, PI3KR1, PGRMC1 and β-Tubulin. MMP2 is an enzyme that
degrades the extracellular matrix and plays a role in cell migration (Wilson et al. 2004; Roomi
et al. 2009) as well as being involved in the Abl/Crk pathway regulated by EphB receptors (Lin
et al. 2008; Pasquale, 2010). A functional relationship between EphB4 and MMP-2 is implied
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from several studies that have shown that in breast cancer cells in which EphB4 gene is
knocked down using siRNA there is a concomitant reduction in MMP-2 gene expression
(Kumar et al, 2006). PI3KR1 (a signal transducer enzymes) is involved in proliferation,
migration, differentiation, insulin levels and cell survival through the PI3K/Akt/mTOR
pathway, which is regulated by EphB4 (Steinle et al. 2003; Hale et al. 2012; Bitting &
Armstrong, 2013). PGRMC1 is known to mediate apoptosis in cancer cells (Hand & Craven,
2003) and β-Tubulin (a component of the cytoskeleton) has also been implicated in prostate
cancer progression (Ploussard et al. 2010).
Additionally, a  number of proteins identified in the 2D-NACE data were also found to be
involved in DNA processing and repair including: Fanconi Anemia group E (FANCE), which is
involved in nuclear regulation and DNA repair and can form a  complex with p53 (D'Andrea,
2010); the histone HIST1H1C, a nuclear proteins involved in maintaining DNA structure
(Konishi et al. 2003) and DNA-dependent protein kinase (PRKDcs),  which is involved in
repairing double-strand breaks in DNA (Meek et al. 2008). All these proteins may potentially
interact with EphB4 in the nucleus. Surprisingly, peptides identifying EphB4 were not
identified in any of the 2D-NACE experiments performed.  There are several potential reasons
why this may be the case.  Accurate identification of proteins from mass spectra is difficult
and current methods typically identify fewer than 50% of the proteins in complex samples
(Wang and Wilson, 2013; Wong et al, 2007; McHugh and Arthur, 2008; Paradela and Alba,
2008). Post-translational modifications can also affect the efficiency of the trypsin digestion
and/or the identification of the peptides in the mass spectrometer.
EphB4 is glycosylated in the extracellular region; phosphorylated on tyrosine, threonine and
serine residues in the intracellular domain and can also by sumoylated (Daub et al, 2008;
Mertens-Walker et al. 2013). This may explain the apparent absence of EphB4 peptide
fragments in the LC-MS/MS spectra (or, the correct spots containing EphB4 may not have
been excised and analysed). It is also interesting to note that the 2D-NACE method varies to
some extent with each application. Although the same conditions are used, repeats of the
method do not always show case the exact same protein staining. This is due to the fact that
biological interactions rely on a number of variables in order to occur and as such, the
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interaction between a protein and a capture antibody within the stacking portion of the gel
may not always occur, or may be a weaker or stronger interaction than in other iterations.
However, strong interactions between a protein and the antibody should usually appear if the
same conditions are maintained between repeats.
Further optimisation of this technique is needed to improve the results and detect EphB4 in
the 2D-NACE gel. Identifying EphB4 could be achieve through running a similar gel and testing
to see if EphB4 can be extracted from the gel specifically and identified through mass
spectrometry. This could be aided through the use of nitrocellulose paper with EphB4
antibody to identify where EphB4 migrates to, as well as spiking the sample with recombinant
EphB4, running it on the gels, and identifying the location to be excised. Further to this,
combining EphB4 and ephrin-B2 together (a known interaction) prior to running on the gel
and then identifying the complexed proteins using antibody detection could also locate the
region to be excised and confirm the presence of EphB4 in the 2D-NACE gel. Another method
of detecting protein partners interacting with the EphB4 antibody would be to run two gels
side by side, one with EphB4 antibody in the stack, and the other without (possibly with
control IgG to identify non-specific and low affinity interactions), and to determine which
proteins are in different locations, thus identifying complexes that are affected by the EphB4
antibody.
Additional washes could also be used to lessen contamination and background noise. One
future method to detect EphB4 in the samples could be through the use of affinity based
procedures an EphB4 antibody-cross-linked to agarose beads. This may allow for more
specific binding of EphB4 and its interacting partners for further proteomic analysis. Other
optimisation steps could include altering reagents (such as the type of buffer, the antibodies
used and the concentration of the detergent) to improve the conditions for the isolation and
identification of EphB4. The addition of soluble ligand ephrin-B2 and determination of
conditions for effective isolation of this known high affinity interacting protein would help
improve the assay. Another potential future experiment to determine whether specific
proteins interact is to use Far Western blotting techniques to determine direct interactions.
A recombinant protein would be transferred onto a membrane and incubating with the
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potential partner protein. An antibody against the potential protein partner could then be
used to detect any interacting complexes at the position of the first protein.
Alternatively, using a cross-linking agent could also be effective in confirming the interaction
of these proteins. Future studies could include optimisation of the crosslinking reagents in
order to test whether proteins interact and are held together using cross-linking agents.
Known binding partners (such as ephrin-B2) could be used to test the conditions prior to use
with putative partner proteins. This could be coupled immunofluorescence as a method to
rapidly detect proteins that are colocalised and possibly interacting prior to cross-linking and
further testing.
Overall, the 2D-NACE method has the potential to be a versatile method for identifying
proteins that interact in native complexes with a target protein of interest. 2D-NACE has the
advantage over many other antibody capture techniques in that it can be adapted for use
with almost any antibody and it allows for capture of both strongly and weakly interacting
proteins from an entire cell lysate. Antibodies suitable for the 2D-NACE method can be easily
identified by a shift in molecular weight after incubation with a native protein lysate and used
in an affinity capture approach to isolate protein complexes containing the target protein.
These can then be identified using mass spectrometry, which can identify a number of
potential interacting proteins and thus lead to uncovering new information concerning the
biological function of these proteins as well as their interactions and the pathways that they
are involved in.
However, further work is still need to further optimise this process and produce cleaner gels
and more distinct spots. The 2D-NACE technique is not robust and difficult to reproduce. It
uses many different reagents involved and is a technically challenging methodology.
Improvements could also be made in the process of preparation for mass spectrometry in
order to ensure that accurate protein cleavage is made and proteins are correctly identified.
Currently the 2D-NACE has a great deal of potential and will be a useful proteomic tool once
it is completely optimised and developed.
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3.3.2 Thrombospondin-1, a novel interacting partner for EphB4
The 2D-NACE method was used to identify a large number of potential protein partners for
the EphB4. However, even after statistical elimination of many of the protein matches, the
number of likely partners for EphB4 was still too large to further confirm all their interactions
with EphB4. As such, initially Thrombospondin-1 chosen for further validation.
Thrombospondin-1 is a secreted protein that has been shown to be involved in mediating cell
to cell and cell to matrix interactions and has been reported to promote tumourigenesis and
to have anti-angiogenic effects, roles in which EphB4 is also involved (Lahav, 1993; Hanahan
& Folkman, 1996; Chen et al. 2000; Sargiannidou et al. 2001). Additionally, Thrombospondin-
1 can be cleaved by Kallikrein-4, the same serine protease that can also cleave EphB4
(personal communication from Ruth Fuhrman-Luck), and can also directly interact with matrix
metalloproteinase 2 (MMP2) (Bein & Simons, 2000). In cancer cells, Thrombospondin-1 acts
as a tumour suppressor, inhibiting cancer progression and metastasis (Weinstat-Saslow et al.
1994; Zabrenetzky et al. 1994; Volpert et al. 1998). This is thought to occur through anti-
angiogenic effects resulting from Thrombospondin-1 signalling events (Campbell et al. 1998).
To test whether Thrombospondin-1 directly interacted with the EphB4 receptor, co-
immunoprecipitation (Co-IP) pull down assays and immunofluorescence based confocal
microscopy co-localisation studies were performed. The immunoprecipitation results (shown
in Figure 3.8) revealed that Thrombospondin-1 was able to be pulled out in EphB4 Co-IPs and
as such, this suggests that EphB4 and Thrombospondin-1 interact directly as predicted by the
2D-NACE study. To further confirm this interaction, co-localisation studies were performed
using confocal microscopy to confirm that the proteins occupied the same cellular space and
were able to physically interact with each other. Cells were stained with immunofluorescent
antibodies specific to EphB4 and Thrombospondin-1. The resulting images (Figure 3.9) show
that EphB4 and Thrombospondin-1 are located in close proximity to each other (however as
the microscope used was not a super resolution microscope, it cannot be said definitely that
the two proteins are in fact collocated). These results indicate that EphB4 and
Thrombospondin-1 are found in the same cellular location and therefore it is possible for
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them interact. Taking together this result with the 2D-NACE and co-immunoprecipitation
studies, it can be concluded that EphB4 and Thrombospondin-1 should interact in 22Rv1 and
LNCaP cells.
The implications of the interaction of Thrombospondin-1 with EphB4 on cellular function and
signalling pathways are currently not known. The most common role for Thrombospondin-1
is in modulating angiogenesis, specifically as an anti-angiogenic protein (Tolsma et al. 1993;
Lawler & Lawler, 2012). EphB4 is also involved in blood vessel formation, specifically having a
pro-angiogenic role when interacting with its ligand ephrin-B2. However, the Eph-ephrin
interaction is tumour suppressive (Rutkowski et al. 2012) so it is hypothesised that
Thrombospondin-1 (which is a tumour suppressor in cancer cells (Weinstat-Saslow et al. 1994;
Zabrenetzky et al. 1994; Volpert et al. 1998)) would interact with EphB4 in this ligand
dependent manner in order to initiate tumour suppressing pathways, potentially through
inhibiting cancer progression by decreasing angiogenesis (Campbell et al. 1998).
Additionally, EphB4 and Thrombospondin-1 are both regulated by p53 and PTEN, two
proteins known to be involved in cancer progression (Bergers & Benjamin, 2003; Xia et al.
2005a). These two modulating proteins are able to mediate angiogenesis through regulation
of Thrombospondin-1 (Dameron et al. 1994). As such there may be some interplay and
interaction between EphB4 and Thrombospondin-1 when affected by p53 or PTEN signalling.
Thombospondin-1 has known roles in mediating angiogenesis and tumourigenesis and has
been linked to cell to cell and cell to matrix attachment (Lahav, 1993; Hanahan & Folkman,
1996; Chen et al. 2000; Sargiannidou et al. 2001). Hypotheses for its role when bound to
EphB4 include mediation of angiogenesis (a pathway that EphB4 is involved) through
interaction of Thrombospondin-1 with EphB4 and its receptor, CD47 (Csányi et al. 2012;
Roberts et al. 2012), as well as tumour suppressive functions when interacting with the
EphB4-ephrin-B2 complex whose signalling results in the initiating of ligand dependent
tumour suppressive pathways (Weinstat-Saslow et al. 1994; Zabrenetzky et al. 1994; Volpert
et al. 1998; Rutkowski et al. 2012).
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Another possible mechanism of action for this interacting complex is in the coagulation
cascade. Thrombospondin-1 is responsible for the cleavage of prothrombin to form thrombin
(Factor II) and also binds to fibrinogen (Factor I) and plasminogen in the blood clotting cascade
(Silverstein et al. 1984; Bajzar et al. 1996). Thrombospondin-1 also binds to its receptor CD47
(a membrane protein involved in vascular signalling) (Csányi et al. 2012; Roberts et al. 2012).
The binding of secreted Thrombospondin-1 to CD47 initiates signalling through cyclic
guanosine monophosphate (cGMP) which is involved in the activation of intracellular kinases
(Francis & Corbin, 1999). In this context it is thought that membrane bound EphB4 binds to
secreted Thrombospondin-1 which also bind CD47 (which is also expressed on the
membrane), forming a larger complex, likely in lipid raft regions of the membrane. However,
it is unclear as to the role that EphB4 would play in these processes when bound to
Thrombospondin-1 and the effects that this interaction has on cellular function. There are
likely a number of other processes and pathways that may be affected by the EphB4-
Thrombospondin-1 complex, but these are still unknown and further research must be
undertaken to understand the mechanisms involved.
Furthermore, it has been reported that both EphB4 and Thrombospondin-1 can be cleaved
by Kallikrein-4 (KLK4), a serine protease (Personal communication from Ruth Fuhrman-Luck).
This opens up the potential for the formation of an EphB4-Thrombospondin-1 complex that
is regulated by KLK4 and it is hypothesised that this may play a role in prostate cancer
regulation. Further experiments such as investigating the effects of EphB4 and
Thrombospondin-1 cleavage by Kallikrein-4, and investigating signalling changes that occur
when Thrombospondin-1 interacts with EphB4 would be required to understand the purpose
of this newly discovered partnership. Specifically, identifying whether this interaction has any
effect on blood vessel growth and cell attachment would be an important step in gaining
understanding of the pathways affected by the interaction of these two proteins.
However, the exact function of the EphB4-Thrombospondin-1 interaction is not unclear and
the pathways this interaction may affect are yet to be fully identified and validated. As such,
further research is required into the roles that these complexes play in a cellular environment
and how the interplay with EphB4 will affect cell function in both normal and disease states
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(specifically in prostate cancer). Future work to further bolster the knowledge of these
interactions could include determining how these interactions are favoured in prostate
cancer, including understanding how the androgen receptor axis and response to androgens
or anti-androgens can affect these proteins and their downstream signalling effects. Other
studies could include investigating the effects of over-expression of Thrombospondin-1 in
cells and observation of the consequences (using assays for morphology, migration,
proliferation, cell adhesion and anchorage independent growth) and then coupled with the
use of Thrombospondin-1 inhibitors to try reverse these changes.
In conclusion, Thrombospondin-1 has been shown to interact directly with EphB4 through 2D-
NACE studies as well as having these interactions confirmed with both co-
immunoprecipitation pull down assays and immunofluorescence-based co-localisation
studies. This novel finding identifies a new interacting protein partners for EphB4 and
validates that the 2D-NACE method is able to be successfully used to identify interacting
protein partners of EphB4.
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Chapter 4: Identification of novel protein partners of EphB4
using co-immunoprecipitation
4.1 Introduction
Receptors and proteins are often found to exist as part of large complexes of interacting
proteins, rather than singular units. The investigation of these interacting proteins has
improved due to advances in protein chemistry, mass spectrometry and the rise of protein
databases. This allows researchers to observe protein-protein interactions in cells and native
tissues through advanced techniques that can provide deeper insights into protein functions
than was possible under more traditional techniques such as yeast two-hybrid systems.
One such technique is co-immunoprecipitation (coIP), a now common approach for the
identification of interacting proteins. This method relies on interacting proteins having strong
covalent links or high affinity interactions with the target protein that can be maintained
during both the production of a protein lysate and the immunoprecipitation process itself.
CoIP is performed in a similar process to the immunoprecipitation of a single protein, except
that the target (a known protein that is hypothesised to be part of a larger complex) that is
precipitated by the antibody is also used to precipitate the binding protein complex, thus
identify unknown protein partners in the complex (Sambrook & Russell, 2006; Lee, 2007; Free
et al. 2009).
Co-immunoprecipitation was used as a complementary technique to 2D-NACE (described in
Chapter 3) to identify additional protein partners of EphB4. A panel of antibodies was used to
immunoprecipitate EphB4 and any interacting protein in complex with the receptor from
prostate cancer cells engineered to over-express EphB4. The coIP was then analysed using
mass spectrometry to identify which proteins were pulled out with EphB4. Proteins that were
identified through this method were then further confirmed to interact with EphB4 through
immunoprecipitation studies.
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4.2 Results
4.2.1 Immunoprecipitation of EphB4 for identification of interacting proteins
Several mouse monoclonal antibodies specific to human EphB4 were available for this study
and to determine which would be useful in an immunoprecipitation approach, each were
coupled with protein G Surebeads and used to capture EphB4 and interacting proteins from
lysates were made from the 22Rv1 prostate cancer cell line engineered to over-express
EphB4, 22Rv1-B4 (unstimulated and cultured in complete media). Half of the
immunoprecipitated sample was reduced, denatured and separated by SDS-PAGE for
Western analysis using two commercially available antibodies that recognise different
epitopes of the EphB4 protein (Figure 4.1).  The other half was stored for trypsin digestion
from the bead and proteomic analysis using liquid chromatography coupled with tandem
mass spectrometry analysis (LC-MS/MS).
In the Western blot, the full length EphB4 protein migrates at approximately 120 kDa and a
band of this size is clearly identified in the lane that corresponds to the total protein lysate
used for the immunoprecipitation reactions (Input in Figure 4.1). Minor bands below this have
been confirmed to be protease-generated fragments of EphB4 (J. Lisle, personal
communication).  A band corresponding to the 120 kDa EphB4 band is also seen in each of
the reactions with the different EphB4 monoclonal antibodies (C1, C2, 6H4 aliquot 1 (6H4#1),
6H4 aliquot 2 (6H4#2), 11H4 and 9B7 as expected. High levels of EphB4 were used to simulate
an environment of over-expressed protein as would be found in a cancer model.
Unfortunately a band of similar size was also present in the lanes corresponding to samples
immunoprecipitated with non-specific mouse IgGs (mIgG1k and mIgG). This is likely overflow
from the nearby lanes.
The samples to which the two different aliquots of 6H4 (6H4#1 and 6H4#2) had been added
did identify one of the lower molecular weight EphB4 fragments (around 85 kDa), suggesting
specificity to that region of EphB4. The samples for 6H4 and 11H4 were therefore chosen for
further investigation and the duplicate samples were trypsin digested and sent for LC-MS/MS
analysis. As the Western blot result potentially contained some non‐specific staining, a
negative control, the mIgG1k sample, was also used.
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Figure 4.1. Western analysis of the immunoprecipitation of EphB4.
A panel of antibodies (C1, C2, 6H4 (from two different aliquots), 11H4, 9B7) was used to immunoprecipitate
EphB4 and interacting proteins from 22Rv1-B4 prostate cancer cells engineered to over-express EphB4. EphB4
has been detected in this blot using the Novus (Rabbit) primary antibody. Full length EphB4 is identified by an
immunoreactive band at approximately 120 kDa and indicated by the arrow and is seen clearly in the input
protein lysate lane (Input). Several bands of smaller molecular weight migrating in the input sample are believed
to be EphB4 fragments generated by protease activity.
4.2.2 LC-MS-MS analysis of EphB4-protein immunoprecipitated samples
To identify proteins within the four immunoprecipitation samples, each was digested with the
general serine protease trypsin and then analysed using a HPLC-Chip QTOF LC-MS/MS
(Proteomics Core Facility, Translational Research Institute, Brisbane, Australia). The identified
targets are shown in Table 4.1.
Of the targets identified PAK4 was chosen for further research because it is a serine/threonine
kinase that interacts with several proteins identified in the study including JNK1 (Ichijo, 1999)
(see Appendix 1 – Full list of putative protein partners of EphB4 identified using 2D-NACE and
immunoprecipitation for full list of proteins identified). PAK4, JNK1, MCF2L and ARHGAP39
(all identified in the mass spectrometry analysis), are also known to be involved in Rho family
GTPase signalling, which is implicated in the control of a wide range of cellular activates
including rearrangement of the cytoskeleton for cell motility and the regulation of epithelial
morphogenesis (Hall, 1998; Dan et al. 2001; Bustelo et al. 2007; Tcherkezian & Lamarche-
Vane, 2007).
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Table 4.1 - Selected putative interacting partners of EphB4 identified by
immunoprecipitation
Protein Probability SequenceCoverage % Notes
ARHGAP39 0.7968 0.8
ARHGAPs, also known as Rho GTPase activating protein
(Rho GAP), facilitate activation of Rho GTPases, through
modulating GTP into GDP. Active Rho GTPases play a role in
cellular processes including proliferation, differentiation
and motility (Tcherkezian & Lamarche-Vane, 2007)
JNK1 (MAPK8) 0.9982 3.4
JNK1 (or Mitogen-activated protein kinase 8) is a signalling
protein kinase involved in many cellular processes including
cell proliferation, differentiation, apoptosis and
development (Gupta et al. 1996)
MCF2L 0.9789 1.0
Guanine nucleotide exchange factor DBS - involved in RAC1
and RHOA signalling pathways through catalyzing guanine
nucleotide exchange (Nagase et al. 1997)
NDUFS1 0.9804 1.9
NADH-ubiquinone oxidoreductase 75 kDa subunit,
mitochondrial - enzyme transfers electrons from NADH to
the respiratory chain in the mitochondria (Sumegi et al.
1985)
OGG1 0.9230 2.0 Oxoguanine glycosylase - DNA glycosylase enzyme involvedin base excision repair (Bjoras et al. 2002)
PAK4 0.9982 2.0
p21 activated kinase 4 - plays a role in cell signaling,
motility, survival, angiogenesis, migration, mitosis, and
metastasis (Abo et al. 1999)
PGLYRP2 0.9568 2.6
N-acetylmuramoyl-L-alanine amidase - part of the immune
system and recognize peptidoglycan in bacterial cell walls
(De Pauw et al. 1995)
PHB2 0.7501 2.7
Prohibitin-2 - implicated in mitochondrial function,
transcription and cell proliferation (Coates et al. 2001;
Gamble et al. 2007)
PRKDcs 0.8966 0.6 DNA-dependent protein kinase, catalytic subunit - involvedin repairing double-strand breaks in DNA (Meek et al. 2008)
SHROOM3 0.8808 0.7 Shroom related protein 3 - involved in regulating cell shapeand neural development (Juriloff & Harris, 2000)
SPRR3 0.9321 4.7 Small proline-rich protein 3 - envelope protein ofkeratinocytes (Gibbs et al. 1993)
VCP 0.9982 4.5
Valosin-containing protein - ATP-binding structural protein
involved in vesicle transport and fusion, ubiquitin-
dependent protein degradation, proteasome function,
peroxisome assembly (Zhang et al. 2000)
4.2.3 Confirming the presence of PAK4 in prostate cancer cells
4.2.3.1 Gene expression profiling of PAK4 in a panel of prostate cancer cell lines
To determine whether expression of the potential EphB4-interacting protein PAK4 was
common in prostate cancer cells, several cell lines were subjected to RT-PCR analysis (Figure
4.2). The panel of cell lines included LNCaP, PC-3, DU145 and 22Rv1 prostate cell lines. The
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engineered 22Rv1 derivatives 22Rv1-VO (empty vector control) and 22Rv1-B4 (engineered to
overexpress EphB4) were also included to assess for any indication of EphB4 regulated
expression. A PCR product of the predicted size for PAK4 (183 bp) was amplified from cDNA
samples from all six prostate cancer cell lines.
Relative expression, determined by comparison with the amplification of a product
corresponding to the 18S rRNA sequence (103 bp), suggests that PAK4may be expressed less
in the PC3 and DU145 cell lines when compared with LNCaP, 22Rv1 and the derivative 22Rv1-
B4 (the 22Rv1 line engineered for constitutive over-expression of EphB4) and 22Rv1-VO (the
corresponding empty vector control) cell lines. Over-expression of EphB4 in the 22Rv1 did not
appear to alter Pak4 expression.
Figure 4.2. RT-PCR amplification of PAK4 in prostate cancer cell lines.
A. Semi-quantitative RT-PCR analyses of relative gene expression for the candidate proteins across a panel of
prostate cancer cell lines including PC3, DU145, LNCaP, 22Rv1 and the 22Rv1 derivative lines 22Rv1-B4
(engineered to over-express EphB4) and 22Rv1-VO (the empty vector control).  PCR products were separated on
1% agarose gels and imaged using the SYBR-Safe DNA stain. Each panel shows expression of the gene indicated
and the size of the PCR amplicon is indicated by the arrow and shown in base pairs (bp).  Semi-quantitative
expression is determined by comparison with the 18S rRNA amplicon. B. During reverse transcription, no RNA
and no enzyme controls were performed for all samples and for the PCR amplification a reagents only control
confirmed the specificity of the reaction.
105
4.2.3.2 Western analysis of protein expression of PAK4 in a panel of prostate cancer cell lines
To determine whether protein expression of PAK4 was consistent with the gene expression
profiles, total protein lysates were prepared from all six prostate cancer cell lines for
separation on SDS-PAGE and transfer to nitrocellulose membranes for Western analysis with
target specific antibodies.  EphB4 protein levels were determined using a commercially
available antibodies (Novus) (Figure 4.3A). A strong band at 120 kDa, which corresponds to
the reported molecular weight of EphB4 was clearly seen in the samples from the 22Rv1 B4
cell line.  Bands of similar size were variably expressed in the other prostate cancer cell lines.
Slight variations in molecular weight may indicate cell-specific post-translational
modifications.
A PAK4-specific antibody identified 2 bands visible at approximately 70 kDa (Figure 4.3B).
PAK4 protein levels reflect the gene expression profile with similar expression levels being
detected for LNCaP and 22Rv1 lines and less protein produced by the androgen-independent
PC3 and DU145 lines. The identity of the protein detected as a band above 75 kDa is not
known. The faintly immunoreactive band observed below 65 kDa PAK4 may be non-specific,
or could alternatively represent one of the known isoforms of PAK4 predicted to have
molecular weights of 55 and 48 kDa.  Equal protein loading was verified by sequential probing
with an antibody to housekeeping protein Glyceraldehyde 3-phosphate Dehydrogenase
(GAPDH) (Figure 4.3C).
106
Figure 4.3. Western analysis of protein expression of candidate proteins in prostate cancer cell lines.
The prostate cancer cell lines PC-3, DU145, LNCaP,22Rv1-P (parental) 22Rv1–VO (empty vector control) and
22Rv1-B4 (EphB4 exogenously overexpressing) were each probed with (A) a commercial antibody (Novus)
showing full length EphB4 protein expression at approximately 120 kDa, and (B) PAK4. A band corresponding to
the predicted size of GAPDH (37 kDa), detected using an anti-GAPDH antibody on the same immunoblot,
confirmed sample integrity and confirmed equal loading (C).
4.2.4 Immunoprecipitation of putative protein partners using antibodies
specific to EphB4
To further validate the interaction of EphB4 and putative protein partners identified through
co-immunoprecipitation (see Section 4.2.2), co-immunoprecipitation was performed using a
panel of antibodies against EphB4 (11H4 and 6H4). In addition co-immunoprecipitation was
also performed using antibodies against PAK4 and proteins identified through mass
spectrometry that are known to be involved in Rho family GTPase signalling with PAK4:
ARHGAP39 and MCF2L. Irrelevant mIgG and rIgG antibodies were used as controls for non-
specific interactions. Samples were analysed by Western analysis by probing the blots with
the EphB4-specific Novus antibody (Figure 4.4A).
Figure 4.4A shows a unique band of approximately 120 kDa (corresponding to full length
EphB4) that can be seen in the lanes where 11H4 and 6H4 have been used to isolate EphB4.
Also of note are bands of the same size visible in the lane corresponding to the PAK4 and
MCF2L immunoprecipitation reactions. This indicates that EphB4 has been retained as a co-
precipitant in these reactions and may interact with PAK4 and with MCF2L. Interaction with
ARHGAP39 could not be similarly confirmed. A non-specific band of approximately 120 kDa
was detected, although only faintly, in the rIgG negative control, which may correspond to
dissociated antibody that has not been reduced in the preparation of samples.
PAK4 is also know to interact with JNK1 (Ichijo, 1999). As such, JNK1, was also selected for
further testing through a co-immunoprecipitation pull down assay to confirm whether it too
can be pulled down with EphB4 as part of the hypothesised complex. Native protein lysate
from LNCaP prostate cells was subjected to a co-immunoprecipitation pull down using the
Zymed EphB4 antibody. The samples were denatured and electrophoresed on a SDS-PAGE gel
which was then probed with antibodies against EphB4, and JNK1 (Figure 4.4B). A band
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corresponding to the size of EphB4 (120 kDa) was observed in the EphB4 immunoprecipitation
pull down. The blot was then probed with JNK1 (without stripping the blot) and bands
corresponding in size to JNK1 (45 kDa) and EphB4 (120 kDa) were seen. This indicates that
JNK1 is co-precipitated with EphB4 and may interact with the receptor as part of a larger
signalling complex.
Figure 4.4.  Immunoprecipitation of EphB4 using antibodies targeting potential interacting partners.
A. Antibodies were used to immunoprecipitate EphB4 (11H4, 6H4), and candidate proteins (ARHGAP39, MCF2L,
PAK4) from 22Rv1-B4 prostate cancer cells. EphB4 was detected using Novus (Rabbit) primary antibody. Full
length EphB4 is identified by an immunoreactive band at approximately 120 kDa and is seen clearly in the input
protein lysate lane (Input), in addition to lanes corresponding with the antibodies 11H4, 6H4 against EphB4 as
well as in reactions targeting MCF2L and PAK4 for immunoprecipitation. B. Western blot analysis of co-
immunoprecipitation pull down of EphB4 using LNCaP protein lysate and Zymed EphB4 antibody. The resulting
Western blots were probed for EphB4 (C1 antibody) and JNK1. A band corresponding to the size of EphB4
(120kDa) was observed in the EphB4 IP pull down. In the JNK1 probed blot, a band corresponding in size to JNK1
(45 kDa) and EphB4 (120 kDa) was seen in the JNK1 IP.
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4.3 Discussion
EphB4 is a receptor tyrosine kinase and is involved in a number of signalling pathways. As
such it is expected that it would interact both directly and indirectly with other proteins. Co-
immunoprecipitation is a useful technique for the identification of high-affinity interacting
proteins that are often found together in larger complexes, and so it was used as a
complementary technique to 2D-NACE to identify proteins that could interact with EphB4.
Immunoprecipitation in conjunction with mass spectrometry analysis was used to identify
potential binding partners of EphB4 (Figure 4.1). This process produced a list (Table 4.1, with
full list of identified proteins included in Appendix 1 – Full list of putative protein partners of
EphB4 identified using 2D-NACE and immunoprecipitation) of putative proteins that could
potentially be interacting partners of EphB4. Of these, PAK4 as well as JNK1, ARHGAP39 and
MCF2L, were selected for further research, to determine if they interacted with EphB4, as
these proteins are known to be involved in Rho family GTPase signalling (this is further
discussed below). Appendix 1 contains a list of protein identified through mass spectrometry
and through immunoprecipitation methods. There are a number of possible explanations for
why this list is so extensive (it is unlikely that EphB4 would interact with all these targets at
one time). It is possible that some of these interactions are due to non-specific binding of
EphB4, some interactions are the result of the antibodies reacting with the intracellular
protein pool, and some of interactions may be artefacts generated by the intracellular protein
pool interactions with the Sepharose beads.
PAK4 is a p21 activated kinase that interacts with several proteins and plays an essential role
in cell signalling and control of cell motility, survival, angiogenesis and mitosis, increasing
migration potential, anchorage independent growth and metastasis (Abo et al. 1999), much
like EphB4. PAK4 is also known to be involved in Rho family GTPase signalling, which is
implicated in the control of a wide range of cellular activates. JNK1, also known as MAPK8, is
a mitogen-activated protein kinase, an intracellular signalling protein known to be activated
by multiple and diverse stimuli with roles in proliferation and both stimulation and inhibition
of apoptosis (Gupta et al. 1996). MCF2L (Guanine nucleotide exchange factor DBS) is involved
in Rac1 and RhoA signalling pathways through catalysing guanine nucleotide exchange
(Nagase et al. 1997). ARHGAP39 is a Rho GTPase activating protein (Rho GAP) and facilitates
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activation of Rho GTPases by modulating GTP into GDP. Active Rho GTPases can then play a
role in cellular processes including proliferation, differentiation and motility (Tcherkezian &
Lamarche-Vane, 2007).
PAK4 was selected as the primary target of interest to test. Initially gene and protein
expression was confirmed (Figure 4.2 and Figure 4.3). This was followed by co-
immunoprecipitation of EphB4 using antibodies targeting the potential interacting partners
that were thought to work in a complex: PAK4, ARHGAP39 and MCF2L and JNK1. EphB4 was
found to be retained as a co-precipitant in the immunoprecipitation of PAK4, MCF2L and
JNK1. These results provide evidence that EphB4 may interact with the PAK4, MCF2L and JNK1
and this may be as part of a larger signalling complex that is involved in Rho GTPase signalling.
However, further testing is still required to confirm these interactions and then to understand
what pathways and signalling networks are effected and what implications this can have on
cellular function.
In future experiments, putative protein partners could be tested using cross-linking
techniques to determine if there is any direct interaction. However, the chemistry of these
interactions is complex and would need to be optimised in order to select the correct cross-
linking agent and conditions to bind interacting proteins. Another experiment to determine
whether specific proteins interact, is using Far Western blotting techniques to determine
direct interaction. This would work by submitting a recombinant protein to SDS-PAGE,
transferring this onto a membrane and incubating with the potential partner protein. After
blocking to reduce non-specific binding, an antibody against the potential protein partner
would be used to detect any interacting complexes at the position of the first protein.
Confocal microscopy is also another powerful tool that can provide insight into the proximity
of proteins and this could provide further evidence for interaction studies.
The demonstration that the anti-PAK4, anti-MCF2L and anti-JNK1 antibodies pull-down EphB4
suggest that PAK4, MCF2L and JNK1 are potential binding partners of EphB4, thus implicating
EphB4 in the Rho GTPase signalling network. Rho GTPases are a group of signalling G proteins
that play a role in organelle development, vesicular trafficking, cytoskeletal dynamics, cell
movement, and other common cellular functions (Ridley, 2006; Bustelo et al. 2007).
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Rho GTPases are part of the Ras superfamily and contain 22 members in mammals. These are
divided into four subfamilies: Rac, CDC42, Rho and other Rho GTPases. Rho protein can affect
other downstream proteins, thus mediating various cellular processes, and mutations in Rho
proteins can cause many detrimental effects in cells, including promoting tumourigenic
phenotypes (Ellenbroek & Collard, 2007). Cross-talk between Rho proteins has been shown
to regulate extension and contraction in cells, allowing for cellular motility. This process
involves three key proteins (Rac1, CDC42 and RhoA) discussed below (Sakumura et al. 2005;
Bustelo et al. 2007). (Interestingly, these proteins were not identified as part of the mass
spectrometry data set as potential binding partners of EphB4. This may be due to the
limitation of mass spectrometry not identifying these proteins, or they may be involved
indirectly with EphB4 through downstream interactions in a signalling network mediated by
EphB4).
Rac1 is a GTPase that is involved in signalling for a range of cellular events, including the cell
growth, cell-cell adhesion, cytoskeletal reorganization, motility and activation of
protein kinases (Ridley, 2006). Mutations of Rac1 have been shown to promote
mesenchymal-type cell movement and this abnormal cell motility may result in epithelial
mesenchymal transition (EMT) a driving mechanism for tumour metastasis, as cancer cells
become more invasive when cell motility is deregulated (Yang et al. 2012). CDC42 is a plasma
membrane-associated GTPase. When active, it binds to a variety of effector proteins to
regulate cellular responses. CDC42 is also involved in the extension and maintenance of actin-
rich filopodia and can mediate cell migration. It has been shown to interact with PAK4 in these
roles. (Abo et al. 1998). RhoA is a small GTPase protein associated with cytoskeleton
regulation actin organisation, cell motility and cell cycle maintenance. RhoA mediates actin
organisation through activation of RhoA kinase, which stimulates LIM kinase, which then
stimulates cofillin which reorganises and stabilises the actin cytoskeleton. RhoA has also been
linked a number of cancer signalling cascades (McBeath et al, 2004; Wheeler & Ridley, 2004;
O’Connor & Chen, 2013).
Rho GTPase signalling is complex and effects many cellular processes both directly and
indirectly, including processes in which EphB4 plays a role. Thus the identification of PAK4,
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MCF2L and JNK1 as an interacting protein complex that may also interact with EphB4 provides
a new area of research that can reveal further insight into the function and regulatory
pathways of EphB4. Specifically, it is hypothesised that EphB4 interacts with PAK4, MCF2L and
JNK1 and the Rho GTPase proteins Rac1, RhoA and CDC42 in pathways that promote cell
motility (see Figure 4.5 for hypothesised signalling complexes and pathways (Hanna & El-
Sibai, 2013; Raftopoulou & Hall, 2004; Schwartz, 2004)).
EphB4 is often associated with cancer (see Table 1.1) and as such, if EphB4 is involved in the
cell motility pathway, then when EphB4 is over-expressed and initiates ligand-independent
tumour promoting signalling, this may affect the Rho mediated pathway and provide a means
for cells to deregulate motility, allowing for invasive phenotypes to develop. Thus, identifying
these interacting proteins is a first step in further understanding a signalling pathway for
EphB4 that has the potential to be involved in tumourigenesis. Once these are clearly defined
and their function in healthy and disease states is better understood, they can then be
investigated as potential targets for cancer therapies. As such, further research is required
into the interacting partners of EphB4 and the signalling networks that they are involved in.
This research forms the groundwork in determining interacting proteins of EphB4 and is
ongoing research in our laboratory.
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Figure 4.5 Interacting proteins of EphB4 are involved in Rho GTPase signalling
A. Proteins identified through co-immunoprecipitation to interact with EphB4 were PAK4, MCF2L and MAPK8.
STRING protein interaction mapping was used to identify how these proteins interacted with key proteins
involved in the Rho GTPase cell motility pathway including CDC42, RhoA, RhoG, Rac1 and ARHGAP39. These
interaction show that there may be a role for EphB4 in regulating this pathway. B. Rho GTPase pathways for
actin modulation related to cell motility are shown in blue with key proteins shown in dark blue and cellular
functions shown in green. Proteins coloured red are those identified by coIP to interact with this signalling
complex and have been hypothesised to interact at specific stages (marked as grey dotted arrows) (Hanna & El-
Sibai, 2013; Raftopoulou & Hall, 2004; Schwartz, 2004).
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Chapter 5: Identification of Importin-α as a novel protein
partner of EphB4
5.1 Introduction
EphB4 is over-expressed in a variety of different epithelial cancers where it is involved in a
number of roles including survival, migration and angiogenesis. EphB4 signals from the
plasma membrane, however, certain RTKs (including EGFR) are able to translocate to the
nucleus and engage in regulation of gene expression [Lo et al. 2006]. As a part of further
investigating the role of the EphB4 in cancer progression, our laboratory conducted research
to determine whether EphB4 localised to the nucleus and was involved in gene regulation.
A bipartite nuclear localisation signal (NLS) was identified in the extracellular domain and a
monopartite NLS sequence in the intracellular kinase domain of EphB4. These NLS sequences
were both found to be functional through tagging them with GFP and observing localisation
of the fusion proteins to nuclei of transfected cells (mutated sequences resulted in reduced
nuclear accumulation). EphB4 was also implicated in gene regulatory functions using
chromatin immunoprecipitation, with Lef1 being confirmed as a potential target of EphB4-
mediated gene regulation (Mertens-Walker, 2013).
Transport of proteins into the nucleus through the nuclear pore complex is often dependent
on importins [Görlich & Kutay, 1999]. Importin (part of the karyopherin family) is a pivotal
component of the nuclear protein import pathway, shuttling nuclear localization signal-
bearing proteins from the cytoplasm to the nucleus. Importin can bind proteins either as
monomeric importin-β, or in complex with importin-α, which functions as an adaptor and
binds to the NLS of proteins. Once bound, the protein is transported into the nucleus via
nuclear pore complexes and interacts with Ran-GTP which causes the dissociation of the
protein from importin. Importin then moves out of the nuclease through association with
Ran-GTP/CAS, a nuclear export factor (Weis, 1984, Görlich et al. 1994; Moroianu et al. 1996;
Lange et al. 2007).
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Our laboratory has shown that EphB4 is present in the nucleus and contains a nuclear
localisation signal, which can be utilised by Importin-α, and as such there is potential for direct
interaction between these proteins. Thus the next stage of research was to confirm if EphB4
and importin could interact and whether this interaction was responsible for the transport of
EphB4 into the nucleus.
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5.2 Results
5.2.1 Preliminary Work
A number of EphB4 specific antibodies were previously developed and tested by Dr Sally-Anne
Stephenson. During analysis of these antibodies using immunofluorescence on MCF10A cells
and MCF10A-B4 cells (MCF10A cells transfected to over-express EphB4), it was observed that
foci in nuclei were stained (see panels for 6H4 and 11H4 antibodies), suggesting the presence
of EphB4 in the nucleus (immunofluorescence results shown in Figure 5.1). However, further
DAPI nuclear staining is need to definitively confirm the nuclear localisation of EphB4 in these
images.
The detection of EphB4 in the nucleus led to the formation of the hypothesis that EphB4 was
transported into the nucleus, likely through importins binding to a nuclear localisation signal
(NLS) on EphB4; and that EphB4 has a role in gene regulation. This work led to further research
into the role of EphB4 in the nucleus in our laboratory (including work described in this thesis)
and led to the publication of a scientific paper.
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Figure 5.1 - Validation of the EphB4-specifici monoclonal antibodies
From Stephenson et al. 2015 – (A) Monoclonal antibodies were screened using flow cytometry to detect EphB4
expression on MCF-7 cells. The shift in peak fluorescence to the right is compared with the matched isotype
control (mIgG1, mIgG2a or rIgG) (red line) and is due to antibody binding. BerEP4 antibody that detects EpCam
was used as the positive control. (B) Western blot analysis showing that denatured and reduced EphB4 (120 kDa)
can be identified using antibodies 13A7, 13B11 and 2D9. Zymed monoclonal antibody was used as a positive
control. (C) EphB4 was immunoprecipitated from total protein lysates was identified in the immunoprecipitated
sample via Western blot analysis using the Zymed antibody. (D) Immunofluorescence comparing EphB4 detection
(green) in the MCF10A and MCF10A-B4 cells using monoclonal antibodies. Bar = 80 μm.
The following summarised results show research conducted by Inga Mertens-Walker et al. in
our laboratory as part of the lead up to the identification of Importin-α as a protein partner
of EphB4 (Section 5.2.2). This work has since been published (Mertens-Walker et al. 2013)
and includes portions of research conducted as part of this thesis (Section 5.2.2).
5.2.1.1 EphB4 has two functional nuclear localisation signals
An in silico study was performed to determine if EphB4 contained NLS motifs (which can be
either monopartite or bipartite (Görlich & Kutay, 1999)). The cNLS mapper program predicted
a classical bipartite nuclear localisation signal (NLS1 - Figure 5.2B) and another program,
NLStradamus, identified a second NLS sequence (NLS2 - Figure 5.2C) in the intracellular
domain of EphB4. NLS sequences require surface presentation to facilitate interaction with
importins. As such, models from the Protein Data Bank for the EphB4 globular ligand binding
domain and the kinase domain were analysed and amino acids corresponding to each of the
NLS sequences were highlighted, confirming that the NLS sequences are part of surface
exposed structures (Figure 5.2).
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Functionality of these two predicted NLS sequences was tested by cloning sequences
spanning each NLS individually into pEGFP-N1 for expression as GFP-fusion proteins. Control
MCF10A cells transfected with the empty pEGFP-N1 vector, showed the GFP signal was evenly
distributed throughout the cytoplasm, with some signal observed in the nucleus (Figure 5.3A).
In cells transfected with the vectors containing either of the putative EphB4 NLS sequences
(NLS1 or NLS2), the GFP signal was more strongly concentrated to the nucleus (Figure 5.3A).
These results confirm that EphB4 possesses functional nuclear localisation signals that are
able to localise GFP-fusion proteins to the nucleus.
Site-directed mutagenesis was then used to confirm the importance of lysine residues in NLS1
and NLS2 by changing either lysine 149 in NLS1 to alanine (K149A) or lysine 639 in NLS2 to
alanine (K639A) (Figure 5.3B & 5.3C). Constructs were transfected into DU145 cells and
immunofluorescence analysis revealed that in these cells, introduction of the K149A or K639A
Figure 5.2. Models of EphB4 showing positions of the NLS sequences accessible on the surface of the protein.
A. EphB4 schematic representation and epitope representation for antibody recognition. B. NLS1 (bold,
underlined) is found in the extracellular globular domain. Two projections of the globular domain model show
NLS1 in yellow and circled in red C. NLS2 (bold, underlined) is found in the intracellular kinase domain. Two
projections of the kinase domain model show NLS2 in yellow and circled in red.
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mutation returned the NLS-GFP nuclear localisation to a pattern more similar to that of the
untagged GFP, thus confirming the importance of the lysine residues in either NLS sequence
for nuclear translocation.
Figure 5.3 - Both NLS sequences target an EGFP fusion protein to the nucleus.
A.MCF10A cells expressing NLS1-EGFP or NLS2-EGFP show increased fluorescence in the nucleus when compared
with EGFP-only cells. B. Amino acid K149 (NLS1) was mutated to alanine. DU145 cells were transfected with
pEGFP vector, pEGFP-NLS1 or mutant construct pEGFP-NLS1K149A and subjected to confocal microscopy. pEGFP
alone shows diffuse distribution in the cell whereas pEGFPNLS1 displays concentrated nuclear expression which
is reversed in the mutant transfectants. C. Amino acid K639 (NLS2) was mutated to alanine. DU145 cells were
transfected with pEGFP vector, pEGFP-NLS2 or mutant constructs pEGFP-NLS2K639A and subjected to confocal
microscopy. pEGFP alone shows diffuse distribution in the cell whereas pEGFP-NLS2 displays concentrated
nuclear expression which is reversed in the mutant transfectants to the diffuse pattern similar to that observed
in pEGFP alone transfectants.
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5.2.1.2 EphB4-specific antibodies identify EphB4 in the nucleus
Transient siRNA knockdown of EphB4 was used to further verify specificity of the
immunofluorescence results. LNCaP and DU145 cells were transfected with siRNAs targeting
EphB4. Cells in which EphB4 knock down was confirmed were then analysed using
immunofluorescence with either the H200 or 11H4 antibodies. This revealed a reduction of
immunoreactivity in the cytoplasm as well as a dramatic reduction of EphB4 immunoreactivity
in the nuclei of these cells (Figure 5.4A).
EphB4 expression is also observed on the surface, in the cytoplasm, and in the nucleus (seen
as almost exclusively distinct nuclear foci) of DU145 and LNCaP prostate cancer cells when
using various EphB4 specific antibodies (11H4 and H200) (Figure 5.4B) and when using
different fixation methods (Figure 5.4C).
As both the BenEphex murine monoclonal antibody 11H4 and the Santa Cruz rabbit polyclonal
H200 antibody recognise sequences in the extracellular domain of EphB4, it was hypothesised
that the full-length receptor translocates to the nucleus. To confirm this, LNCaP cells were
subjected to sub-cellular fractionation and EphB4 was immunoprecipitated from these
fractions using the EphB4 specific monoclonal antibody 11H4 and then detected by Western
blot analysis using the commercial C-terminal mAb. Full-length EphB4 (molecular weight ~120
kDa) was enriched from both the cytoplasmic and nuclear fractions (Figure 5.4D). These
results demonstrate that full length EphB4 can reside in the nucleus of endogenously EphB4
expressing prostate cancer cells.
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Figure 5.4 - EphB4 resides in the nucleus of prostate cancer cell lines.
A. LNCaP cells were transfected with either a non-silencing negative control siRNA (-ve siRNA) or a siRNA
targeting EphB4 (#10) and subjected to immunofluorescence analysis using the 11H4 mAb to detect EphB4
(green). EphB4 immunoreactivity is greatly reduced in EphB4 knockdown cells compared to –ve siRNA cells. Red:
F-actin identified with phalloidin; Blue: nuclei identified with DAPI. B. Immunofluorescence analyses of DU145
prostate cancer cells using either monoclonal 11H4 (maB 11H4) or polyclonal H200 (pAb H200) antibody to detect
EphB4 in the nucleus. 11H4 also detects cytoplasmic EphB4 (green) whereas H200 shows almost exclusive nuclear
foci (red, white arrows). A z-stack was performed to show that nuclear EphB4 foci are located in nuclei (shown in
blue). C. Immunofluorescence analyses of LNCaP prostate cancer cells using the 11H4 antibody. Cells were fixed
using either methanol or paraformaldehyde as indicated. Green: EphB4 identified with 11H4; Red: F-actin
identified with phalloidin; Blue: nuclei identified with DAPI.  Arrows indicate nuclear foci. D. Cytosolic (Cyt) and
nuclear (Nuc) extracts were prepared from LNCaP cells and immunoprecipitated (IP) using the 11H4 mAb or a
mouse IgG and western immunoblotted (WB) with a different EphB4-specific mAb (Life Technologies). The
cytosolic fraction shows a band corresponding to the size of EphB4 and is greatly enriched. In the nuclear fraction
a band of similar size is observed indicating presence of EphB4. To assess purity of the nuclear and cytosolic
fractions, western blotting for GAPDH (cytosolic marker) was also performed.
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5.2.2 Investigating the interaction of Importin-α with EphB4
5.2.2.1 Importin-α is shown to interact with EphB4 through co-immunoprecipitation.
The preliminary research by Dr Inga Mertens-Walker et al. (Section 5.2.1 above), showed that
EphB4 is present in the nucleus of cancer cells and that it contains a bipartite nuclear
localisation signal (NLS) motif (See also Appendix 3 - Further work on nuclear localisation of
EphB4 - Mertens-Walker et al. 2013). As such, investigating whether importin-α could be a
potential interacting partner of EphB4 was the next stage of work and is the subject of this
chapter of the thesis. Importin-α recognises and binds the NLS sequence to transport proteins
through the nuclear pore into the nucleus (Görlich et al. 1994) and therefore it was
hypothesised that Importin-α interacted directly with EphB4 through the NLS sequence and
is the mechanism responsible for transporting EphB4 into the nucleus.
To validate Importin- as an EphB4 binding protein and to test this hypothesis, a co-
immunoprecipitation (Co-IP) pull down assay was performed using native protein lysate
extracted with RIPA buffer from 22Rv1B4 (EphB4 overexpressing) prostate cells as described
in Chapter 2. An EphB4 antibody (C1), a pan Importin-α antibody and an antibody against
irrelevant IgGs (as a negative control for non-specific interactions) were used in three
separate co-immunoprecipitation pull down assays. The samples and a whole cell lysate from
22Rv1B4 cells (as a positive control) were loaded onto polyacrylamide gels and subjected to
electrophoresis. The blots were then blocked and probed with both EphB4 and Importin-α
antibodies.
The resulting blots (Figure 5.5) show a band corresponding to the size of EphB4 (~ 120 kDa)
in both the EphB4 Co-IP and the Importin-α Co-IP samples as well as in the positive control
cell lysate samples on the blot probed with the EphB4 specific antibody. No band at this size
is seen in the negative control IgG Co-IP lane as expected, indicating that no non-specific
binding was occurring. An identical result was observed on the blot probed with the Importin-
α specific antibody, where a band corresponding to the size of Importin-α (55 kDa) was visible
in both EphB4 and Importin-α Co-IP samples and in the lysate control samples (additionally
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indicating that Importin-α is expressed by 22Rv1B4 cells), but not the IgG Co-IP negative
control samples.
This result suggests that EphB4 and Importin-α do in fact directly as the Importin-α Co-IP
pulled out both EphB4 and Importin-α and the same was true in the EphB4 Co-IP. As both
proteins are present in the co-immunoprecipitation pull down assays, they would thus be
expected to be interacting in order to be isolated and detected by the specific antibodies to
each protein in both samples.
Figure 5.5 - Co-immunoprecipitation assays show that Importin-α directly interacts with EphB4.
Co-immunoprecipitation pull down assays were performed on 22Rv1B4 cell lysates with anti-EphB4, anti-
Importin-α and anti-IgG antibodies. A band corresponding to the size of EphB4 (120kDa) and a band at 55 kDa
corresponding to the size of Importin-α can be seen in both the EphB4 and Importin-α pull down assays as well
as in the protein lysate control. The IgG control is negative for both the EphB4 and Importin-α antibodies.
5.2.2.2 Importin-α co-localises with EphB4 in prostate cancer cells.
Co-immunoprecipitation pull down assays supported that EphB4 was directly interacting with
Importin-α. However, in order for this interaction to be confirmed, both proteins would need
to occupy the same cellular location i.e. they would have to co-localise in order to interact.
To test whether both proteins are found in the same location and further confirm that they
interact directly, a co-localisation study was performed using immunofluorescence coupled
with confocal microscopy.
The cells were stained overnight with either anti-EphB4 or anti-Importin-α primary
antibodies, and for the controls with anti-EphB4 primary antibody only (no secondary mouse
Ab), anti-Importin-α primary antibody only (no secondary rabbit Ab), anti-mouse secondary
antibody only (no primary Ab), or anti-rabbit secondary antibody only (no primary Ab). EphB4
appears as a red colour, Importin-α as a green colour and the cell nuclei are shown in blue.
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Figure 5.6 shows that EphB4 and Importin-α are in close proximity (seen as a yellow colour)
for 22Rv1B4 cells, a finding seen across all cell lines (co-localisation could not be definitively
ascertained as the microscope used was not capable of super-resolution imaging). This close
proximity is particularly evident around the peri-nuclear region, as well as appearing as dots
within the LNCaP cell nucleus, which would be expected as Importin-α is a nuclear transport
protein that binds proteins and moves them into the nucleus. Importin-α is seen in both the
cytoplasm and the nucleus of all cell lines as expected, and is also seen to be localising to an
organelles which may be the Golgi apparatus in 22Rv1 cells.
EphB4 is dispersed throughout the cells, but some surface expression can be seen in 22Rv1
cells, while LNCaP cells had a low visible intensity of cell surface EphB4 when compared to the
22Rv1 cells. The primary only and secondary only controls did not show any specific staining,
indicating that antibodies were binding to the correct targets. Considering this result, which
indicates that EphB4 and Importin-α are found in the same cellular location and therefore are
able to interact, with the 2D-NACE and co-immunoprecipitation studies shown previously, it
can be concluded that EphB4 and Importin-α do in fact directly interact and that the formation
of the EphB4-Importin-α complex is likely the driving mechanism in the nuclear transport of
EphB4.
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22Rv1VO: EphB4 and Importin-α 22Rv1VO: EphB4 and Importin-α
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Figure 5.6 - Importin-α colocalises with EphB4 in prostate cancer cells.
Confocal microscopy images of 22Rv1VO, 22Rv1B4 and LNCaP cells probed with both anti-EphB4 and anti-Importin-α antibodies as well as control slides stained with anti-Importin-
α primary antibody only (no secondary Ab); anti-EphB4 primary antibody only (no secondary Ab); anti-mouse secondary antibody only (no primary Ab); and anti-rabbit secondary
antibody only (no primary Ab). Individual channels are shown along with the combined overlayed image. EphB4 is shown in red, Importin-α in green and the nuclei in blue while
co-localisation of EphB4 and Importin-α appears yellow. Co-localisation can be seen throughout the cells in all cell lines, particularly in the peri-nuclear region in 22Rv1 cells and
within the cell nucleus in LNCaP cells. Importin-α can be seen in the cytoplasm and the nucleus of all cell lines as well as in an organelles that may be associated with the Golgi
apparatus in 22Rv1 cells. EphB4 is dispersed throughout the cells with some surface expression in 22Rv1 cells and lower levels in LNCaP cells. Representative control slides of
LNCaP cells with primary antibody only and secondary antibody only staining do not show any specific staining (shown in green with nuclei in blue).
Representative ControlsLNCaP: EphB4 and Importin-α
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5.2.3 Ongoing and Future Research
The data shown above provides strong and compelling evidence for EphB4 and importin-α
interactions and complex translocation into the nucleus. However, once in the nucleus, the
role and function of EphB4 is not known and so preliminary research investigating the nuclear
role of EphB4 has been undertaken in our laboratory by Lez Burke. This work has identified
that EphB4 has a role in regulating specific genes that can affect the expression of a number
of proteins. These genes will present interesting candidates for future study to improve the
understanding of the role of EphB4 in the nucleus.
5.2.3.1 EphB4 can bind to DNA sequences and affects expression of Lef1
A chromatin immunoprecipitation method was use to explore the function of EphB4 in the
nucleus. EphB4, complexed with genomic DNA sequences, was isolated from nuclear DNA
preparations and analysed for loci to which EphB4 may bind to (Figure 5.7A). Sequences
identified included the 5’ upstream sequences of the G-protein coupled receptor GPR103,
Lymphoid enhancer-binding factor 1 (Lef1), protocadherin 20 (PCDH20), Coiled-coil domain
containing protein 68 (CCDC68), UDP-N-acetyl-alpha-D-galactosamine: polypeptide N-acetyl-
galactosaminyl-transferase 16 (GALNTL1) and within the T cell receptor alpha delta locus.
One sequence was validated as an EphB4 target by designing specific primers to that
sequence and demonstrating amplification from genomic DNA isolated using the 11H4
antibody only and not antibodies that do not recognise nuclear EphB4 (EphB4 antibody C2
and Mouse IgG) (Figure 5.7B). To analyse if manipulating EphB4 levels would influence
expression of Lef1, LNCaP cells were transiently transfected with EphB4 siRNA and DU145
were stably transfected with the pIRESNeo2 vector encoding EphB4. Real-time PCR revealed
that Lef1 was downregulated by approximately 40% when EphB4 was knocked down and
upregulated almost 2.5 fold when EphB4 was overexpressed (Figure 5.7C). These results
indicate that nuclear EphB4 could directly impact on gene expression and is work that is part
of ongoing research in our laboratory to further elucidate the role of EphB on gene regulation.
129
Figure 5.7 - EphB4 binds to genomic DNA sequences
A. Maps of the loci identified as potential EphB4 binding sequences. Chromosome loci and position of features
within these loci (including genes, regulatory RNA sequences, transcription factor binding sites (TF)) are shown
with approximate distances (kb). B. Specific primers for an isolated 175 bp ChIP DNA sequence (from Chr 13)
were used in a PCR reaction to validate sequence isolation. The product was amplified as expected from the input
DNA (lane 2), LNCaP genomic DNA (lane 9) and the DNA immunoprecipitated by the EphB4 mAb 11H4 (lane 5),
but not by the C2 mAb (lane 8), which does not recognise nuclear EphB4 or a control mouse IgG (lane 6). C. Real-
time PCR analyses showing relative mRNA levels of Lef1 in LNCaP cells transfected with negative or EphB4-specific
siRNAs (#2 and #5) or DU145 cells stably transfected with pIRESNeo2-EphB4 (DU145 B4) or vector control (DU145
VO) plasmids. Lef1 expression significantly decreases in EphB4 knockdown samples and significantly increases
when EphB4 is overexpressed. * p = 0.01 vs -ve siRNA; # p = 0.005 vs control (VO).
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5.3 Discussion
Dr Sally-Anne Stephenson identified that nuclear foci showed immunoreactivity for EphB4
through the use of EphB4 specific antibodies (Figure 5.1). Based on this a hypothesis was
formed: EphB4 can be transported into the nucleus through importin mediated transport;
and may then play a role in gene regulation within the nucleus. This is a scenario that is
common to other RTKs as 18 of 58 human RTKs have been found to locate to the nucleus (Xia
et al. 2009; Hsu et al. 2009; Aleksic et al. 2010; Stephenson et al. 2012).
As such it was important to investigate whether EphB4 contained NLS motifs and whether
importins could bind to these to facilitate nuclear transport. To this this end, research was
conducted in our laboratory by Dr Inga Mertens-Walker (see Appendix 3 - Further work on
nuclear localisation of EphB4). EphB4 was found to contain two functioning NLS sequences
that were utilised in directing the protein into the nucleus (Figure 5.2, 5.3 and 5.4 above)
suggesting that nuclear translocation of full length EphB4 can occur and most likely requires
a functional NLS.
For the full-length protein to move out of the membrane and into the nucleus, it must first be
released from the lipid bilayer (Wells & Marti, 2002). This could include the use of
mechanisms such as retrograde transport to the Golgi and the ER followed by diffusion from
the ER and transport through the nuclear pore by means of importins binding to a NLS (Hsu
& Hung, 2007; Wang & Hung, 2012).
The most common mechanism for transport of receptors into the nucleus is by means of the
Importin-α-Importin-β complex. Importin-α is a nuclear transport protein, that along with its
other subunit, Importin-β, binds to the NLS motif found on proteins, and moves them into the
nucleus through nuclear pore. As such, the validation of EphB4 and Importin-α interaction is
an important step to not only identifying a novel binding partner of EphB4, but also to
increase the understanding of the nuclear transport process of this receptor.
To test whether Importin-α directly interacted with the EphB4 receptor, co-
immunoprecipitation (Co-IP) pull down assays were performed. The results (Figure 5.5)
showed that Importin-α was able to be pulled out in EphB4 Co-IP experiments. This supports
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the hypothesis that EphB4 and Importin-α interact directly. To further confirm this
interaction, immunofluorescence based confocal microscopy co-localisation studies were
performed to verify that the proteins occupied the same cellular space and were able to
physically interact with each other. Cells were stained with immunofluorescent antibodies
specific to EphB4 and Importin-α. The resulting images (Figure 5.6) show that EphB4 is in close
proximity with Importin-α (colocalisation could not be confirmed with the equipment used as
the microscope was not capable of super resolution).
Proximity of EphB4 and Importin-α was observed throughout the cytoplasm of the cells and
around the peri-nuclear region, as well as appearing within the cell nucleus itself. This is
expected for the nuclear transport protein Importin-α which appears to bind the EphB4
receptor and transport it into the nucleus. These results indicate that EphB4 and Importin-α
are found in the same cellular location and therefore it is possible for them to interact. In
summary, the above research shows that:
 EphB4 contains a functional bipartite NLS in the extracellular domain and a functional
monopartite NLS in the intracellular kinase domain (Figure 5.2 and 5.3)
 EphB4 is found in the nucleus of prostate cancer cells (Figure 5.4)
 EphB4 and Importin-α can interact in prostate cancer cells (Figure 5.5 and 5.6)
Taking this data together, the research strongly suggests that the interaction of EphB4 and
Importin-α facilitates the nuclear transport of EphB4. It would be assumed that this would
occur through classical know pathways where Importin-α would bind to the functional NLS
motifs of EphB4 as an adaptor protein and then forming a complex with Importin-β which
would then transport EphB4 through the nuclear pore (Weis, 1984; Görlich et al. 1994).
However, further research is still required to fully understand and validate the exact
mechanisms of EphB4 nuclear transport. This could include studies where importin-α function
is blocked (Wagstaff et al. 2012) as well as generating mutated EphB4 NLS motifs and
observing whether nuclear transport takes place.
Currently, the function that EphB4 has inside the nucleus is not well known, though other
RTKs have been shown to be involved in regulating gene expression and this may be the role
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that EphB4 plays within the nucleus. For example, nuclear EGFR has been identified as a
prognostic factor in breast cancer (Lo et al. 2005), a predictor of poorer outcomes in various
cancers (Psyrri et al. 2005), a driver of chemo- and radiation-resistance (Chen & Nirodi, 2007;
Li et al, 2009), and a co-activator for transcription of genes (Tao et al. 2005).
Preliminary research into the nuclear role of EphB4 was conducted by Lez Burke (shown in
Figure 5.7) and has since been published (Mertens-Walker et al. 2013) along with the work
presented here in this thesis. A number of genomic sequences to which EphB4 could bind
were identified including sequences linked to prostate cancer such as GPR103 (Alonzeau et
al. 2013) and Lef1, which when over-expressed causes an increase in androgen receptor
expression, enhanced growth and invasion in LNCaP cells (Li et al 2009). Lef1 was found to be
regulated when EphB4 levels were manipulated (Figure 5.7), however additional research is
still needed to define the relationship between EphB4 and Lef1, and to determine whether
the presence of EphB4 in the nucleus correlates with more aggressive and resistant cancer
phenotypes. Additionally, the results could be further strengthened with confirmation of
siRNA knockdown and over‐expression of EphB4 at the protein level.
As reported above, EphB4 contains two functional NLS motifs and can localises to the nucleus
through interaction with importin-α, where it could play a direct role in gene regulation. This
provides a novel insight into Eph receptor localisation and function and presents and area of
further study of novel functions and pathways for this RTK.
Specific research presented as part of this thesis (that builds on research from our laboratory
(Mertens-Walker et al. 2013)) confirms Importin-α is able to interact with EphB4. This was
shown through both co-immunoprecipitation pull down assays and immunofluorescence-
based co-localisation studies, and identifies importin-α as a novel interacting protein partner
for EphB4. However, further research is required into how the interplay of EphB4 and
importin-α will affect cellular processes in both normal and disease states, as well as
understanding how these interactions are favoured in a prostate cancer cell model.
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Chapter 6
Investigating the extracellular role of
EphB4
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Chapter 6: Investigating the extracellular role of EphB4
6.1 Introduction
EphB4 is a membrane bound RTK which under normal circumstances interacts with its sole
physiologically relevant ligand, ephrin-B2, (expressed on an adjacent cell type) to initiate a
cellular responses, both forward into the receptor expressing cell and reverse into the ligand
expressing cell. In cancer cells, however, EphB4 has also been shown to signal independently
of its ligand through over-expression and clustering of the receptor resulting in auto-
phosphorylation of the adjacent kinase domains. As EphB4 is a transmembrane protein, it is
not normally expected to be released in a soluble form into the extracellular environment.
However, in my research it was found that full length EphB4 was present in the medium
collected from prostate cancer cells. This is a novel finding for which the mechanisms and
purposes are yet to be determined.
One hypothesis is that the EphB4 protein is released from the cell in microvesicular structures
called exosomes. Cancer cells are known to release a variety of microvesicular structures
(MVBs) into their surroundings. Exosomes are a subspecies of microvesicles and are small
membrane vesicles of approximately 30-100 nm released by many cell types into their
extracellular environment where they are involved in many different cellular processes
including intercellular communication, immune system regulation, cancer progression and
removal of excess proteins (Février & Raposo, 2004; Théry 2011; Witwer et al. 2013).
Exosomes are formed in the host cell through the endocytotic process and incorporate cell-
specific cargo from the plasma membrane and cytosol including proteins, lipids and nucleic
acids (Valadi et al. 2007; Théry, 2011; Azmi et al. 2013; Rapaso et al. 2013). Exosome release
from cells is thought to be influenced by mechanisms including the p53 pathway (Yu et al.
2006) or by means of Rab proteins (Rab3, Rab11, Rab27, Rab35) (Azmi et al. 2013), as well as
based on cellular calcium levels, cholesterol levels and membrane pH (Jaiswal et al. 2002;
Savina et al. 2002; Tolmachova et al. 2004; Stoeck et al. 2006; Llorente et al. 2007; Hosseini-
Beheshti et al. 2012; Azmi et al. 2013).
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Calcium levels, potassium ion levels and oligodendrocytes have also been implicated in
exosome release (immune cells release exosomes through a Ca2+ mediated response to
transfer antigens) (Fitzner et al. 2011, Urbanelli et al. 2013), whereas the fusion of exosomes
with target cells may be dependent on a number of factors including the presence of certain
molecules including tetraspanins and integrins (Raposo & Stoorvoge, 2013). Once exosomes
are released from the cell, they are able to transfer their molecular cargo to neighbouring
cells and initiate signalling events. This can occur through a number of mechanisms including:
activating signalling partners by the interaction of exosome receptors to their cell bound
ligands (without internalisation); the cleavage of exosome bound receptors which then are
free to interact with cell surface ligands (again without internalisation); the fusion of
exosomes with the cell membrane and the subsequent release of exosomal cargo into the
target cell cytoplasm; and finally the internalisation of exosomes through endocytocis which
again releases the contents of the exosomes within the target cell (Théry et al. 2002; de
Gassart et al. 2003; Février & Raposo, 2004; Miranda et al. 2010; Urbanelli et al. 2013).
Many of the components of exosomes and their cargo have been associated with tumour
growth and progression (Dolo et al. 2005; Lee et al. 2011). One hypothesis for the release of
exosomes from tumour tissue is that the cancer cells release exosomes as a mechanism to
increase survival and cell growth through initiation of proliferation and angiogenesis signals
and modulation of the immune response. Furthermore, it has been suggested that exosomes
may also be used as distant messengers, being sent out from the cancer mass to establish
premetastatic niches and, together with cancer initiating cells, generate a favourable
environment for metastasis by instigating signalling pathways which will increase growth and
angiogenesis in the surrounding area (Al-Nedawi et al. 2009; Castellana et al. 2009; Jung et al.
2009; Théry, 2011; Alderton, 2012). Additionally, a number of studies have reported that
tumour derived exosomes have the ability to increase proliferation, angiogenesis, metastasis,
invasion and survival in tumour cells, thus progressing the cells to a more aggressive cancer
phenotype (Janowska-Wieczorek et al. 2005; Ratajczak et al. 2006; Di Vizio et al. 2009; Jung
et al. 2009; Lima et al. 2009; Rak, 2010).
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Exosomes have been shown to regulate a number of important pathways, some of which
overlap with those pathways regulated by Eph family RTKs, thereby leading to the hypothesis
that exosomes work in conjunction with the Eph family kinases during cancer progression. As
such, it is unsurprising that several studies have reported the presence of Eph receptors and
ephrins in exosomes originating from various cancer cells including EphA2 - EphA8; EphB1 -
EphB4; and ephrinB1 and ephrin-B2 in colon cancer-derived exosomes (Tauro et al. 2012) and
ephrinA2 in PC3 prostate cancer cell exosomes (Sandvig & Llorente, 2012). Additionally, other
prostate cancer related proteins that have been reported to interact with the Eph family have
also been shown to be carried as cargo in exosomes, such as the ADAM10 protease which
cleaves ephrins and Thrombospondin-1, which has been shown to directly interact with
EphB4 (Chapter 4) (Janes et al. 2005; Jansen et al. 2009; Avouac et al. 2011).
Despite these studies, no reports have yet been published identifying the EphB4 receptor in
exosomes released by prostate cancer. As such, the study reported in this chapter aimed to
first identify whether EphB4 was found as cargo of prostate cancer cell-derived exosomes and
second, to determine whether these EphB4 positive exosomes were functional in
supporting/maintaining prostate cancer progression. The results showed that EphB4 was
indeed released outside the cell in its full-length form and that the receptor was found to be
present within exosomes collected from 22Rv1 prostate cancer cells. Stimulation of 22Rv1
and LNCaP prostate cancer cells with EphB4-positive exosomes significantly increased the
proliferation rates of both cell types and the increase in proliferation correlated with a
decrease in caspase 3/7 mediated apoptosis. Intriguingly, the opposite effect was observed
in HUVEC endothelial cells, where the proliferation rate decreased and caspase 3/7-mediated
apoptosis increased in cells stimulated with EphB4-positive exosomes. These results suggest
that EphB4 is not only transported from the cell in exosomes, but that these EphB4-positive
exosomes may play a role in cancer progression through mechanisms that are still unclear.
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6.2 Results
6.2.1 Full length EphB4 is present in media from 22Rv1 cells
6.2.1.1 Full length EphB4 is present in conditioned medium of 22Rv1B4 cells
EphB4 is a transmembrane protein and as such is not expected to be found in a soluble form
in conditioned cell culture medium, though degradation and cleavage fragments could be
present as our laboratory has shown that EphB4 can be cleaved by a number of proteases
including Kallikrein-4 (Lisle et al. 2013)). However, the prostate cell line 22Rv1B4 (which was
engineered to over-express EphB4 on the cell surface) expresses EphB4 at much higher than
normal levels (Rutkowski et al. 2012). As such, it was hypothesised that some of the excess
EphB4 protein may be transported or released from the cell for a yet unknown purpose
through an unidentified mechanism.
As such, the medium of 22Rv1B4 cells was investigated for the presence of EphB4
immunoreactive protein through Western blot analysis. The conditioned serum-free medium
from both 22Rv1VO control cells and 22Rv1B4 EphB4 over-expressing cells was collected and
centrifuged to remove dead cells. The supernatant was then filtered to further purify the
sample. The sample was subjected to Western blotting and the blot was probed for EphB4
with the Zymed anti-EphB4 commercial antibody which detects the C-terminal of EphB4. After
developing the blot, a band corresponding in size to full length EphB4 can be seen at 120 kDa
in medium taken from 22Rv1B4 cells, but not in 22Rv1VO cells. Bands of lower molecular
weight, observed at approximately 70 kDa in medium collected from both cell lines, may be
non-specific protein (or residual serum albumin non-specifically absorbed by the cells), as the
band is observed in both 22Rv1VO and 22Rv1B4 samples. Bands of approximately 45 kDa and
48 kDa seen only in the 22Rv1B4 medium lane may be cleavage or degradation fragments of
EphB4 (Lisle et al. 2013)). No bands corresponding to the size of EphB4 are visible in the
control 22Rv1VO cells.
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Figure 6.1 - Full length EphB4 present in conditioned medium of 22Rv1B4 cells.
Serum free growth medium collected from 22Rv1VO and EphB4 over-expressing 22Rv1B4 cells after 24 hours and
subjected to Western blotting probing with EphB4 specific antibody (Zymed). A band corresponding in size to
EphB4 (120 kDa) as well as a double band at around 50 kDa (potentially a breakdown product of EphB4) was
detected in medium collected from EphB4 over-expressing 22Rv1B4 cells and not in medium from 22Rv1VO cells.
Additional bands were seen at 70 kDa in both cell lines which may indicate non-specific binding.
6.2.1.2 Full length EphB4 is present in conditioned medium of 22Rv1B4 cells over 3 day period
A time course experiment was run to determine the presence of extracellular EphB4 found in
the medium of 22Rv1B4 cells over several time points (1 h, 24 h and 72 h). Conditioned serum-
free medium was collected from control 22Rv1VO cells and EphB4 over-expressing 22Rv1B4
cells and centrifuged for 10 min at 1000 g to remove dead cells and filtered to further purify
the sample. The medium was then analysed by Western blotting. After electrophoresis, the
gel was transferred to nitrocellulose and this blot was blocked and probed with the Zymed
anti-EphB4 commercial antibody which detects the C-terminal region of EphB4. The medium
was collected from cell culture flasks after 1 hour, 24 hours and 72 hours of incubation with
the cells. The medium samples were electrophoresed alongside cell protein lysates from
22Rv1 wild type and 22Rv1B4 cells. A band corresponding to full length EphB4 (120 kDa,
consistent with full length EphB4 identified in the cell lysate positive control) is visible in
139
medium taken from 22Rv1B4 cells, but not in the negative control 22Rv1VO cells, over the
entire three day time period.
Figure 6.2 - Full length EphB4 is present in medium of 22Rv1B4 cells over a 3 day period.
Serum-free growth medium collected from both 22Rv1VO (VO) and EphB4 over-expressing 22Rv1B4 (B4) cells
after 1 hr, 24 hrs and 72 hrs analysed by Western blotting along with protein lysates from 22Rv1 wild type (WT)
and 22Rv1B4 (B4) cells as EphB4-positive controls. The blot was probed with the Zymed EphB4 specific antibody.
A band of 120 kDa, corresponding to full length EphB4, was present in the medium from 22Rv1B4 cells up to the
72 hr period sample, but was absent in medium from 22Rv1VO cells. The lysate controls also showed the presence
of this 120 kDa band.
6.2.2 Isolation and purification of exosomes from 22Rv1 prostate cells
6.2.2.1 EphB4 is depleted from medium when EphB4 positive exosomes are extracted
Through reviewing literature, it was hypothesised that the full length EphB4 present in the
medium of 22Rv1 cells was contained within microvesicular structures called exosomes. To
confirm this, medium was collected from these cells and exosomes were extracted and then
the medium was compared before and after to determine if depleting the medium of
exosomes also depleted the levels of full length EphB4. To do this, serum-free growth medium
was collected from both 22Rv1VO (VO) and EphB4 over-expressing 22Rv1B4 (B4) cells after
24 hrs and centrifuged at 1000 g for 10 minutes to remove dead cells and debris. A portion of
the medium was also then sequentially centrifuged as described in Section 2.2.16 to extract
exosomes.
The exosomes and remaining medium, as well as the initial source medium were analysed by
Western blotting alongside a 22Rv1B4 (EphB4 positive) cell lysate positive control. The
resulting blot was probed with an EphB4 specific antibody (Zymed) and with an exosome
EphB4
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marker, TSG101 antibody.  A double band (due to differences in post-translational
modifications) of 120 kDa, corresponding to full length EphB4, was present in the cell medium
taken from 22Rv1VO and in EphB4 over-expressing 22Rv1B4 cells. This band was then fainter
in the depleted medium after the exosomes were extracted in the 22Rv1 B4 cells and was not
visible in the 22Rv1 cell depleted medium. The lysate controls also showed the presence of
this 120 kDa band indicating that it is in fact EphB4. The EphB4 was seen to be present in the
exosomes extracted from 22Rv1B4 cell medium, suggesting that full length EphB4 present in
the cell medium of 22Rv1B4 cells is mostly found in exosomes and that removing the
exosomes also depletes the medium of full length EphB4 (Figure 6.3).
Figure 6.3 – EphB4 is depleted from media when EphB4 positive exosomes are extracted
Serum-free growth medium collected from 22Rv1VO (VO) and EphB4 over-expressing 22Rv1B4 (B4) cells after 24
hrs was centrifuged as described in Section 6.2.2 to recover exosomes. The exosomes and remaining (depleted)
media, as well as the initial source media were analysed by Western blotting alongside a 22Rv1B4 (EphB4
positive) cell lysate positive control. The blot was probed with an EphB4 specific antibody (Zymed) and with an
exosome marker, TSG101 antibody.  A band of 120 kDa, corresponding to full length EphB4, was present in the
cell medium from 22Rv1VO and in 22Rv1B4 cells. Bands were fainter in the depleted medium. The lysate controls
also showed the presence of this 120 kDa.
6.2.2.2 Transmission Electron Microscopy image of centrifuged 22Rv1B4 cell medium
Exosomes were collected through sequential centrifugation as described in Section 6.2.2. The
resulting isolated exosomes were analysed for purity by visualising the samples using TEM.
The exosomes from the 22Rv1B4 cells were placed onto a copper mesh and negatively stained
with uranyl acetate as described in Section 6.2.4. Exosomes observed by TEM are usually seen
as spheres of 30-100 nm in size with a cup-shaped indentation in the normal spherical
structure of the exosomes caused by the staining process. The large numbers of exosomes
visible in the following TEM image (Figure 6.4) are of the expected size and morphology;
however a few larger pieces of cellular debris can also be seen among the exosomes,
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suggesting that the sequential centrifugation protocol is not completely efficient at producing
a pure sample containing only exosomes (and this may have resulted in increased TSG101
levels in Figure 6.3 in the exosome lanes).
Figure 6.4 – TEM image of exosomes isolated
from 22Rv1B4 cell medium
Exosomes collected from 22Rv1B4 cells after
24 hrs of incubation analysed through TEM
using a negative staining method with 1%
uranyl acetate. Examples of exosomes are
indicated by red arrows and appear as cup
shaped spherical objects of approximately 30-
100 nm. Additional cellular fragments can
also be seen. The image is at a magnification
of 25000 X and the microscope was operating
at 80 kV.
6.2.2.3 Extraction from prostate cancer cell medium of EphB4-positive exosomes enriched
through ultracentrifugation
The sequential centrifugation protocol was modified to produce an enriched sample of
exosomes as the previous technique resulted in cellular debris present in the sample. An
additional high speed ultracentrifugation step at a force of 100 000 g for 90 min was added
to the protocol to further remove cell debris and enrich the sample medium for exosomes
(see Section 6.2.2). Medium from both 22Rv1VO control cells and 22Rv1B4 EphB4 over-
expressing cells was processed and enriched using this new protocol and a BCA assay was
performed which provided protein levels of 1.9 mg/mL for the 22Rv1VO derived exosomes
and 2.1 mg/mL for the 22Rv1B4 exosomes. The samples were then subjected to
electrophoresis alongside a 22Rv1B4 cell protein lysate positive control and probed for EphB4
with the Zymed antibody, and for TSG101 with the anti-TSG101 antibody (Figure 6.5). A band
at 120 kDa, the predicted size of full-length EphB4, was observed in the positive control
(22Rv1B4 lysate) and the enriched exosome preparation collected from the 22Rv1B4 cells,
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and a faint band was observed in the 22Rv1VO negative control. Furthermore, bands
corresponding in size to TSG101 (47 kDa) can be seen in the lysate control and the enriched
medium samples. This suggests that exosomes were collected from both cell types but the
exosomes from 22Rv1B4 cells contained more EphB4 than those from 22Rv1VO cells as
expected. Additionally, the exosomes were analysed by TEMusing a negative staining method
with 1% uranyl acetate (however, the TEM was a different model to that used previously and
used a different imaging technique, hence why Figure 6.4 and 6.5 differ). Exosomes were
observed as dark spheres and cup shaped spherical objects of approximately 30-100 nm.
Furthermore, no cellular debris was observed suggesting the exosomes have been enriched
by means of the additional centrifuge step resulting in a purer sample compared to that seen
in Figure 6.4.
Figure 6.5 – Extraction of enriched EphB4-positive exosomes from prostate cancer cell medium
Serum-free growth medium collected from 22Rv1VO and 22Rv1B4 cells after 24 hrs of incubation and centrifuged
twice to collect and enrich exosomes. A. The enriched medium from 22Rv1VO and 22Rv1B4 cells analysed on a
gel alongside a 22Rv1B4 protein lysate sample. The gel was probed with an EphB4 specific antibody (Zymed) and
an antibody against TSG101. Bands corresponding to the size of EphB4 (120 kDa) are present in the lysate control
lane and in the enriched exosome preparation collected from the 22Rv1B4 cells. Bands at 47 kDa corresponding
to TSG101 can also be observed in the lysate control lane and both the enriched samples. B. Exosomes were also
analysed by TEM using a negative staining method. Exosomes can be seen as dark spheres and cup shaped
spherical objects of approximately 30-100 nm. The left image is at a magnification of 8000X and the right is at
20000X and the microscope was operating at 80 kV.
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6.2.3 Characterisation of exosomes exuded from prostate cells
6.2.3.1 Isolation and characterisation of EphB4-positive prostate cancer cell derived
exosomes
The preceding results have identified EphB4 as part of the cargo of exosomes released by
22Rv1 prostate cancer cells and have shown that these exosomes also contain the common
exosomal marker TSG101. To further characterise prostate derived exosomes and their
origins, a panel of prostate cancer cell lines (22Rv1B4 EphB4 over-expressing, 22Rv1VO,
22Rv1 wild type, C42B, PC3, LNCaP, DU145) were analysed for the presence of EphB4-positive
exosomes. The collected exosomes were also examined for the presence of proteins known
to be associated with exosomes, as well as specific membrane, endoplasmic reticulum and
Golgi apparatus protein markers known to not be present in exosomes to ensure purity.
Serum-free medium was collected from the prostate cells after 24 hrs of incubation and
processed through two sequential ultracentrifugation cycles to  purify and concentrate the
exosomes from the cell lines. The exosomes were loaded onto a gel and subjected to
electrophoresis on a polyacrylamide gel and analysed by Western blot. Specific cell markers
were used to determine the cellular origins of the collected exosomes. Initially, the blots were
probed with the Zymed anti-EphB4 antibody to confirm the presence of this protein in the
exosomes. Following this, the blots were probed with antibodies for proteins that may be
associated with exosomes i.e. Clathrin (a marker of coated vesicles found on the plasma
membrane and involved in the initial vesiculation process in exosome formation), and Early
Endosome Antigen 1 protein (EEA1, a marker of early endosomes which accumulate cargo for
packaging into exosomes). The blots were finally probed for proteins not found in exosomes
i.e. GM130 (a Golgi apparatus marker) and Calnexin (an endoplasmic reticulum marker). The
blot was stripped between each treatment and confirmed to not retain residual luminescence
of previous antibodies.
In Figure 6.6, bands were observed in both the lysate positive control lanes and the exosome
sample lanes of all cell types corresponding in size to EphB4 (120 kDa), Clathrin (180 kDa) and
EEA1 (180 kDa) as was expected. No bands were detected in the exosome lanes for GM130
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(130 kDa) and Calnexin (75 kDa) showing that the exosome sample was not contaminated
with other membranes, but the positive lysate controls showed bands of the expected
molecular size for each of these proteins. This indicates that exosomes collected from a
variety of prostate cell lines express EphB4 as well as the exosome markers EEA1 and clathrin
and do not express GM130 and Calnexin, proteins not associated with exosomes.
Figure 6.6 - Isolation and characterization of EphB4-positive prostate cancer cell derived exosomes
Exosomes were collected from the following prostate cell lines: 22Rv1B4 (B4), 22Rv1VO (VO), C42B (C42), 22Rv1
wild type (WT), PC3, LNCaP (LN) and DU145 (DU) after a 24 hr incubation. The samples were analysed on a gel
along with protein cell lysates from 22Rv1B4 and 22Rv1 wild type cells and probed with antibodies against EphB4
(Zymed), Clathrin, Early Endosome Antigen 1 protein (EEA1), GM130, and Calnexin. Bands were seen in the
positive control cell lysates and in exosome extracts taken from all the prostate cell lines corresponding to the
size of EphB4 (120 kDa), Clathrin (180 kDa) and EEA1 (180 kDa) respectively. No bands were detected in the
exosome sample lanes when the blot was probed for GM130 (130 kDa) and Calnexin (75 kDa), but bands were
seen in the positive control lysate samples corresponding in size to these proteins.
6.2.4 EphB4-positive prostate cancer cell-derived exosomes affect the
proliferation rate of prostate cancer cells and HUVEC cells
6.2.4.1 EphB4-positive prostate cancer cell derived exosomes increase the proliferation rate
and decrease caspase 3/7 activity of prostate cancer cells
Having previously isolated and characterised prostate cell derived exosomes, the subsequent
step was to ascertain their role and function in their immediate extracellular environment.
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EphB4 is a known tumour promoter when signalling occurs independently of its ligand ephrin-
B2 (Chen et al. 2008) and the transport of EphB4 in exosomal structures may allow EphB4 to
initiate ligand-independent signalling events in neighbouring cells. Tumour derived exosomes
have been implicated in increasing the proliferation of cells they target (Koga et al. 2005; Qu
et al. 2009). As such, it is hypothesised that the addition of EphB4-positive exosomes to
prostate cancer cells that already express EphB4 will induce a tumour promoting response
through ligand independent signalling (such as increased proliferation) as the exosomes
deliver EphB4 to neighbouring cells, fuse with the cell membrane and re-incorporate the
exosomal EphB4 into the neighbouring cell membrane. This would increase the level of EphB4
and allow for clustering to occur which in turn would lead to autophosphorylation of the
EphB4 kinase domains and subsequent ligand independent signalling.
To test this, exosomes were collected after a 24 hr incubation from both 22Rv1VO cells and
22Rv1B4 cells at the same level of confluency. Equal amounts (50 µl added each day) of these
two types of exosomes, along with growth medium as a control, were added to 22Rv1VO cells
(expressing EphB4 at low levels), 22Rv1B4 cells (over-expressing EphB4) and LNCaP prostate
cancer cells (expressing low levels of EphB4) growing in cell culture flasks. The proliferation
rate of these cells was observed over a five day period using a metabolic proliferation assay
kit. Caspase 3/7 activity (associated with apoptosis) was also monitored over this timeframe.
Figure 6.7 shows a significant increase in proliferation was observed when the cells were
treated with 22Rv1B4 derived EphB4-positive exosomes compared to the proliferation rate
of the cells treated with 22Rv1VO derived exosome or the culture medium control cells. This
was true across all cell lines but the proliferation rate was most increased in the EphB4 over-
expressing 22Rv1B4 cells.
The increased proliferation was correlated with a lower Caspase 3/7 activity (a marker of
apoptosis) which was significantly lower in the 22Rv1B4 exosome-stimulated cells compared
to the 22Rv1VO exosome-stimulated cells and the medium-stimulated cells, but still increased
overall, as expected for a growing population of cells where normal apoptosis still occurs over
time. Interestingly, cells stimulated with 22Rv1VO-derived exosomes (containing low levels
amounts of EphB4) also showed a trend towards an increased proliferation rated when
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compared to the baseline medium stimulate control cells across all cell types (though this was
not statistically significant), suggesting that exosomes in general are able to increase
proliferation (as reported by Koga et al. 2005 and Qu et al. 2009), or the low levels of EphB4
aided in increased cell growth. However, the proliferation rate is most increased when EphB4
is abundantly present in the exosomes.
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Caspase 3/7 Assay
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Figure 6.7 – EphB4-positive prostate cancer cell-derived exosomes increase the proliferation rate and caspase
3/7 activity of prostate cancer cells
22Rv1VO (VO), 22Rv1B4 (B4) and LNCaP (LN) prostate cancer cells were stimulated with either medium from
22Rv1VO cells (VO exo) enriched for exosomes, medium from 22Rv1B4 cells over-expressing EphB4 (B4 exo)
enriched for exosomes, or unaltered growth medium. The proliferation rate and Caspase 3/7 activity of the cells
was observed over a 5 day period. An increase in proliferation was observed for all cell types treated with
22Rv1B4-derived EphB4-positive exosomes. This correlated with a lower Caspase 3/7 activity in the cells
stimulated with 22Rv1B4 exosomes compared to the other two treatments. No significant difference in
proliferation was observed between 22Rv1VO exosome-treated cells or medium control-treated cells across all
cell types and this correlated to statistically similar Caspase 3/7 activity in these treatments. (X axis shows
duration in days and Y axis shows proliferation rate standardised to the first day’s proliferation score which was
set at 1.0). Statistical significance was determined by a two-tailed Student t-test with * indicating a p<0.05, **
indicating a p<0.01 and *** indicating a p<0.001 statistically significant difference when compared to the media
control samples.
6.2.4.2 EphB4-positive prostate cancer cell derived exosomes decrease the proliferation rate
and increase caspase 3/7 activity in HUVEC cells
EphB4 has been shown to act as tumour suppressor when stimulated by its ligand ephrin-B2
(Chen et al. 2008) and exosomes have also been shown to affect cell proliferation (Koga et al.
2005; Qu et al. 2009). As such, it is postulated that the addition of EphB4-positive exosomes
to Human Umbilical Vein Endothelial Cells (HUVECs), which express ephrin-B2 (Korff et al.
2006), will result in an interaction between the exosomal EphB4 and the ephrin-B2. This could
occur through direct interaction of the EphB4 carried by the exosomes with the ephrin-B2
expressed on the HUVECs. This interaction would then initiate signalling into the ligand host
cell resulting in decreased proliferation of the HUVECs.
Exosomes were collected from both 22Rv1VO cells (low amounts of EphB4-positive
exosomes) and 22Rv1B4 cells (high amounts of EphB4-positive exosomes). These exosomes,
along with growth medium as a negative control, were added to the HUVECs. The
proliferation rate of these cells was observed over a four day period using a metabolic
proliferation assay kit. Caspase 3/7 activity (associated with apoptosis) was also monitored
over this timeframe. These experiments were replicated three times.
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A significant decrease in the proliferation rate was observed after cells were treated with
22Rv1B4-derived EphB4-positive exosomes, while cells treated with either 22Rv1VO-derived
exosomes or with the medium control continued to proliferate as normal, though cells
treated with 22Rv1VO exosomes did show a slight increase in proliferation above the base
growth rate of medium control-stimulated cells, but this was not statistically significant. The
sharp decrease in proliferation of the 22Rv1B4 exosome-treated cells correlated with a
significant increase in Caspase 3/7 activity (a marker of apoptosis) above the 22Rv1VO
exosome- and medium-treated cells.
Proliferation Assay
Caspase Assay
Figure 6.8 – EphB4-positive prostate cancer cell-derived exosomes decrease proliferation of HUVECs through
Caspase 3/7 dependent apoptosis
HUVECs were stimulated with either medium from 22Rv1VO cells (VO exo) enriched for exosomes, medium from
22Rv1B4 cells (B4 exo) enriched for exosomes, or unaltered growth medium. The proliferation rate and Caspase
3/7 activity of the cells was observed over 4 days. The experiment was repeated three times. A decrease in
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proliferation was observed for cells treated with 22Rv1B4-derived EphB4-positive exosomes when compared to
22Rv1VO exosome- or medium-stimulated cells. This correlated with a higher Caspase 3/7 activity in the cells
stimulated with 22Rv1B4 exosomes compared to the other two treatments. No statistically significant difference
in proliferation was observed between 22Rv1VO exosome-treated cells or medium control-treated cells and this
correlated to statistically similar Caspase 3/7 activity in these treatments. (X axis shows duration in days and Y
axis shows proliferation rate standardised to the first day’s proliferation score which was set at 1.0). Statistical
significance was determined by a two-tailed Student t-test with * indicating a p<0.05, ** indicating a p<0.01 and
*** indicating a p<0.001 statistically significant difference when compared to the media control samples.
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6.3 Discussion
The RTK EphB4 is a transmembrane protein that is bound within the plasma membrane of its
host cell. As such, it is not expected to be present as a full length, potentially functioning
protein in conditioned medium. However, this study has identified the presence of full length
EphB4 in the medium collected from 22Rv1B4 prostate cancer cells, which have been
engineered to over-express EphB4 and several PCa lines that endogenously express EphB4
(Rutkowski et al. 2012). Furthermore, it was shown that the protein persisted in the medium
even after 72 hours. This indicates that the protein was either somewhat protected from
being degraded once it is released from the cells, or it was being consistently released from
the cells (Figure 6.2).
EphB4 interacts with its ligand ephrin-B2 within the context of the cell membrane, initiating
signalling into the receptor-expressing cell through the phosphorylation of the kinase domain
of the receptor which in turn stimulates downstream signalling within the host cell. Similarly
EphB4 interaction with ephrinB2 activates reverse signalling into the ligand expressing cell
through Src-family kinase activation. The purpose and function of EphB4 when it is
transported outside of the cell by exosomes (as demonstrated in this study) is currently
unknown, but it may be through activation of reverse signalling pathways. A number of
mechanisms are able to transport full length proteins from the cell to the external
environment including secretion and vesiculation. Secretory proteins include hormones and
enzymes and these are typically smaller than most transmembrane proteins. Transmembrane
proteins are not usually secreted from the cell as they are intrinsic portions of the plasma
membrane through their hydrophobic transmembrane domain. However, EphB4 does
possess a secretion signal, but also contains a transmembrane domain which anchors it within
the membrane, making this mechanism an unlikely one for transporting EphB4 out of the cell.
A more likely candidate is vesiculation. Cells produce many different types of vesicles which
can be released by activation, stress, transformation or cell death. These vesicles can either
be shed from the plasma membrane of the cell, form as membrane blebs during apoptosis,
or form through the indentation of the plasma membrane and endosomal processing which
forms exosomes (Rak, 2010).
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A number of receptors have been identified to be transported out of cells as part of exosomal
cargo including some Eph receptors, integrins and EGFR (Mathivanan et al. 2009; Welton et
al. 2010). Furthermore, EphB4 has also been reported to be present in exosomes released by
colorectal cancer cells (Choi et al. 2008). As such, it was hypothesised that the presence of
EphB4 in the medium of 22Rv1B4 cells was as a result of exosome transportation. This
hypothesis would not only explain how full length EphB4 was able to exit the cell, but would
also elucidate why EphB4 was able to be detected in the medium even after 72 hours, as it
would be protected from degradation by the exosomal structure by either presenting on the
membrane of the exosomes through initial endocytocis in the host cell, or by being packaged
inside the exosomes through the endosomal sorting complexes required for transport (ESCRT)
processing mechanism (Valadi et al. 2007; Théry, 2011).
To test whether full length EphB4 was transported in exosomes out of the cell, exosomes
were isolated from 22Rv1 prostate cancer cells and analysed for the presence of EphB4 and a
common marker of exosomes, TSG101. A sequential centrifugation extraction technique was
used where the medium collected from the cells was centrifuged at 500 g, 3000 g and 10 000
g so as to remove cell debris, other intracellular vesicles of larger size and organelles. Finally,
the medium was ultracentrifuged to pellet the exosomes. The analysis by Western blot
revealed that as exosomes were extracted, EphB4 was depleted from the medium; suggesting
that EphB4 (120kDa) is transported as a full length protein out of 22Rv1 cells in exosomes
(Figure 6.3). TEM was also used to confirm the presence of exosomes by their size, 30-100nm,
and spherical shape (Figure 6.4). The staining procedure causes the characteristic cup shaped
indentations on the surface of the vesicles that is used to identify them, as can be seen as
purer preparations after a second ultracentrifugation step (which removed unwanted
material and to enrich the sample for exosomes) shown in Figure 6.5. (However, the
microscopy equipment used for these experiments was updated and used different imaging
techniques, hence Figure 6.4 and Figure 6.5B have a different appearance).
Figure 6.5A showed that the exosomes isolated from the 22Rv1B4 EphB4-positive cells were
positive for both full length EphB4 (seen at its predicted size of 120 kDa) and the exosome
marker TSG101 (additionally, testing in future could use a marker such as Calnexin as a
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negative control to confirm the absence of cellular contamination). Low levels of EphB4 were
also detected in exosomes collected from 22Rv1VO cells and these were also positive for
TSG101. The TEM images in Figure 6.5B indicated that the additional centrifugation step
produced exosome samples that had much less cell debris (as none was visible in the images),
resulting in a purer exosome preparation.
Cancer cells have been reported to have higher rates of vesicle release, including exosome
secretion (Dolo et al. 2005; Ratajczak et al. 2006) and other studies have reported on the
release of exosomes from prostate tumours (Lehmann et al. 2008; Nilsson et al. 2009;
Duijvesz et al. 2011). No study has yet reported EphB4 as cargo of prostate cancer derived
exosomes. As such, exosomes were isolated using the double centrifugation method from a
panel of prostate cancer cells. These vesicles contain EphB4 and additionally, other exosomal
proteins (Clathrin and EEA1) and proteins known not to be carried by exosomes (GM130 and
Calnexin). These additional protein markers were used in the analysis in order to ascertain
the cellular origin of the exosomes as they each were associated with different organelles
within the cell.
Specifically, EEA1 (Early endosome antigen 1) is involved in endosomal trafficking and is a
marker of early endosomes, which are involved in the early stages of exosome biogenesis,
and Clathrin coats membrane pits which bud inwardly to form internal vesicles which carry
proteins from the membrane to be packaged into exosomes. GM130 (GOLGA2) is a member
of the golgin family of proteins that localise to the Golgi apparatus and as such, GM130 is a
marker of the Golgi apparatus (Fritzler et al. 1993). Calnexin is a marker of the endoplasmic
reticulum (ER) where it is involved in protein folding. Neither the Golgi apparatus nor the ER
has any involvement with the formation of exosomes. The Western blot analysis (Figure 6.6)
confirmed that exosomes derived from all the prostate cancer cell lines investigated carried
full length EphB4. Additionally, the exosomes from these cell lines contained EEA1 and
Clathrin as expected for proteins involved in exosome biogenesis, but did not contain GM130
and Calnexin (also as expected). This result indicated that the EphB4 present in these vesicles
was internalised through the inward budding of Clathrin coated pits and processed through
the endosomal pathway, which is the same pathway used for exosome production, thus
155
further confirming that full length EphB4 expressed on the surface of cells can be internalised,
processed and released from the host cell in exosomes.
However, it was yet unknown whether the EphB4 was functional and able to signal, and what
purpose this signalling would have. Many studies have reported on various roles of tumour
derived exosomes, including premetastatic niche formation, tumour growth and immune
system modulation. However, of particular interest were studies which implicated tumour
derived exosomes in increasing angiogenesis and increasing cell proliferation, two roles which
EphB4 also performs (Koga et al. 2005; Qu et al. 2009). Thus, to determine whether EphB4
containing exosomes was functionally able to produce an effect on cellular growth, both
EphB4-high and EphB4-low exosomes were collected from 22Rv1B4 and 22Rv1VO cells,
respectively, as previously described. The vesicles were then added to cancer cell lines
including LNCaP, 22Rv1VO and the exosome host cells, 22Rv1B4; as well as HUVECs. The
proliferation rate of these cell lines and their Caspase 3/7 activity (a measure of apoptosis)
was recorded over a number of days.
It was hypothesised that the addition of EphB4 positive exosomes to 22Rv1B4 cells (which
over-express EphB4 and express very low levels of ephrin-B2) would boost the tumour
promoting ligand-independent signalling event by fusing with the plasma membrane, and
therefore increase proliferation. A mechanism through which this could occur would be by
the incorporation of the exosomes and subsequent re-expression of EphB4 on the cell surface,
increasing the level of EphB4 and initiating tumour promoting signalling through
autophosphorylation of the adjacent kinases domains of the receptors.
The proliferation study revealed that stimulation of cancer cells with EphB4-positive
exosomes significantly increased the proliferation of these cells while concurrently lowering
the amount of Caspase 3/7 activity when compared to cells stimulated with 22Rv1VO
exosomes or with a medium-only control. The most marked difference was seen in the EphB4
over-expressing 22Rv1B4 cells. Additionally, cells stimulated with the 22Rv1VO exosomes
(which contain minimal levels of EphB4) were able to slightly increase proliferation above the
control base levels though this was not statistically significant. These result indicate that the
EphB4 containing exosomes derived from 22Rv1B4 cells were able to induce a change within
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the target cells, though whether this was a direct result of EphB4 as the active element, or
some other factor co-transported in the exosomes as a result of EphB4 over-expression within
the prostate cells, is yet to be tested. These results show that stimulating cells with EphB4
positive exosomes induces proliferation and decreases apoptosis, though further
experimentation, where the activity of EphB4 is neutralised (such as with an antibody), is
needed to confirm whether EphB4 is the direct instigator of this effect.
If EphB4 is in fact the primary instigator of the effects observed, then this would provide a
novel role for EphB4 as an initiator of signalling outside of its host cell, as it is able to be
transported and signal neighbouring cells by being carried by exosomes. Exosomes have also
been shown to travel to distant sites and interact with endothelial cells to set up
premetastatic niches by conditioning the environment to improve the survival of circulating
tumour cells at these locations (Jung et al. 2009; Grange et al. 2011; Alderton 2012). If these
exosomes can carry EphB4 to these sites, then they could further enhance proliferation and
reduce cell death of the circulating tumour cells, thus increasing the likelihood of metastasis
through the tumour promoting ligand-independent signalling pathway of EphB4. However, in
endothelial cells, the alternative may occur, where EphB4 containing exosomes may be
released by tumour cells over-expressing to protein and be used to invade and metastasise
to other sites by establishing distant premetastatic niches that could promote tumour growth
and spread. In vivo studies where tumour growth and metastasis are assayed after the
addition of EphB4-positive exosomes to endothelial cells could be used to test this hypothesis.
Visualising EphB4-exosome transport out of cells and the interaction and subsequent intake
of exosomes into neighbouring cells using immuno-photoelectron microscopy utilising
colloidal gold coated with antibodies specific to EphB4 to track the exosome structures (Birrell
et al. 1985), would yield greater understanding into the mechanism of actions of EphB4-
positive exosomes with their surrounding environment. The fusion of exosomes with the
plasma membrane has also been demonstrated by means of fluorescence microscopy in live
cells by labelling exosomes with the lipophilic dye R18. This dye is self-quenching when diluted
through fusion of the exosomes with their target cells and results in fluorescence of target
cells. However, this technique has a limited resolution (Montecalvo et al. 2012). Additionally,
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the release of exosomes from the cells and the mechanism that this uses could be studied by
using inhibitors of clathrin mediated endocytocis (such as Pitstop 2) through the
encapsulation of clathrin coated pits, or using inhibitors of dynamin (such as Dynasore or
Dyngo-4a) a protein involved in endocytocis, to understand the mechanism through which
EphB4 positive exosomes are formed.
The exact mechanism of this function is still unknown, but it is hypothesised that it may be
through the incorporation of the exosomes into the cell and the subsequent recycling of the
cargo EphB4 on the surface of the target cell (see Figure 6.9). This could then increase the
amount of protein present and producing a ligand-independent signalling event which is
known to be tumour promoting. The incorporation of these exosomes could be tested by
using fluorescent labelling and tracking exosome migration and incorporation into cells
(Mineo et al. 2012; Suetsugu et al. 2013). This increased expression of the receptor could then
result in increased cross-phosphorylation of the adjacent kinase domains thus initiating
signalling pathways within the cell which enhance the proliferation rate of the cells and
decrease Caspase 3/7 apoptosis (Rutkowski et al. 2012). This is a potential future experiment,
to observe phosphorylation, and thus activation, of EphB4 in exosomes.
Likely mechanisms for this are the MAPK/ERK (mitogen-activated protein
kinase/extracellular-regulated protein kinase) pathway and the PI3K/Akt/mTOR
(Phosphatidylinositide 3-kinases/Akt/mammalian target of rapamycin) pathway. The
MAPK/ERK pathway is frequently manipulated by cancer cells in order to achieve uncontrolled
growth (Hilger et al. 2002; Roberts & Der, 2007), while the PI3K/Akt pathway is utilised by
cancer cells to decrease apoptosis and increase proliferation (Morgensztern & McLeod, 2005;
Yap et al. 2008). Both of these pathways have also been shown to be activated by tumour-
derived exosomes to increase proliferation in their target cells (Qu et al. 2009).
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Figure 6.9 – Mechanism of EphB4-positive exosome formation and action
The host cell membrane buds into the cell forming an early endosome containing membrane bound proteins (in
red) (A). Intraluminal vesicles (ILVs) are formed through early endosomal internal budding and contain lipids,
nucleic acids and proteins (now orientated to their original position with the extracellular domain facing out) (B).
The ILVs collect together to form multivesicular bodies (MVBs) (C) which can be targeted for degradation by
fusing with the lysosomes (D) or alternatively, the MVBs can fuse with the plasma membrane, releasing the
intraluminal vesicles as exosomes (E). The exosomes can travel to neighbouring cells were they can be
incorporated into the target cell through endocytocis (F) which leads to their encapsulation and processing by
the target cell (G) and the subsequent re-expression of the exosome cargo by the target cell (H). Alternatively,
the exosomes can fuse directly with the membrane of the target cell, releasing their contents into the cytoplasm
(I). Exosomes may also act as signalling elements when the proteins on the surface of the exosomes interact with
proteins expressed on the target cell, initiating signalling in the target cell (J).
It is thus hypothesised that the EphB4 carried by exosomes enhances these pathways, in
addition to normal exosome signalling, to dramatically increase proliferation in cancer cells
while lowering Caspase 3/7-mediated apoptosis. This would provide a novel role for EphB4 as
a potential initiator of signalling outside of its host cell as a cargo of exosomes, as it would be
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able to be transported and signal neighbouring cells by being carried around in exosomes.
Exosomes have also been shown to travel to distant sites to set up premetastatic niches by
conditioning the environment to improve the survival of circulating tumour cells at these
locations. If these exosomes can carry EphB4 to these sites, then they can further enhance
proliferation and reduce cell death of the circulating tumour cells, thus increasing the
likelihood of metastasis through the tumour promoting ligand-independent signalling
pathway of EphB4.
However, when EphB4-positive exosomes were used to stimulate HUVECs, the opposite
effect to that described above was observed. HUVEC proliferation significantly decreased
while Caspase 3/7 apoptosis increased when cells were stimulated with exosomes derived
from 22Rv1B4 cells compared to the cells stimulated with 22Rv1VO exosomes or with the
medium-only control. The addition of EphB4-positive exosomes had a severely detrimental
effect on the HUVECs, causing cell death and lower growth rates. Although this has not been
specifically attributed to the presence of the EphB4 receptor, as other factors within the
exosomes could be activated as a result of EphB4 over-expression (though this still needs to
be tested), it is clear the exosomes derived from cells over-expressing EphB4 do in fact cause
a dramatic effect on the target cells where as it was observed that 22Rv1VO exosomes (which
contain minimal levels of EphB4) did not cause a similar effect (in fact, proliferation increased
slightly under stimulation with 22Rv1VO derived exosomes, though this was not statistically
significant).
Under normal circumstances, Eph-ephrin interaction results in bidirectional signalling with
forward signalling into the receptor cell and reverse signalling into the ligand cell
(Krasnoperov et al. 2010; Noren et al. 2004). However, it is interesting to note that in this
case, with EphB4 being contained in exosomes, signalling can only occur in the reverse
direction into the HUVECs through stimulation of the ephrin-B2 ligand by the exosomal
EphB4-receptor. Traditional forward signalling of the receptor would not generate an effect
even if the kinase domains of the EphB4 receptor were phosphorylated as a result of
interaction, as the receptor is carried by the exosomes which do not contain the necessary
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downstream components (such as specific proteins or a nucleus etc.) that could be acted on
to induce a signalling event.
As such, the observed decrease in proliferation and increase in Caspase activity in the HUVECs
must come about through ephrin-B2 signalling into its expressing cell. However, it is currently
unclear as to how this is achieved. Two mechanisms are hypothesised: either a) the direct
interaction of the EphB4 receptor on the exosomes with its ligand ephrin-B2, expressed by
HUVECs results in reverse signalling into the HUVECs and subsequent activation of signalling
pathways which lead to a decrease in proliferation (this would likely occur through the
recruitment of Src family kinases and subsequent phosphorylation of the cytoplasmic domain
of ephrin-B2) (Kullander & Klein, 2002; Pasquale, 2010)); or b) the fusion of the exosomes
with the HUVECs results in EphB4 being internalised and re-expressed on the cell surface, and
the receptor and ligand interacting in cis thereby blocking either normal Eph-ephrin signalling
(Yin et al. 2004) and perhaps initiating some as yet unknown pathway which would decrease
phosphorylation, or blocking receptor independent ephrin-B2 signalling which may be
maintaining positive cell growth (Bochenek et al. 2010) (Figure 6.10). Finally, it should be
noted that the number of exosomes used to stimulate the cells in all experiments was likely
much higher than normal physiological levels found in cells as the exosomes were collected
from medium that had been incubated with the cells for 24 hours and were further enriched
from the medium through sequential centrifugation. This would likely explain why the
changes observed in the experiments were so far above normal control levels of cell
proliferation and Caspase activity as the cells were spiked with exosomes containing higher
than physiologically normal amounts of EphB4.
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In conclusion, it can be seen that exosomes derived from EphB4 over-expressing cells can
initiate signalling which results in increased proliferation and decreased Caspase 3/7
mediated apoptosis activity in cancer cells; and decreased proliferation and increased
Caspase 3/7 mediated apoptosis activity in endothelial cells, and that this is hypothesised to
be as a direct result of the EphB4 receptor. This is a novel finding, identifying a potential
extracellular role for EphB4 in prostate cancer, a disease known to over-express EphB4 (Xia
et al. 2005; Lee et al. 2005) and to release EphB4-positive exosomes (shown in Figure 6.6).
This new role for EphB4 is still poorly understood, but may reveal new insights into prostate
cancer development and growth, particularly in utilising EphB4-positive exosomes to
establish premetastatic niches and increase the proliferation of the tumour mass.
Figure 6.10 Hypothesised mechanism of EphB4-positive exosomes interacting with HUVECs
EphB4-positive exosomes are released from prostate cells (A) and can enter into one of two paths: either the
exosomes transport EphB4 to the HUVEC cell surface where the receptor interacts directly with its ligand ephrin-
B2 (B), initiating reverse signaling into the HUVECs (through Src kinase phosphorylation). Alternatively, the
exosomes fuse with the HUVECs (C) and are incorporated into the cells and processed (D), and are then re-
expressed on the HUVEC cell surface (E). This causes the receptor to interact with the ligand in trans, blocking
normal signaling of the ligand.
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Chapter 7
Discussion and future directions
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Chapter 7: Discussion and future directions
7.1 Overview
Prostate cancer accounts for almost a third of all cancer diagnoses in men and is the most
common cancer in men in Australia. Once the cancer metastasises outside the prostate it
becomes incurable and so it is vitally important that new therapeutic targets for this disease
are developed in order to prolong and improve the life of prostate cancer patients. EphB4, a
membrane bound RTK, has recently come to the fore as a potential novel therapeutic target.
The Eph family is unique among RTKs in that its members require cell to cell contact in order
to interact with their ligands, the ephrins, which are attached to neighbouring and opposing
cells (Pasquale, 2005).
This interaction results in bidirectional signalling, with forward signalling taking place within
the receptor cell and reverse signalling in the ligand cell. Alternatively, Eph receptors have
also been shown to be able to initiate signalling events independently of their ligand through
cross-talk between aggregated receptors (Noren et al. 2006; Pasquale, 2010). The EphB4-
ephrin-B2 signalling network has been shown to contribute to a number of different
developmental processes including axon guidance, formation of neural networks, cell
migration, patterning and morphogenesis, and angiogenesis. EphB4 activation also initiates
signalling cascades which affect downstream processes including proliferation, differentiation
and bone remodelling (Wang & Anderson, 1997; Helbling et al. 2000; Poliakov et al. 2004;
Zhao et al. 2006; Pasquale, 2010; Matsuo, 2010).
EphB4 up-regulation has now been shown to be a common occurrence in many cancers
including prostate cancer, and increased expression is often associated with cancer
progression (Kumar et al. 2007; Kumar et al. 2009; Noren & Pasquale, 2007). However, the
main focus of this research has been investigating the role of EphB4 in prostate cancer
development and progression. EphB4 has been reported to be over-expressed in
approximately 60% of prostate tumours, and has been shown to be essential for cancer cell
survival, invasion and spread (Xia et al. 2005a). Another report in 2002 found high levels of
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EphB4 expression on the invasive front of tumours (Berclaz et al. 2002), further implicating
EphB4 in cancer progression and invasion.
These studies clearly show that EphB4 plays an important role in prostate cancer cell survival
and appears to contribute to key hallmarks of cancer progression including increased invasive
potential and avoidance of apoptosis. However, it is not yet clear exactly how EphB4 performs
these functions and which pathways are affected and regulated by the receptor. EphB4 has
been identified as both a tumour promoter and a tumour suppressor (Noren & Pasquale,
2007; Chen et al. 2008). This signalling paradox is thought to be a result of the dual signalling
mechanism that EphB4 possesses because EphB4 is involved in both ligand-dependent and
ligand-independent signalling pathways (Noren, 2004; Rutkowski et al. 2012). A model for
EphB4 dual signalling has been proposed where the interaction of ephrin-B2 with EphB4
promotes forward signalling of the receptor that leads to tumour suppression (inhibiting
tumour cell growth and motility through activation of the Abl/Crk pathway) and reverse
signalling through the ligand that stabilizes cell-cell adhesion (Noren & Pasquale, 2007; Chen
et al. 2008).
In tumour cells where EphB4 is over-expressed, ligand-receptor interaction is decreased as
evidenced by the lack of detectable EphB4 phosphorylation, which then leads to the use of
ligand-independent signalling pathways, thereby promoting tumour development (Noren et
al. 2006; Pasquale, 2010). This was shown in experiments when the over-expression of EphB4
in prostate cells significantly increased anchorage-independent growth, migration and
invasion. These increases in metastatic characteristics were reversed after stimulation with
the ligand ephrin-B2 which initiated forward signalling and decreased EphB4 protein levels
and proliferation of the cells (Rutkowski et al. 2012). This suggests that EphB4 ligand-
independent signalling directs cells towards a metastatic phenotype and this can be reversed
through ligand mediated forward signalling, which indicates that the ephrin-dependent
forward signalling of Eph receptors leads to tumour suppression.
However the exact mechanisms of action of the EphB4 receptor in prostate cancer are still
mostly unknown. It may be that through different mechanisms, EphB4 can be both a cancer
suppressor and cancer promoter depending on its environment and cell type, other protein
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interactions, and the interplay and balance of ligand to receptor (Noren & Pasquale, 2007).
However further study into the role, function and signalling pathways of the EphB4 receptor
needs to be conducted before this is made clear. Understanding this mechanism of action will
clarify the role that EphB4 plays in cancer development and progression.
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7.2 Summary of Results
The aims of this study were to:
1. To identify proteins which interact with EphB4 at the cell membrane and within the
cell using a variety of techniques including the novel 2-Dimensional Native Affinity
Compromised Electrophoresis (2D-NACE) method, co-immunoprecipitation, and
confocal microscopy.
2. To determine whether EphB4 is a cargo protein in exosomes secreted from prostate
cancer cells and to investigate the potential effect of the EphB4-positive vesicles on
both cancer and endothelial cells.
This thesis presents a novel method for identifying protein-protein interactions; identifies
Thrombospondin-1, PAK4, JNK1, MCF2L and Importin-α as novel interacting protein partners
for EphB4 (with novel pathways and signalling networks as a result); and describes a novel
mechanism of action for this receptor, through exosome transport of EphB4.
7.2.1 Developing and optimising the 2D-NACE method
EphB4 signalling is known to recruit other intracellular proteins which through signalling
cascades affect various cellular processes (Pasquale, 2010). However, the proteins that are
recruited by EphB4 during signalling events are largely unknown. A new method was
developed, called 2-Dimensional Native Affinity Compromised Electrophoresis (2D-NACE),
which uses native conditions which allow for the isolation and identification of the protein
partners of EphB4 in their native state. Initial optimisation included: 1) selecting the optimum
detergent and the concentration of the detergent to use in the NACE buffer in order to
maintain the structure and function of native complexes, 2) selecting the gel thickness and
polyacrylamide concentration that would produce the tightest migration of the protein into
the gel, 3) confirming that the buffer and gel conditions were able to maintain protein
complexes during electrophoresis through the gel, 4) and finally, selecting the optimum
antibody and concentration to use in the stacking region of the gel that would best retain
EphB4 complexes through affinity interactions.
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2D-NACE was optimised for use with DDM at a concentration of 2.5 g detergent/g protein
with a gel thickness of 1.5 mm with a polyacrylamide concentration of 4% - 13% and a 5%
polyacrylamide stacking region. These conditions were able to maintain a complex of
recombinant EphB4 and ephrin-B2 during electrophoresis. Finally, it was determined that the
EphB4 specific antibody C1 was best able to retain recombinant EphB4 complexes in the
stacking region of the gel, at a concentration of 5 µg, and isolate high molecular weight
protein complexes containing EphB4.
The 2D-NACE method was then used to isolate and identify interacting partners of EphB4
from an LNCaP prostate cell total lysate. A large number of potential binding partners of
EphB4 were identified, as well as a number of commonly occurring proteins that are
considered to be general environmental contaminants (e.g. keratin). Many of the proteins of
interest had roles in prostate cancer progression or were involved in pathways that EphB4
was also known to regulate. From these proteins, Thrombospondin-1 was selected for further
validation.
7.2.2 Validating putative interacting protein partners of EphB4
The 2D-NACE study produce a large number of possible binding partners for EphB4, however
there were too many to confirm all their interactions. Thrombospondin-1 was selected as a
candidate for further testing, as it was necessary to validate that it could interact with EphB4
through co-immunoprecipitation assays and immunofluorescence based co-localisation
studies. Identifying binding partners of EphB4 will greatly help in understanding the signalling
pathways and functions that this receptor is involved in. The 2D-NACE method is versatile and
could be adapted to identify interacting partners of almost any protein target, provided that
a suitable antibody is available to place in the stacking portion of the gel. This novel
technology could be used to identify a myriad of different protein interactions in any number
of cell types, greatly adding to the understanding of cell function and signalling pathways.
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Thrombospondin-1
Thrombospondin-1 was selected for validation studies as it is involved in similar roles to
EphB4, including mediating cell to cell and cell to matrix interactions and promoting
tumourigenesis (Lahav, 1993; Hanahan & Folkman, 1996; Chen et al. 2000; Sargiannidou et
al. 2001). As such, theremay be cooperation between these two proteins. Additionally, EphB4
and Thrombospondin-1 can be cleaved by the same serine proteinase; Kallikrein-4 (personal
communication from Ruth Fuhrman-Luck; Lisle et al. 2013) suggesting homologous cleavage
sites and potentially indicating shared or overlapping regulation and signalling mechanisms.
Co-immunoprecipitation (Co-IP) pull down assays confirmed the interaction of
Thrombospondin-1 with EphB4 and this was further confirmed using co-localisation with
EphB4 and Thrombospondin-1 occupying the same cellular space. However, further research
into the interaction of these two proteins is required to elucidate the role that this coupling
plays in signalling networks in both normal and disease states.
PAK4 (and JNK1, MCF2L)
Co-immunoprecipitation was alongside 2D-NACE to identify additional protein partners of
EphB4. A panel of antibodies was used to immunoprecipitate EphB4 and any interacting
protein in complex with the receptor. This was then analysed using mass spectrometry to
identify which proteins were pulled out with EphB4.
PAK4 was selected as a protein of interest to further validate. Gene and protein expression
was confirmed followed by co-immunoprecipitation of EphB4 using antibodies targeting
PAK4, ARHGAP39 and MCF2L and JNK1. EphB4 was found to be retained as a co-precipitant
in the immunoprecipitation of PAK4, MCF2L and JNK1, providing evidence that EphB4 may
interact with these proteins and this may be part of a larger signalling complex that is involved
in Rho GTPase signalling. Rho GTPases are involved in a number of processes including
proliferation, differentiation and motility (Tcherkezian & Lamarche-Vane, 2007), and
mutations in Rho proteins can promote tumourigenic phenotypes in cells (Ellenbroek &
Collard, 2007). However, further testing is still required to confirm these interactions and to
understand what pathways and signalling networks are effected.
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Importin-α
Concurrently in our laboratory, studies had identified EphB4 in the nucleus of prostate cancer
cell line cells, and in preliminary research, in silico methods were used to identify two
functional NLS sequences in EphB4. It was observed that EphB4 was transported into the
nucleus by means of these NLS sequences.
From this, it was hypothesised that EphB4 was transported into the nucleus through the
importin nuclear transport mechanism, through the interaction of EphB4 with importin-α.
Importin-α is a nuclear transport protein that binds to the NLSmotif of proteins tomove them
into the nucleus (Görlich et al. 1994; Moroianu et al. 1996; Lange et al. 2007; Mertens-Walker
et al. 2013). As such the validation of EphB4 and Importin-α interaction was an important step
in not only identifying a novel binding partner of EphB4, but also in increasing the
understanding of the nuclear transport process of this receptor.
Co-immunoprecipitation (Co-IP) pull down assays confirmed the interaction of Importin-α
with EphB4 and this was further confirmed using co-localisation with EphB4 and Importin-α
occupying the same cellular space. The confirmation of the interaction of EphB4 with
importin-α strongly suggests that this protein coupling is the mechanism which transports
EphB4 into the nucleus. The role that EphB4 plays inside the nucleus is still largely unknown,
however research from our laboratory (partly based on the experiments presented in this
thesis) has identified several genomic sequences to which EphB4 can potentially bind,
including regions associated with the GPR103 gene and LEF1 gene, and resulted with the
identification of Lef1 as a potential target of EphB4-mediated gene regulation (Mertens-
Walker et al. 2013).
Other potential interacting proteins
A number of other proteins were identified as potential interacting partners of EphB4, and
given the breadth of signalling events and pathways that EphB4 is involved in, it is likely that
there are many more proteins that interact directly with this RTK. Understanding these
protein partners and the signalling events they effect can lead to greater insights into the role
of EphB4 in both normal and diseased conditions. A number of hypothetical pathways have
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been described in Figure 7.1 based on targets identified by the 2D-NACE and co-
immunoprecipitation analysis (Appendix 1 – Full list of putative protein partners of EphB4
identified using 2D-NACE All of these putative protein partners could be further investigated
using the techniques described in this thesis, providing greater understanding of EphB4 and
its signalling pathways.
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Figure 7.1 – Hypothesised pathways of selected targets identified by 2D-NACE when interacting with EphB4
Known functions and mechanisms of potential binding partners of EphB4 are outlined in Appendix 1. Hypothetical pathways for the potential interaction of a selection of these
targets with EphB4 (based on literature and known functions and signaling pathways of these proteins) have been outlined in this figure. A. MAPK-EphB4 Signaling – JNK1
and MAP4K1 MAP kinases may interact directly with EphB4 and initiate signaling pathways which activate Transcription Factors (which stimulate differentiation), and Myc
signaling (which stimulates proliferation). B. Protease-EphB4 Signaling – ADAM23 and MMP2 may regulate EphB4 by cleaving it, releasing the extracellular domain of the
receptor which may signal through as yet unknown mechanisms. EphB4 cleavage may also activate cell signaling pathways within the cell which can stimulate apoptosis and
proliferation. SERPINA10 (a protease inhibitor) may block the action of MMP2 and ADAM23, preventing the cleavage of EphB4. C. Nuclear EphB4 Signaling – Importin-α can
bind EphB4 and complexes with Importin-β to transport EphB4 into the nucleus where the receptor may interact with a number of gene regulating proteins. These including
FANCE and PRKDcs (which stimulate DNA repair), as well as SYCP2 and the histone HISTH1C (which stimulate DNA processing). D. Signal Transduction – PAK4 may bind directly
with EphB4, activating the PI3K-Akt-mTOR pathway which promotes cell survival, migration and metastasis. PGRMC1 mediates Akt and may also interact with EphB4. E.
Angiogenesis and Exosomes – Thrombospondin-1 (TSP1) interacts with EphB4 and may activate angiogenesis and tumourigenesis pathways. Both EphB4 and Thrombospondin-
1 can be cleaved by Kallikrein 4 (KLK4) which may mediate this interaction and lead to activation of tumourigenic pathways. Additionally, Plasminogen may also work in
conjunction with Thrombospondin-1 in stimulating angiogenesis. Valosin-containing protein (VCP) is thought to interact with EphB4 to stimulate exosome release from the
cell.
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7.2.3 Extracellular EphB4 is carried by exosomes
As EphB4 is a transmembrane protein it was not expected to be present as a full length,
functioning protein in conditioned medium. However, this study has identified the presence
of full length EphB4 in the medium collected from 22Rv1B4 prostate cancer cells, which have
been engineered to over-express EphB4 (Rutkowski et al. 2012). Mechanisms that are able to
transport full length proteins from the cell membrane to the external environment include
vesiculation and through encapsulation into exosomes and subsequent release outside of the
host cell. A number of receptors have already been identified to be transported out of cells
as part of exosomal cargo including full length EphB4 (in this case from colorectal cells
(Mathivanan et al. 2009; Welton et al. 2010; Choi et al. 2008). As such, it was hypothesised
that the identified full length EphB4 in the medium of 22Rv1B4 cells was as a result of
exosome transportation and this was confirmed by the isolation of exosomes from medium
supporting the growth of 22Rv1 prostate cancer cells in which the presence of EphB4 and
other common markers of exosomes was detected using immunoblotting.
This is the first study to report EphB-positive exosomes can be released from prostate cancer
cells. Given that the 22Rv1 cells used here were engineered to over-express EphB4 and
secretion of exosomes may have been a consequence of this artificial over-expression, several
other prostate cancer cell lines that express EphB4 were tested for the presence of EphB4.
Exosomes were isolated from a panel of these prostate cancer cells and then subjected to
Western blot analysis to confirm the presence of EphB4 and additionally, other exosomal
proteins (Clathrin and EEA1) and proteins known not to be carried by exosomes (GM130 and
Calnexin). These additional protein markers were used in the analysis in order to ascertain
the cellular origin of the exosomes. Western blot analysis confirmed that exosomes derived
from all the prostate cancer cell lines investigated carried full length EphB4. Additionally, the
exosomes from these cell lines contained EEA1 and Clathrin, but not GM130 and Calnexin (as
expected). This result further confirmed that full length EphB4 expressed on the surface of
cells can be internalised, processed and released from the host cell in exosomes and that this
is a common mechanism in prostate cancer.
173
However, it was yet unknown whether the exosomal EphB4 was functional and able to signal,
and what purpose this signalling would have. A number of studies have linked tumour-derived
exosomes to increased proliferation (Koga et al. 2005; Qu et al. 2009). Thus, to confirm
whether EphB4 in exosomes was active and able to produce a cellular effect, both EphB4-
positive and EphB4-negative exosomes were added to the prostate cancer cell lines LNCaP,
22Rv1VO and 22Rv1B4; as well as HUVECs. The proliferation rate of these cell lines and their
Caspase 3/7 activity (a measure of apoptosis) was recorded over a number of days. It was
found that stimulation of cancer cells with EphB4-positive exosomes significantly increased
the proliferation of these cells while concurrently lowering the amount of Caspase 3/7 activity
compared to the control cells. This indicates that the EphB4 positive exosomes derived from
22Rv1-B4-cells are able to interact, signal and induce a change within the target cells, though
whether this is through a direct result of EphB4 or potentially through some other factor as a
result of EphB4 over-expression is yet to be determined and is a part of future work to be
completed.
The exact mechanism of this function is still unknown, but it is hypothesised that it may be
through the incorporation of the exosomes into the cell and the subsequent re-expression of
the cargo EphB4 on the surface of the target cell. This would lead to an increased expression
of the receptor and thereby an increase in the activation of tumour promoting ligand-
independent signalling pathways, which in turn would enhance the proliferation rate of the
cells and decrease Caspase 3/7 apoptosis (Rutkowski et al. 2012). Future experiments to
further this work could include assessing EphB4 and ephrin-B2 tyrosine phosphorylation in
prostate cancer cells and comparing this to activation of these proteins in HUVECs to
determine what type of signalling, forward or reverse, is occurring and when.
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7.3 Final Conclusion
In conclusion, results presented in this thesis describe a novel method for identifying
interacting proteins of EphB4, as well as identifying and confirming new protein binding
partners of EphB4 (Thrombospondin-1, PAK4, JNK1, MCF2L and Importin-α), which may play
important roles in both normal and tumour cell signalling and function.
Additionally, a new mechanism of action of EphB4 has been identified where the receptor is
found in its full form in the extracellular environment being transported by exosomes which
then can affect signalling pathways in both endothelial and prostate cancer cells. The purpose
of this novel role for EphB4 is also currently unknown and requires further study.
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Appendix 1 – Full list of putative protein partners of EphB4
identified using 2D-NACE and immunoprecipitation
Protein Name Peptides Probability Notes
ACTA2 2 0.9997 Alpha-Actin 2 - involved in smooth muscle contraction, cell
motility and structure (Snásel et al. 1997)
ACTN1 2 0.9720 Alpha-actinin-1 - actin-binding cytoskeletal protein (Youssoufian
et al. 1990)
ADAM23 1 0.8797 Disintegrin and metalloproteinase domain-containing protein
23 - protease which is highly expressed in the brain and is
involved in cell-cell and cell-matrix interactions (Poindexter et
al. 1999)
AHNAK 1 0.9010 Neuroblast differentiation protein (or desmoyokin) - essential
for pseudopod protrusion and cell motility (Shankar 2010)
ARHGAP39
1
0.7968
ARHGAPs, also known as Rho GTPase activating protein (Rho
GAP), facilitate activation of Rho GTPases, through modulating
GTP into GDP. Active Rho GTPases play a role in cellular
processes including proliferation, differentiation and motility
(Tcherkezian & Lamarche-Vane, 2007)
APOB 3 0.9798 Apolipoprotein B - involved in carrying cholesterol to tissues
(Contois et al. 2011)
ARRDC3 1 0.9584 Arrestin domain-containing protein 3 - involved in
ubiquitination of β2-adrenergic receptor (Nabhan et al. 2010)
ATP1A3 1 0.9885 Na+/K+ transporting ATPase subunit alpha-3 - involved in
maintaining electrochemical cellular gradients of Na+ and K+
(Sverdlov et al. 1988)
AZGP1 2 0.9988 Zinc-alpha-2-glycoprotein - involved in the breakdown of lipids
(Araki et al. 1988)
C1S 1 0.9982 Complement C1s subcomponent - involved in complement
system, part of the immune system (Thielens et al. 1999)
CDH23 1 0.9887 Cadherin 23 - Expressed in the neurosensory epithelium and
involved in stereocilia organization (Kazmierczak et al. 2007)
CDK4 1 0.7441 Cell dependent kinase 4 - Ser/Thr protein kinase involved in cell
cycle G1 phase progression and regulated by Cyclin D (Gogolin
et al. 2013)
CLIC2 1 0.8519 Chloride intracellular channel protein 2 - involved in maintaining
cell membrane potential, intracellular pH and cell volume
(Thiemann et al. 1992)
COL1A1 2 0.8395 Collagen, type I, alpha 1 - major component of type I collagen
found in most connective tissues (Falanga et al. 2002)
COL6A1 1 0.9961 Collagen, type VI, alpha 1 - major structural component of
microfibrils (Lampe 2006)
CSNK1D 1 0.8207 Casein kinase I isoform delta - casein kinase enzyme involved in
cytoplasmic and nuclear processes (Fish et al. 1995)
CYP3A7 2 0.9982 Cytochrome P450 3A7 - part of the cytochrome P450 family and
involved in oxidation of organic substances (Paulussen et al.
2000)
DSC3 1 0.9982 Desmocollin-3 - glycoprotein required for cell adhesion and
desmosome formation (Oshiro et al. 2005)
EEF1A2 2 0.9476 Elongation factor 1-alpha 2 - involved in delivery of aminoacyl
tRNAs to the ribosome and in ovarian cancer development
(Lund et al. 1997)
ENSP00382160 1 0.9985 Uncharacterized protein
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FABP5 22 0.9820 Fatty Acid binding protein 5 - cytoplasmic protein that binds
long-chain fatty acids and is involved in their uptake, transport
and metabolism (Madsen et al. 1992)
FANCE 1 0.7828 Fanconi Anemia group E - involved in Fanconi anemia, a genetic
disease with deregulated DNA repair (D'Andrea et al. 2010)
FN1 2 1.0000 Fibronectin - binds extracellular matrix components and is
involved in cell adhesion, migration and differentiation (Pankov
et al. 2002)
GOLGB1 24 0.9967 Golgin subfamily B member 1 (or Giantin) - member of golgin
family of proteins expressed in Golgi apparatus (Linstedt et al.
1993)
HIST1H1C 4 1.0000 Histone H1.2 - involved in compacting chromatin and in DNA
structure as well as in apoptosis during DNA damage (Konishi et
al. 2003)
HNRPA2B1 2 0.9889 Heterogeneous nuclear ribonucleo-proteins A2/B1 - influence
mRNA processing, metabolism and transport (Biamonti et al.
1994)
HNRPL1 1 0.9990 Heterogeneous nuclear ribonucleo-protein L1 - part of the
HNRP complex  involved in mRNA processing (Pinol-Roma et al.
1990)
HNRPF 1 0.9987 Heterogeneous nuclear ribonucleo-protein F - part of the HNRP
complex  involved in mRNA processing (Honore et al. 1996)
HSN2 1 0.9987 Hereditary sensory neuropathy, type II - involved in
transmission of sensory signals as part of the nervous system
(Lafreniere et al. 2004)
IGG 1 0.9991 Immunoglobulin G - an antibody, produced by B cells and part
of the immune system (Litman et al. 1993)
IGHA1 1 0.7947 Immunoglobulin heavy constant alpha 1 - subunit of an
antibody, produced by B cells and part of the immune system
(Litman et al. 1993)
IGHV4-31 1 0.9971 immunoglobulin heavy chain variable group 4-31 - subunit of an
antibody, produced by B cells and part of the immune system
(Litman et al. 1993)
IGK 2 0.7483 Immunoglobulin kappa locus - subunit of an antibody, produced
by B cells and part of the immune system (Litman et al. 1993)
IGKV4-1 1 0.9991 Immunoglobulin kappa locus variable group 4-1 - subunit of an
antibody, produced by B cells and part of the immune system
(Litman et al. 1993)
IGL 6 0.4990 Immunoglobulin lambda locus - subunit of an antibody,
produced by B cells and part of the immune system (Litman et
al. 1993)
IGLL3 3 0.4952 Immunoglobulin lambda-like polypeptide 3 - subunit of an
antibody, produced by B cells and part of the immune system
(Litman et al. 1993)
IMMT 1 0.8588 Mitochondrial inner membrane protein - found in the inner
membrane of mitochondria (Gieffers et al. 1997)
KIAA1688 1 0.8452 Uncharacterized protein
KRT1 63 1.0000 Keratin 1 - member of the keratin family: structural filament
proteins found in skin, hair and nails (Schweizer et al. 2006)
KRT10 198 1.0000 Keratin 10 - member of the keratin family: structural filament
proteins found in skin, hair and nails (Schweizer et al. 2006)
KRT14 2 0.9976 Keratin 14 - member of the keratin family: structural filament
proteins found in skin, hair and nails (Schweizer et al. 2006)
KRT16 3 1.0000 Keratin 16 - member of the keratin family: structural filament
proteins found in skin, hair and nails (Schweizer et al. 2006)
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KRT2 70 1.0000 Keratin 2 - member of the keratin family: structural filament
proteins found in skin, hair and nails (Schweizer et al. 2006)
KRT3 2 0.9990 Keratin 3 - member of the keratin family: structural filament
proteins found in skin, hair and nails (Schweizer et al. 2006)
KRT5 2 0.9994 Keratin 5 - member of the keratin family: structural filament
proteins found in skin, hair and nails (Schweizer et al. 2006)
KRT6A 5 1.0000 Keratin 6A - member of the keratin family: structural filament
proteins found in skin, hair and nails (Schweizer et al. 2006)
KRT8 8 1.0000 Keratin 8 - member of the keratin family: structural filament
proteins found in skin, hair and nails (Schweizer et al. 2006)
KRT9 14 0.9753 Keratin 9 - member of the keratin family: structural filament
proteins found in skin, hair and nails (Schweizer et al. 2006)
LIF 1 0.9276 Leukemia inhibitory factor - cytokine involved in cell growth and
differentiation (Wenwei et al. 2007)
LOC730465 1 0.9985 Uncharacterized protein
LRRC4C 1 0.9989 Leucine rich repeat containing 4C (or NGL1) - binds with netrin
G1 (NTNG1 which is involved in axon guidance (Lin et al. 2003)
MAP4K1 1 0.8861 Mitogen-activated protein kinase 1 (or HPK1) - May play a role
in hematopoietic growth and differentiation pathways (Hu et al.
1996)
MAPK8 (JNK1) 2 0.9982 Mitogen-activated protein kinase 8 (or JNK1) - signaling protein
kinase involved in many cellular processes including cell
proliferation, differentiation, apoptosis and development
(Gupta et al. 1996)
MCF2L 1 0.9789 Guanine nucleotide exchange factor DBS - involved in RAC1 and
RHOA signaling pathways through catalyzing guanine nucleotide
exchange (Nagase et al. 1997)
MMP2 1 0.9982 Matrix metalloproteinase-2 (or gelatinase) - enzyme that
degrades the extracellular matrix and plays a role in cell
migration (including during prostate cancer progression (Wilson
et al. 2004; Roomi et al. 2009). Also involved in Abl/Crk pathway
regulated by EphB receptors which MMP2 can cleave (Lin et al.
2008; Pasquale et al. 2010)
MSLN 1 0.9982 Mesothelin (or CAK1) - expressed by mesothelial cells and
overexpressed in mesotheliomal, ovarian and pancreatic
cancers (Chang et al. 1992)
MTTP 1 0.9982 Microsomal triglyceride transfer protein large subunit - involved
in lipoprotein assembly (Shoulders et al. 1994)
MYH10 1 0.9982 Myosin-10 - motor protein involved in muscle contraction and
motility (Simons et al. 1991)
MYO15A 1 0.9970 Myosin-15 - unconventional myosin (motor protein) with long
N-terminal extension involved in actin organization in hair cells
of the cochlea (Wang et al. 1998b)
NAMPT 1 0.9783 Nicotinamide phosphoribosyltransferase (or pre-B-cell colony-
enhancing factor 1 - PBEF1) - enzyme involved in B cell
maturation and inhibits neutrophil cell death (Samal et al. 1994)
NDUFS1 9 0.9804 NADH-ubiquinone oxidoreductase 75 kDa subunit,
mitochondrial - enzyme transfers electrons from NADH to the
respiratory chain in the mitochondria (Sumegi et al. 1985)
OGG1 2 0.9230 Oxoguanine glycosylase - DNA glycosylase enzyme involved in
base excision repair (Bjoras et al. 2002)
OSCAR 2 0.9766 Osteoclast-associated immunoglobulin-like receptor - expressed
by osteoclasts and involved in regulating immune responses
(Kim et al. 2002)
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PAK4 1 0.9982 p21 activated kinase 4 - plays a role in cell signaling, motility,
survival, angiogenesis, migration, mitosis, and metastasis (Abo
et al. 1999)
PGLYRP2 1 0.9568 N-acetylmuramoyl-L-alanine amidase - part of the immune
system and recognize peptidoglycan in bacterial cell walls (De
Pauw et al. 1995)
PGRMC1 1 0.9726 Progesterone receptor membrane component 1 - mediates
apoptosis in cancer cells and modulates Akt protein kinase
(Hand et al. 2003)
PHB2 1 0.7501 Prohibitin-2 - implicated in mitochondrial function, transcription
and cell proliferation (Coates et al. 2001; Gamble et al. 2007)
PI3KR1 1 0.7908 Phosphatidylinositol 3-kinase regulatory subunit alpha - subunit
of PI3K (signal transducer enzymes) and is involved in
proliferation, migration, differentiation, insulin levels and cell
survival through the PI3K/Akt/mTOR pathway, which is
regulated by EphB4 (Steinle et al. 2003; Hale et al. 2012; Bitting
et al. 2013)
PLG 7 0.9412 Plasmin - serine protease found in blood involved in
degradation of  blood plasma proteins, including fibrin (Wiman
et al. 1979)
PLXNB3 2 0.9962 Plexin B3 - receptor for semaphorin and signal transduction
protein which is part of the neuropilin-plexin receptor complex
(Tamagnone et al. 1999)
PRKDcs 6 0.8966 DNA-dependent protein kinase, catalytic subunit - involved in
repairing double-strand breaks in DNA (Meek et al. 2008)
PTK2B 1 0.9982 Protein tyrosine kinase 2 beta (or Pyk2) - regulates ion channels
and activates map kinase signaling (Lev et al. 1995)
RPL11 2 0.7899 60S ribosomal protein L11 - 60S subunit of ribosomes which
synthesize proteins (Kenmochi et al. 1998)
RPL14 1 0.9991 60S ribosomal protein L14 - 60S subunit of ribosomes which
synthesize proteins (Kenmochi et al. 1998)
RPL36 1 0.9636 60S ribosomal protein L36 - 60S subunit of ribosomes which
synthesize proteins (Kenmochi et al. 1998)
RPL6 4 0.9971 60S ribosomal protein L6 - 60S subunit of ribosomes which
synthesize proteins (Kenmochi et al. 1998)
RPLP0 4 1.0000 60S ribosomal protein P0 - 60S subunit of ribosomes which
synthesize proteins (Kenmochi et al. 1998)
RPS12 1 0.9990 40S ribosomal protein S12 - 40S subunit of ribosomes which
synthesize proteins (Kenmochi et al. 1998)
S100A8 2 1.0000 S100 calcium binding protein A8 - involved in cell cycle
progression and differentiation and binds to AHNAK (Schäfer et
al. 1996; Gentil et al. 2001)
SERPINA10 1 0.8027 Protein Z-dependent protease inhibitor - a serine protease
inhibitor (serpin) with roles in blocking factors in the
coagulation cascade (Han et al. 2000)
SHROOM3 1 0.8808 Shroom related protein 3 - involved in regulating cell shape and
neural development (Juriloff et al. 2000)
SLC35F4 6 0.9990 Solute carrier family 35, member F4 - solute carrier family
protein involved in nucleotide sugar transport (Ishida et al.
2004)
SPRR3 2 0.9321 Small proline-rich protein 3 - envelope protein of keratinocytes
(Gibbs et al. 1993)
STK33 1 0.9982 Serine/threonine-protein kinase 33 - part of the
calcium/calmodulin dependent family of kinases. Its function is
unknown (Mujica et al. 2001)
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STOML2 1 0.9982 Stomatin-like protein 2 (or SLP-2) - homolog of stomatin, a
membrane protein found in blood cells (Wang et al. 2000)
SYCP2 1 0.9933 Synaptonemal complex protein 2 - central subunit of scaffold
used during chromosome pairing (Moses 1968)
TASP1 16 0.9804 Threonine aspartase 1 - endopeptidase that cleaves substrates
after aspartate residues and is involved in cancer cell
proliferation and apoptosis (Chen et al. 2010)
THBS1 1 0.9355 Thrombospondin-1 (or TSP1) - secreted protein that mediates
cell to cell and cell to matrix interaction and is involved in
angiogenesis and tumourigenesis, pathways it shares with
EphB4 (Hanahan et al. 1996; Chen et al. 2000; Sargiannidou et
al. 2001)
TNRC6B 1 0.8865 Trinucleotide repeat-containing gene 6B protein - required for
miRNA-guided gene silencing in HeLa cells (Meister et al. 2005)
TPD52L2 1 0.9280 Tumour protein D54 - unknown function but implicated in
affecting body length in mice (Gerdin 2010)
TPM1 1 0.9408 Tropomyosin alpha-1 chain - actin-binding protein involved in
muscle contraction (Brown et al. 1985)
TRAPPC9 1 0.9045 Trafficking protein particle complex 9 - activator of NF-kappa-B
and may be involved in neuronal cells differentiation and
vesicular transport (Mochida et al. 2009)
TRPRS 1 0.9753 Tryptophanyl-tRNA synthetase (or WARS) - involved in transfer
RNA (tRNA) synthesis by catalyzing aminoacylation of tRNA with
tryptophan (Fleckner et al. 1992)
TUBB 6 1.0000 β-Tubulin - subunits of the globular protein family of tubulins
that dimerise to form microtubules; components of the
cytoskeleton (Dutcher, 2001). EphB4 was able to indirectly
modify microtubules during development (Meima et al. 1997;
Pasquale, 2005). β-Tubulin has also been implicated in prostate
cancer progression (Ploussard et al. 2010)
UHRF2 1 0.9918 E3 ubiquitin-protein ligase - ubiquitin-ligase involved in cell
cycle regulation (Mori et al. 2002)
VCP 2 0.9982 Valosin-containing protein - ATP-binding structural protein
involved in vesicle transport and fusion, ubiquitin-dependent
protein degradation, proteasome function, peroxisome
assembly (Zhang et al. 2000)
VIM 1 0.9980 Vimentin - intermediate filament and cytoskeletal component
that is expressed in mesenchymal cells (Eriksson et al. 2009)
WWC3 2 0.9951 WW domain-containing protein 3 - unknown function
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Appendix 2 - Preliminary work from Honours project
Rutkowski R, Mertens-Walker I, Lisle JE, Herington AC, Stephenson SA. (2012) Evidence for a
dual function of EphB4 as tumor promoter and suppressor regulated by the absence or
presence of the ephrin-B2 ligand. Int J Cancer 131(5):E614-624
This paper contains research from my Honours project that continued on into my PhD thesis.
The paper describes the creation of the 22Rv1-B4 EphB4 over-expressing prostate cancer cell
line and the effects that the over-expression of EphB4 have on tumour growth in relation to
interaction with the ligand ephrin-B2.
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Appendix 3 - Further work on nuclear localisation of EphB4
Mertens-Walker I, Lisle JE, Nyberg WA, Stephens CR, Burke L, Rutkowski R, Herington AC,
Stephenson SA. (2015) EphB4 localises to the nucleus of prostate cancer cells. Experimental
Cell Research 333(1):105-115
This paper details further research into the role of EphB4 in the cell nucleus of prostate cancer
cell lines. The research identifies a nuclear localisation signal on the EphB4 protein and
outlines the potential interaction of EphB4 and Importin-α as a mechanism of transport into
the nucleus.
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Appendix 4 - In depth literature review of Eph receptors
Lisle JE, Mertens-Walker I, Rutkowski R, Herington AC, Stephenson SA. (2013) Eph Receptors
and Their Ligands: Promising Molecular Biomarkers and Therapeutic Targets in Prostate
Cancer. Biochim Biophys Acta 1835(2):243-257
This paper provides a detailed literature review of the Eph receptors and their ligands in the
context of prostate cancer.

